Compound, use of a compound, combination, pharmaceutical composition, and pharmaceutically acceptabl

专利摘要:
compound, use of a compound, combination, pharmaceutical composition, and pharmaceutically acceptable salt of a compound The present invention relates to 6 to 5 membered fused pyridine ring compounds according to formula i or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and their use in therapy. in particular, the present invention relates to the use of 6 to 5 membered fused pyridine ring compounds according to formula i in the treatment of bruton tyrosine kinase (btk) mediated disorders.
公开号:BR112014001255B1
申请号:R112014001255-5
申请日:2012-07-11
公开日:2019-07-02
发明作者:Tjeerd A. Barf；Christiaan Gerardus Johannes Maria Jans；Adrianus Petrus Antonius Man；Arthur A. Oubrie；Hans C. A. Raaijmakers；Johannes Bernardus Maria Rewinkel；Jan-Gerard Sterrenburg；Jacobus C. H. M. Wijkmans
申请人:Merck Sharp & Dohme B.V.；
IPC主号:

专利说明:

“COMPOUND, USE OF A COMPOUND, COMBINATION, PHARMACEUTICAL COMPOSITION, AND PHARMACEUTICALLY ACCEPTABLE SALT FROM A COMPOUND”
FIELD OF THE INVENTION [0001] The present invention relates to the fused pyridine ring compounds of 5 to 6 members, the pharmaceutical compositions comprising these compounds and their use in therapy. In particular, the present invention relates to the use of fused 5- to 6-membered pyridine ring compounds in the treatment of disorders mediated by Bruton's Tyrosine Kinase (Btk). BACKGROUND OF THE INVENTION [0002] Activation of B lymphocyte is key in generating adaptive immune responses. Activation of off-course B lymphocyte is a distinctive attribute of many autoimmune diseases and the modulation of this immune response is therefore of therapeutic interest. Recently, the success of B cell therapies in autoimmune diseases has been established. The treatment of patients with rheumatic arthritis (RA) with Rituximab (anti-CD20 therapy) is currently accepted clinical therapy. More recent clinical trial studies show that treatment with Rituximab also improves symptoms of the disease in patients with recurrent remissive multiple sclerosis (RRMS) and systemic lupus erythematosus (SLE). This success holds the potential for future therapies in autoimmune diseases that target B cell immunity.
[0003] Bruton tyrosine kinase (Btk) is a non-receptor protein kinase of the Tec family, expressed in B cells and myeloid cells. The function of Btk in the signaling pathways activated by impairment of the B cell receptor (BCR) and FcsR1 in the mastoids is well established. In addition, a function for Btk as a downstream target in Toll as receptor signaling has been suggested. Functional mutations in Btk in humans results in the primary immunodeficiency disease called XLA which is characterized by a defect in B cell development with a / 123 block between B cell pro- and pre-stage. This results in an almost complete absence of B lymphocytes in humans causing a pronounced reduction in serum immunoglobulin of all classes. This invention supports the key role for Btk in regulating the production of autoantibodies in the induced production of autoimmune diseases. In addition, the regulation of Btk may affect the BCR-induced production of pro-inflammatory cytokines and chemokines by B cells, indicating a broad potential for Btk in the treatment of autoimmune diseases.
[0004] With the reported regulatory role for Btk in FcsR-mediated mastoid activation, Btk inhibitors may also show potential in the treatment of allergic responses [Gilfillan et al, Immunological Reviews 288 (2009) pages. 149-169].
[0005] In addition, Btk is also reported to be involved in RANKL-induced osteoclast differentiation [Shinohara et al, Cell 132 (2008) p. 794-806] and therefore may also be of interest for the treatment of bone resorption disorders.
[0006] Other diseases with an important role for dysfunctional B cells are B cell malignancies. In fact, anti-CD20 therapy is effectively used in the clinic for the treatment of follicular lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia [ Lim et al, Haematologica, 95 (2010) pgs. 135-143]. The related role reported for Btk in regulating B cell proliferation and apoptosis indicates that there is a potential for Btk inhibitors also in the treatment of B cell lymphomas. Btk inhibition appears to be particularly relevant for B cell lymphomas due to chronic active BCR signaling [Davis et al, Nature, 463 (2010) pgs. 88-94].
[0007] Some classes of the 5- to 6-membered fused pyridine ring compounds have been described as kinase inhibitors, for example, the Imidazo [1,5-f] [1,2,4] triazine compounds have been described in / 123
WO2005097800 and WO2007064993; Imidazo [1,5-a] pyrazine compounds have been described in WO2005037836 and WO2001019828 as inhibitors of the IGF-1R enzyme.
[0008] Some of the reported Btk inhibitors are not completely selective for the Src family kinases. With dramatic adverse effects reported for silences in the Src family kinases, especially for double and triple silences, this is seen as prohibitive for the development of Btk inhibitors that are not completely selective for Src family kinases.
[0009] Mice both deficient in Lyn and deficient in
Fyn exhibit autoimmunity that mimics the human lupus nephritis phenotype. In addition, Fyn-deficient mice also have pronounced neurological defects. Lyn-silenced mice also have an allergic-like phenotype, indicating Lyn as a broad negative regulator of IgE-mediated allergic response by controlling mastoid responsiveness and traits associated with allergy [Odom et al, J. Exp. Med., 199 (2004) pgs. 1491-1502]. In addition, aged silenced mice in Lyn develop severe splenomegaly (myeloid expansion) and disseminated monocyte / macrophage tumors [Harder et al, Immunity, 15 (2001) pages. 603-615]. These observations are in line with hyperresponsive B cells, mastoids and myeloid cells, and increased Ig levels seen in Lyn deficient mice. Female mice silenced in Src are infertile due to reduced follicle and ovulation development [Roby et al, Endocrine, 26 (2005) pgs. 169-176]. The double silences Src ^{- / -} Fyn ^{- / -} and Src ^{- / -} Yes ^{- /} present a severe phenotype with effects on movement and breathing. The Src ^{- / -} Fyn ^{- / -} Yes ^{- / -} triple silences died on day 9.5 [Klinghoffer et al, EMBO J., 18 (1999) pgs. 2459-2471]. For Src ^{/ -} Hck ^{- / -} double silences, two-thirds of the mice died at birth, with the / 123 surviving mice developing osteopetrosis, extramedullary hematopoiesis, anemia, leukopenia [Lowell et al, Blood, 87 (1996) pages.17801792] .
[00010] Consequently, an inhibitor that inhibits multiple or all of the kinases of the Src family simultaneously can cause serious adverse effects.
Detailed description of the invention [00011] The purpose of the present invention is to provide the fused pyridine ring compounds of 5 to 6 members, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, the present invention relates to the use of fused 5- to 6-membered pyridine ring compounds in the treatment of Bruton Tyrosine Kinase (Btk) mediated disorders.
[00012] More specifically, the present invention provides 5 to 6-membered fused pyridine ring compounds according to Formula I or their pharmaceutically acceptable salts.
Formula I
In this formula the substituents are defined as X is CH, N, O or S;
Y is C (R6), N, O or S;
[00013] / 123
Z is CH, N or bond;
A is CH or N;
B1 is N or C (R7);
B2 is N or C (R8);
B3 is N or C (R9);
B4 is N or C (R10);
R1 is R11C (O), R12S (O), R13SO2 or alkyl (1-6C) optionally substituted with R14;
R2 is H, alkyl (1-3C) or cycloalkyl (3-7C);
R3 is H, alkyl (1-6C) or cycloalkyl (3-7C)); or
R2 and R3 form, together with the N and C atom to which they are attached, a heterocycloalkyl (3-7C) optionally substituted with one or more fluorine, hydroxyl, alkyl (1-3C), alkoxy (1-3C) or oxo;
[00014] R4 is H or alkyl (1-3C);
[00015] R5 is H, halogen, cyano, alkyl (1-4C), alkoxy (1-3C), cycloalkyl (3-6C); all alkyl groups of R5 are optionally substituted with one or more halogens; or R5 is aryl (6-10C) or heterocycloalkyl (2-6C);
[00016] R6 is H or alkyl (1-3C); or [00017] R5 and R6 together can form a cycloalkenyl (3-7C), or heterocycloalkenyl (2-6C); each optionally substituted with (1-3C) alkyl, or one or more halogens;
[00018] R7 is H, halogen or alkoxy (1-3C);
[00019] R8 is H or alkyl (1-3C); or [00020] R7 and R8 form, together with the carbon atom to which they are attached, an aryl (6-10C) or heteroaryl (1-9C);
[00021] R9 is H, halogen or alkoxy (1-3C);
[00022] R10 is H, halogen, or alkoxy (1-3C);
/ 123 [00023] R11 is independently selected from a group consisting of alkyl (1-6C), alkenyl (2-6C) and alkynyl (2-6C) each alkyl, alkenyl or alkynyl optionally substituted with one or more groups selected from hydroxyl, alkyl (1-4C), cycloalkyl (3-7C), [alkyl (14C)] amino, di [alkyl (1-4C)] amino, alkoxy (1-3C), cycloalkoxy (3-7C), aryl (6-10C) or heterocycloalkyl (3-7C); or [00024] R11 is (1-3C) alkyl -C (O) -S-alkyl (1-3C); or [00025] R11 is heteroaryl (1-5C) optionally substituted with one or more groups selected from halogen or cyano.
[00026] R12 and R13 are independently selected from a group consisting of alkenyl (2-6C) or alkynyl (2-6C) both optionally substituted with one or more selected groups of hydroxyl, alkyl (14C), cycloalkyl (3-7C ), [alkyl (1-4C)] amino, di [alkyl (1-4C)] amino, alkoxy (1-3C), cycloalkoxy (3-7C), aryl (6-10C), or heterocycloalkyl (3-7C ); or [00027] heteroaryl (1-5C) optionally substituted with one or more selected groups of halogen or cyano;
[00028] R14 is independently selected from a group consisting of halogen, cyano or alkenyl (2-6C) or alkynyl (2-6C) both optionally substituted with one or more selected groups of hydroxyl, alkyl (1-4C), cycloalkyl (3-7C), [alkyl (1-4C)] amino, di [alkyl (14C)] amino, alkoxy (1-3C), cycloalkoxy (3-7C), aryl (6-10C), heteroaryl (1- 5C) or heterocycloalkyl (3-7C).
[00029] Provided that:
- from 0 to 2 atoms of X, Y, Z can be simultaneously a hetero atom;
- when an atom selected from X, Y is O or S, then Z is a bond and the other atom selected from X, Y may not be O or S;
- when Z is C or N then Y is C (R6) or N and X is C or N;
- from 0 to 2 atoms of B1, B2, B3 and B4 are N.
/ 123 [00030] The terms as used herein refer to the following:
[00031] Alkyl (1-2C) means an alkyl group having 1 to 2 carbon atoms, which are methyl or ethyl.
[00032] Alkyl (1-2C) means an alkyl group having 1 to 2 carbon atoms, being methyl or ethyl. A methyl group can be indicated as Me or CH ₃ .
[00033] Alkyl (1-3C) means a branched or unbranched alkyl group having 1 to 3 carbon atoms, being methyl, ethyl, propyl or isopropyl.
[00034] Alkyl (1-4C) means a branched or unbranched alkyl group having 1 to 4 carbon atoms, being methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, alkyl groups (1-3C) being preferred.
[00035] Alkyl (1-5C) means a branched or unbranched alkyl group having 1 to 5 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl and isopentyl, alkyl groups (1-4C) being preferred.
[00036] Alkyl (1-6C) means a branched or unbranched alkyl group having from 1 to 6 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, n-pentyl and n- hexyl. Alkyl groups (1-5C) are preferred, alkyl (1-4C) being most preferred.
[00037] Aloxy (1-2C) means an alkoxy group having 1 to 2 carbon atoms, the alkyl portion having the same meaning as previously defined.
[00038] Aloxy (1-3C) means an alkoxy group having 1 to 3 carbon atoms, the alkyl portion having the same meaning as previously defined. Alkoxy groups (1-2C) are preferred.
[00039] Alkoxy (1-4C) means an alkoxy group having 1 to 4 carbon atoms, the alkyl portion having the same meaning as previously defined / 123. Alkoxy groups (1-3C) are preferred, alkoxy groups (1-2C) are most preferred.
[00040] Alkenyl (2-4C) means a branched or unbranched alkenyl group having 2 to 4 carbon atoms, such as ethylene, 2propenyl, isobutenyl or 2-butenyl.
[00041] Alkenyl (2-6C) means a branched or unbranched alkenyl group having 2 to 6 carbon atoms, such as ethylene, 2butenyl, and n-pentenyl. Alkenyl groups (2-4C) are preferred.
[00042] Alquinyl (2-4C) means a branched or unbranched alkynyl group having 2 to 4 carbon atoms, such as ethynyl, 2-propynyl or 2-butynyl.
[00043] Alquinyl (2-6C) means a branched or unbranched alkynyl group having 2 to 6 carbon atoms, such as ethynyl, propynyl, n-butynyl, n-pentynyl, isopentinyl, isohexynyl or n-hexynyl. Alkynyl groups (2-4C) are preferred.
[00044] Cycloalkyl (3-6C) means a cycloalkyl group having 3 to 6 carbon atoms, which are cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[00045] Cycloalkyl (3-7C) means a cycloalkyl group having 3 to 7 carbon atoms, which are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
[00046] Heterocycloalkyl (2-6C) means a heterocycloalkyl group having 2 to 6 carbon atoms, preferably 3 to 5 carbon atoms, and one or two hetero atoms selected from N, O and / or S, which can be bonded through a heteroatom if practicable, or a carbon atom. Preferred heteroatoms are N or O. Preferred are piperidine, morpholine, pyrrolidine and piperazine. The most preferred heterocycloalkyl (2-6C) is pyrrolidine. The heterocycloalkyl group can be linked via a heteroatom if practicable.
/ 123 [00047] Heterocycloalkyl (3-7C) means a heterocycloalkyl group having 3 to 7 carbon atoms, preferably 3 to 5 carbon atoms, and one or two hetero atoms selected from N, O and / or S. The hetero atoms preferred are N or O. Preferred heterocycloalkyl (3-7C) groups are azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl. The most preferred heterocycloalkyl (3-7C) groups are piperidine, morpholine and pyrrolidine. The heterocycloalkyl group can be linked via a heteroatom if practicable.
[00048] Cycloalkoxy (3-7C) means a cycloalkyl group having 3 to 7 carbon atoms, with the same meaning as previously defined, attached via a ring carbon atom to an exocyclic oxygen atom.
[00049] Aryl (6-10C) means an aromatic hydrocarbon group having 6 to 10 carbon atoms, such as phenyl, naphthyl, tetrahydronaphthyl or indenyl. The preferred aryl group (6-10C) is phenyl.
[00050] Heteroaryl (1-5C) means a substituted or unsubstituted aromatic group having 1 to 5 carbon atoms and 1 to 4 heteroatoms selected from N, O and / or S. The heteroaryl (1-5C) can be optionally replaced. Preferred heteroaryl (1-5C) groups are tetrazolyl, imidazolyl, thiadiazolyl, pyridyl, pyrimidyl, triazinyl, thienyl or furyl, the most preferred heteroaryl (1-5C) is pyrimidyl.
[00051] Heteroaryl (1-9C) means a substituted or unsubstituted aromatic group having 1 to 9 carbon atoms and 1 to 4 heteroatoms selected from N, O and / or S. The heteroaryl (1-9C) can be optionally replaced. Preferred heteroaryl (1-9C) groups are quinoline, isoquinoline and indole.
[00052] [Alkyl (1-4C)] amino means an amino group, monosubstituted with an alkyl group containing 1 to 4 carbon atoms having the same meaning as previously defined. The preferred / 123 [(1-4C) alkyl] amino group is methylamino.
[00053] Di [alkyl (1-4C)] amino means an amino group, disubstituted with alkyl group (s), each containing from 1 to 4 carbon atoms and having the same meaning as previously defined. The preferred di [(1-4C) alkyl] amino group is dimethylamino.
[00054] Halogen means fluorine, chlorine, bromine or iodine.
[00055] Alkyl (1-3C) -C (O) -S-alkyl (1-3C) means an alkyl-carbonyl-thio-alkyl group, each of the alkyl groups having 1 to 3 carbon atoms with the same meaning as previously defined.
[00056] Cycloalkenyl (3-7C) means a cycloalkenyl group having 3 to 7 carbon atoms, preferably 5 to 7 carbon atoms. Preferred cycloalkenyl (3-7C) groups are cyclopentenyl or cyclohexenyl. Cyclohexenyl groups are most preferred.
[00057] Heterocycloalkenyl (2-6C) means a heterocycloalkenyl group having from 2 to 6 carbon atoms, preferably from 3 to 5 carbon atoms; and 1 heteroatom selected from N, O and / or S. The preferred heterocycloalkenyl (2-6C) groups are the oxycyclohexenyl and azacyclohexenyl groups.
[00058] In the definitions above with multifunctional groups, the connection point is in the last group.
[00059] When, in the definition of a substituent, it is indicated that "all alkyl groups" of said substituent are optionally substituted, this also includes the alkyl portion of an alkoxy group.
[00060] A circle on a Formula I ring indicates that the ring is aromatic.
[00061] Depending on the ring formed, nitrogen, if present in W, X, Y or Z, can carry a hydrogen.
[00062] The term "substituted" means that one or more hydrogens in the designated atom / atoms is / are replaced with a selection from the indicated / 123 group, provided that the normal valence of the designated atom under the existing circumstances is not exceeded, and that the replacement results in a stable compound. Combinations of substituents and / or variables are permissible only if such combinations result in stable compounds. "Stable compound" or "stable structure" is defined as a compound or structure that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an effective therapeutic agent.
[00063] The term "optionally substituted" means optional substitution with the specified groups, radicals or portions.
Aspects of the invention [00064] In one aspect the invention relates to a compound according to formula I wherein B1 is C (R7); B2 is C (R8); B3 is C (R9) and B4 is C (R10). [00065] In another aspect the invention relates to a compound according to formula I wherein B1 is C (R7); B2 is C (R8); B3 is C (R9); B4 is C (R10); R7, R9, and R10 are each H; and R8 is selected from the group consisting of hydrogen and methyl.
[00066] In one aspect the invention relates to a compound according to formula I wherein R8 is hydrogen or methyl, in particular R8 is hydrogen.
[00067] In another aspect the invention relates to a compound according to formula I wherein R7 is hydrogen, fluorine or alkoxy (1-3C). In particular, R7 is hydrogen, fluorine or methoxy. Even more particularly, an aspect of the invention relates to a compound according to formula I wherein R7 is hydrogen.
[00068] In yet another aspect the invention relates to a compound according to formula I wherein R9 is hydrogen, fluorine or alkoxy (1-3C). In particular, R9 is hydrogen, fluorine or methoxy. Even more particularly, an aspect of the invention relates to a compound according to / 123 of formula I wherein R9 is hydrogen.
[00069] In another aspect the invention relates to a compound according to formula I wherein R10 is hydrogen, fluorine or alkoxy (1-3C). In particular, R10 is hydrogen, fluorine or methoxy. Even more particularly, an aspect of the invention relates to a compound according to formula I wherein R10 is hydrogen.
[00070] In yet another aspect the invention relates to a compound according to formula I in which R7 and R8 form, together with the carbon atom to which they are attached, an indole or quinoline or naphthyl.
[00071] In another aspect, the invention relates to a compound according to formula I wherein B1 is C (R7); B2 is C (R8); B3 is C (R9); B4 is C (R10) and R7, R8, R9, and R10 are each H;
[00072] In yet another aspect the invention relates to a compound according to formula I in which R4 is hydrogen or methyl. In particular, R4 is hydrogen.
[00073] In yet another aspect the invention relates to a compound according to formula I where A is N.
[00074] In another aspect the invention relates to a compound according to formula I in which A is CH.
[00075] In another aspect the invention relates to a compound according to formula I in which the ring containing X, Y and Z is selected from a group consisting of pyridyl, pyrimidyl, pyridazyl, triazinyl, thiazolyl, oxazolyl, and isoxazolyl. In particular, the invention relates to a compound according to formula I in which the ring containing X, Y and Z is selected from a group consisting of pyridyl, pyrimidyl and thiazolyl. The definition of R5 and R6 is independent of the selection of X, Y, and Z. The place of attachment of R5 and optionally R6 to these heteroaryl rings follows from formula I.
[00076] The invention also relates to a compound according to a / 123 formula I in which R5 is selected from a group consisting of hydrogen, halogen, cyano, alkyl (1-4C), alkoxy (1-3C) and cycloalkyl (3-6C). All alkyl groups of R5 are optionally substituted with one or more halogens. In particular, the alkyl group (1-4C) in R5 is optionally substituted with one or more halogens.
[00077] In another aspect the invention relates to a compound according to formula I in which R5 is selected from a group consisting of hydrogen, fluorine, chlorine, alkyl (1-3C) and alkoxy (1-2C ), all R5 alkyl groups are optionally substituted with one or more halogens. In particular, the alkyl group (1-3C) in R5 is optionally substituted with one or more fluorine. Even more particularly, the invention relates to a compound according to formula I wherein R5 is hydrogen, fluorine, methyl, ethyl, propyl, methoxy or trifluoromethyl.
[00078] In yet another aspect the invention relates to a compound according to formula I wherein R5 is pyrrolidine or phenyl. [00079] In another aspect, the invention relates to a compound according to formula I in which R6 is hydrogen or alkyl (1-3C), preferably R6 is hydrogen.
[00080] In yet another aspect the invention relates to a compound according to formula I wherein R5 and R6 together form a cycloalkenyl (3-7C) or a heterocycloalkenyl (2-6C) both optionally substituted with alkyl ( 1-3C) or one or more halogens. In particular, cycloalkenyl groups (3-7C) are cyclohexenyl and cyclopentenyl. In particular, the heterocycloalkenyl groups (2-6C) are azacyclohexenyl and oxocyclohexenyl. Even more particularly, the invention relates to a compound according to formula I wherein the cycloalkenyl (3-7C) in R5 is cyclohexenyl.
[00081] In another aspect, the invention relates to a compound according to formula I wherein R2 is hydrogen or alkyl (1-3C). In / 123 in particular, R2 is hydrogen or methyl. R2 is hydrogen which are most preferred.
[00082] In yet another aspect the invention relates to a compound according to formula I wherein R3 is alkyl (1-6C). In particular, R3 is alkyl (1-3C). R3 is methyl which are most preferred.
[00083] In another aspect the invention relates to a compound according to formula I wherein R3 is cycloalkyl (3-7C).
[00084] In another aspect the invention relates to a compound according to formula I wherein R2 is hydrogen or alkyl (1-3C) and R3 is alkyl (1-6C). In particular, R2 is hydrogen or methyl and R3 is (13C) alkyl. Even more particularly, the invention relates to a compound according to formula I wherein R2 is hydrogen and R3 is methyl.
[00085] In yet another aspect the invention relates to a compound according to formula I wherein R2 or R3 are independently selected from a group consisting of cyclopropyl, cyclobutyl and cyclopentyl.
[00086] In another aspect the invention relates to a compound of the formula I in which R2 and R3 form, together with the N and C atom to which they are attached, a heterocycloalkyl (3-7C) optionally substituted with a or more halogens, hydroxyl, alkyl (1-3C). In particular, R2 and R3 form, together with the N and C atom to which they are attached, an azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl ring each optionally substituted with one or more halogens, hydroxyl, alkyl (1-3C ), alkoxy (1-3C) or oxo, the preferred halogen substituent being fluorine.
[00087] In yet another aspect the invention relates to a compound of the formula I in which, R2 and R3 form together with the atom N and C to which they are attached an azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl each optionally / 123 replaced with fluorine, hydroxyl, alkyl (1-3C), alkoxy (1-3C) or oxo. In particular, R2 and R3 together with the N and C atom to which they are attached form a pyrrolidinyl, piperidinyl, morpholinyl or homopiperidinyl ring.
[00088] In yet another aspect the invention relates to a compound according to formula I wherein, R1 is R11C (O) and R11 is alkyl (1-6C), alkenyl (2-6C) or alkynyl ( 2-6C) each optionally independently substituted with one or more groups selected from hydroxyl, alkyl (1-4C), cycloalkyl (3-7C), heterocycloalkyl (3-7C), [alkyl (14C)] amino, di [alkyl (1-4C)] amino, alkoxy (1-3C), cycloalkoxy (3-7C), aryl (6-10C), heteroaryl (1-5C) or alkyl (1-3C) -SC (O) - alkyl (1-3C). In particular, the heteroaryl group (1-5C) is pyrimidyl or triazinyl optionally substituted with one or more selected groups of halogen or cyano. In particular, heterocycloalkyl (3-7C) is pyrrolidinyl. Even more particularly, the invention relates to a compound according to formula I wherein the cycloalkyl (3-7C) substituent of R11 is cyclopropyl. In particular, the aryl substituent (6-10C) of R11 is phenyl.
[00089] In yet another aspect the invention relates to a compound according to formula I wherein, [00090] R1 is C (O) R11 and R11 is alkenyl (2-6C) or alkynyl (2-6C ) each optionally substituted with one or more groups selected from hydroxyl, alkyl (1-4C), cycloalkyl (3-7C), heterocycloalkyl (3-7C), (di) [alkyl (1-4C)] amino, alkoxy ( 1-3C) or cycloalkoxy (3-7C). In particular, the heterocycloalkyl (3-7C) substituent of R11 is pyrrolidinyl and the cycloalkyl (3-7C) substituent of R11 is cyclopropyl.
[00091] In another aspect the invention relates to a compound according to formula I wherein, R1 is C (O) R11 and R11 is alkenyl (2-4C) or alkynyl (2-4C) each optionally substituted with one or more selected groups of alkyl (1-4C), cycloalkyl (3-7C), heterocycloalkyl (3-7C), / 123 (di) [alkyl (1-4C)] amino or alkoxy (1-3C) . In particular, the heterocycloalkyl (3-7C) substituent of R11 is pyrrolidinyl and the cycloalkyl (3-7C) substituent is cyclopropyl. Even more particularly, R11 is alkenyl (2-4C) or alkynyl (2-4C) each optionally substituted with one or more groups selected from methyl, ethyl, cyclopropyl, pyrrolidinyl, dimethylamino, methoxy or ethoxy.
[00092] In another aspect the invention relates to compounds according to formula I in which R1 is C (O) R11 in which R11 is heteroaryl (15C) optionally substituted with one or more groups selected from halogen or cyano. In particular, the heteroaryl (1-5C) substituent is pyrimidyl or triazinyl, pyrimidyl rings being preferred, optionally substituted with one or more selected groups of halogen or cyano. In particular, the halogen substituent is chlorine.
[00093] In another aspect, the invention relates to compounds according to formula I in which R1 is R13SO2, in which R13 is alkenyl (2-6C) or alkynyl (2-6C). In particular, R13 is alkenyl (2-4C). Even more particularly, R13 is ethylene.
[00094] In another aspect, the invention relates to compounds according to formula I wherein R1 is R12S (O), where R12 is alkenyl (2-6C) or alkynyl (2-6C). In particular, R13 is alkenyl (2-4C). Even more particularly, R12 is ethylene.
[00095] In yet another aspect, the invention relates to compounds according to formula I wherein R1 is alkyl (1-3C) optionally substituted with R14 where R14 is alkenyl (2-4C) or alkynyl (2 -4C). [00096] In yet another aspect the invention relates to a compound according to formula I selected from the group consisting of (5) -4- (3- (1-Acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N (pyridin-2-yl) benzamide, (5, £ ') - 4- (8-amino-3- (1- (4- (pyrrolidin-1 -yl) but-2-enoyl) pyrrolidin-217/123 yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide, (5, £ ') - 4 - (8-Amino-3- (1- (4- (dimethylamino) but-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2-yl ) benzamide, (5, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N - (pyridin-2-yl) benzamide, (5) -4- (8-amino-3- (1- (2-chloropyrimidine-4-carbonyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1 -yl) -N- (pyridin-2-yl) benzamide, (5) -4- (8-amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin -1-yl) -N (pyridin-2-yl) benzamide, (5, £ ') - 4- (8-Amino-3- (1- (4- (dimethylamino) but-2-enoyl) pyrrolidin-2il ) imidazo [1,5-a] pyrazin-1-yl) -N- (4-fluoropyridin-2-yl) benzamide, (5) -4- (8-Amino-3- (1-but-2-inoylpyrrolidin - 2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (4-methylpyridin-2-yl) benzamide, (5, £ ') - 4- (8-Amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-propylpyridin-2-yl) benzamide, (5) -4- (8- Amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (4- (trifluoromethyl) pyridin-2-yl) benzamide, (5, £ ') - 4- (8-Amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-ethylpyridine -2-yl) benzamide, (5) -4- (8-Amino-3- (1-but-2-yoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N ( 4,5,6,7-tetrahydrobenzo [d] thiazol-2-yl) benzamide, (5) -4- (3- (1-Acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin -1-yl) -2fluoro-N- (pyridin-2-yl) benzamide, (5) -4- (3- (1-Acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin- 1-yl) -2methoxy-N- (pyridin-2-yl) benzamide, (5, £ ') - 4- (8-Amino-3- (1- (4- (dimethylamino) but-2-enoyl) pyrrolidin -2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (thiazol-2-yl) benzamide, (5, £ ') - 4- (8-Amino-3- (1- (4 -methoxybut-2-enoyl) piperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2-yl) ben zamide, / 123 (5) -4- (3- (1-Acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N- (4fluoropyridin-2-yl) benzamide , (5) -4- (3- (1-Acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N- (4cyanopyridin-2-yl) benzamide, (5 ) -4- (8-Amino-3- (1- (vinylsulfonyl) piperidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) N- (4- (trifluoromethyl) pyridin-2-yl ) benzamide, (5) -4- (3- (1-Acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N (pyrimidin-2-yl) benzamide, ( 5) -4- (3- (1-Acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N- (4methylpyrimidin-2-yl) benzamide, (5) - 4- (8-Amino-3- (1-but-2-yoylpiperidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (pyrimidin-4-yl) benzamide, (5) -4- (8-Amino-3- (1-but-2-inoylpiperidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (pyridazin-3-yl) benzamide, (5 ) -4- (8-Amino-3- (1-but-2-inoylpiperidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (isoxazol-3-yl) benzamide, ( 5, £ ') - 4- (8-Amino-3- (1- (4-methoxybut-2-enoyl) piperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (5 -ethylthiazol-2-yl) benzamide, (5) -4- (3- (1-Acryloylpiper idin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -2fluoro-N- (4-propylpyridin-2-yl) benzamide, (5, £ ') - 4- (8 -Amino-3- (1- (4- (dimethylamino) but-2-enoyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -2-methoxy-N- (4-propylpyridin- 2-yl) benzamide,
4- (8-Amino-3 - ((5) -1-but-2-yoylpiperidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -3methyl-N- (pyridin-2- il) benzamide,
4- (3- (Acrylamidomethyl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2yl) benzamide, (5) -4- (8-Amino-3- (1 -but-2-inamidoethyl) imidazo [1,5-a] pyrazin-1-yl) -N (pyridin-2-yl) benzamide, (5) -S-2- (2- (8-Amino-1- (4- (pyridin-2-ylcarbamoyl) phenyl) imidazo [1,5-a] pyrazin19 / 123
3-yl) pyrrolidin-1-yl) -2-oxoethyl ethananate, (5) -4- (8-Amino-3- (1- (4-hydroxy-4-methylpent-2-inoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide, (5) -4- (8-Amino-3- (1- (6-chloropyrimidine-4-carbonyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide, (5) -4- (8-Amino-3- (1-pent-2- inoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (pyridin-2-yl) benzamide, (5) -4- (8-Amino-3- (1- (3- cyclopropylpropioloyl) pyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide, (5) -4- (8-Amino-3- (1-hex- 2-inoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (pyridin-2-yl) benzamide,
4- (3- (1-Acryloylazepan-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2yl) benzamide, (Ã) -4- (8- Amino-3- (4-but-2-inoylmorpholin-3-yl) imidazo [1,5-a] pyrazin-1-yl) -N (pyridin-2-yl) benzamide, (5) -4- (8 -amino-3- (1- (N-methylbut-2-yamido) ethyl) imidazo [1,5-a] pyrazin-1-yl) N- (4- (trifluoromethyl) pyridin-2-yl) benzamide, ( 5) -4- (8-Amino-3- (1- (4- (dimethylamino) but-2-inoyl) pyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin -2-yl) benzamide, (5) -4- (8-Amino-3- (1- (4-methoxybut-2-yl) pyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide, (5) -4- (3- (1-acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N- (4fluoropyridin-2-yl) benzamide, (5) -4- (3- (1-acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N- (4 ( pyrrolidin-1-yl) pyridin-2-yl) benzamide, (5) -4- (8-amino-3- (1-but-2-inoylpiperidin-2-yl) imidazo [1,5-a] pyrazin- 1-yl) -N (4-fluoropyridin-2-yl) benzamide, (5) -4- (8-amino-3- (1-but-2-inoylpiperidin-2-yl) imidazo [1,5-a ] pyrazin-1-yl) -N (pyridin-2-yl) benzamide, / 123 (5) -4- (3- (1-acryloylpip eridin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N (pyridin-2-yl) benzamide, (5) -4- (8-amino-3- (1- but-2-inoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (4-propylpyridin-2-yl) benzamide, (5, £) -4- (8-amino- 3- (1- (4-methoxy-N-methylbut-2-enamido) ethyl) imidazo [1,5a] pyrazin-1-yl) -N- (4-propylpyridin-2-yl) benzamide, (5) - 4- (8-amino-3- (1- (vinylsulfonyl) piperidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) N - (4-propylpyridin-2-yl) benzamide, (5 ) -4- (8-amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -2fluoro-N - (pyridin-2-yl) benzamide, (5, £ ') - 4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N - (4-methoxypyridin-2-yl) benzamide, (5, £ ') - 4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2-yl) imidazo [1, 5a] pyrazin-1-yl) -2-fluoro-N- (4-methoxypyridin-2-yl) benzamide, (5, £ ') - 4- (8-amino-3- (1- (4-methoxybutyl- 2-enoyl) pyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-fluoropyridin-2-yl) benzamide, (5, £ ') - 4- (8-amino- 3- (1- (4-methoxybut-2-enoyl) piperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N - (isoxazol-3-yl) benzamide, (5, £ ') - 4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyrimidin-2-yl) benzamide,
4- (8-amino-3 - ((5) -1- (2-chloropyrimidine-4-carbonyl) piperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -3-methyl-N- (pyridin-2-yl) benzamide, (5, £ ') - 4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2-yl) imidazo [1,5a] pyrazin -1-yl) -N- (4-methylpyridin-2-yl) benzamide, (5, £ ') - 4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2 -yl) imidazo [1,5a] pyrazin-1 -yl) -N- (4-isopropylpyridin-2-yl) benzamide, (5, £ ') - 4- (8-amino-3- (1- (4 - (dimethylamino) but-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4-methylpyridin-2-yl) benzamide, (5) -4- (8 -amino-3- (1-but-2-yoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N21 / 123 (thiazol-2-yl) benzamide, (5) -4 - (3- (1-acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N- (4propylpyridin-2-yl) benzamide, (5) -4- (3 - (1-acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N- (4 (trifluoromethyl) pyridin-2-yl) benzamide, (5) -4- ( 8-amino-3- (1-but-2-yoylpiperidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (4- (trifluoromethyl) pyridin-2-yl) benzamide, ( 5) -4- (8-amino-3- (1-but-2-yoylpiperidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (4-propylpyridin-2-yl) benzamide, (5, £) -4- (8-amino-3- (1- (4- (dimethylamino ) but-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4-isopropylpyridin-2-yl) benzamide,
4- (8-amino-3 - ((5) -1- (vinylsulfonyl) piperidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) 3-methyl-N- (pyridin-2- yl) benzamide, (5) -4- (8-amino-3- (1-but-2-yoylpiperidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -2fluoro-N- ( 4-propylpyridin-2-yl) benzamide,
4- (3 - ((5) -1-acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -3-methylN- (pyridin-2-yl) benzamide, ( £) -4- (8-amino-3 - ((4- (dimethyl amino) but-2-enamido) methyl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide, (5) -4- (8-amino-3- (1- (2-chloropyrimidine-4-carbonyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4 -isopropylpyridin-2-yl) benzamide, (5) -4- (8-amino-3- (1- (2-chloropyrimidine-4-carbonyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1- yl) -N- (4,5,6,7-tetrahydrobenzo [d] thiazol-2yl) benzamide, (5, £ ') - 4- (8-amino-3- (1- (4-methoxybut-2- enoyl) piperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridazin-3-yl) benzamide, (5, £ ') - 4- (8-amino-3- (1 - (4- (dimethylamino) but-2-enoyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridazin-3-yl) benzamide, (5) -4- ( 8-amino-3- (1- (2-chloropyrimidine-4-carbonyl) piperidin-2-yl) imidazo [1,522 / 123
a] pyrazin-1-yl) -N- (pyridazin-3-yl) benzamide, (5, £ ') - 4- (8-amino-3- (1- (4-methoxy-N-methylbut-2- enamido) ethyl) imidazo [1,5a] pyrazin-1-yl) -N- (4- (trifluoromethyl) pyridin-2-yl) benzamide, (5, £) -4- (8-amino-3- (1 - (4- (dimethylamino) -N-methylbut-2enamido) ethyl) imidazo [1,5-a] pyrazin-1-yl) -N- (4-propylpyridin-2-yl) benzamide, (5, £ ') -4- (8-amino-3- (1- (4- (pyrrolidin-1-yl) but-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4-propylpyridin-2-yl) benzamide, (5, £ ') - 4- (8-amino-3- (1- (4- (dimethylamino) but-2-enoyl) piperidin-2yl) imidazo [1, 5-a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide, (5) -4- (8-amino-3- (1- (2-chloropyrimidine-4-carbonyl) pyrrolidin-2il ) imidazo [1,5-a] pyrazin-1-yl) -N- (4-propylpyridin-2-yl) benzamide, (5) -4- (8-amino-3- (1- (2-chloropyrimidine- 4-carbonyl) piperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-fluoropyridin-2-yl) benzamide, (5, £) -4- (8-amino-3 - (1- (4-methoxybut-2-enoyl) piperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-fluoropyridin-2-yl) benzamide, (5, £ ' ) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2- il) imidazo [1,5a] pyrazin-1-yl) -N- (4,5,6,7-tetrahydrobenzo [d] thiazol-2-yl) benzamide, (5) -4- (8-amino-3 - (1- (2-chloropyrimidine-4-carbonyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -2-methoxy-N- (pyridin-2-yl) benzamide, (5) -4- (8-amino-3- (1- (2-chloropyrimidine-4-carbonyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -2-fluoro-N- (pyridin- 2-yl) benzamide,
4- (8-amino-3 - ((5) -1 - ((£) -4-methoxybut-2-enoyl) piperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -3- methyl-N- (pyridin-2-yl) benzamide, (5, £ ') - 4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidin-2-yl) imidazo [1 , 5a] pyrazin-1-yl) -N- (pyrimidin-4-yl) benzamide,
4- (8-amino-3 - ((5) -1 - ((£) -4-methoxybut-2-enoyl) pyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -3- methyl-N- (4-propylpyridin-2-yl) benzamide, (5, £ ') - 4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-methylpyrimidin-2-yl) benzamide, / 123 (5) -4- (8-amino-3- (1-but-2-inoylpiperidin-2 -yl) imidazo [1,5-a] pyrazin-1-yl) -N (4-methylpyrimidin-2-yl) benzamide, (5) -4- (8-amino-3- (1- (2-chloropyrimidine -4-carbonyl) piperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyrimidin-2-yl) benzamide, (5) -4- (8-amino-3- (1 -methacryloylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (pyridin-2-yl) benzamide, (S) -4- (8-amino-3- (1- (2 - (trifluoromethyl) acryloyl) pyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide, (5, £) -4- (8-amino-3 - (1-but-2-enoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) N- (pyridin-2-yl) benzamide, (5) -4- (8-amino- 3- (1- (cyanomethyl) pyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (pyridin-2-yl) benzamide, (£) -4- (8-amino- 3 - (((4-methoxybut-2-enamido) methyl) imidazo [1,5-a] pyrazin-1-yl) N- (pyridine n-2-yl) benzamide, (5) -4- (8-amino-3- (1-but-2-yoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (4- (pyrrolidin-1-yl) pyridin-2-yl) benzamide, (£) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) azepan-2-yl) imidazo [1,5-a] pyrazin1-yl) -N- (pyridin-2-yl) benzamide, (5, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-cyanopyridin-2-yl) benzamide, (5) -4- (8-amino-3- (1-but- 2-inoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -2methoxy-N- (pyridin-2-yl) benzamide, (5) -4- (3- (1-acrylamidoethyl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2yl) benzamide, (5) -4- (3- (1-acryloylpyrrolidin-2-yl) -8-aminoimidazo [ 1,5-a] pyrazin-1-yl) -N (thiazol-2-yl) benzamide, (5) -4- (8-amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (4-isopropylpyridin-2-yl) benzamide, (5, £ ') - 4- (8-amino-3- (1- (4-methoxybutyl- 2-enoyl) pyrrolidin-2-yl) imidazo [1,524 / 123
a] pyrazin-1-yl) -2-methoxy-N- (pyridin-2-yl) benzamide, (5, £ ') - 4- (8-amino-3- (1-cinamoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (pyridin-2-yl) benzamide, (5) -N- (1- (8-amino-1- (4- (pyridin-2-ylcarbamoyl) phenyl) imidazo [1,5-a] pyrazin-3yl) ethyl) -2-chloropyrimidine-4-carboxamide, (5) -4- (8-amino-3- (1-but-2-inoylpyrrolidin-2-yl ) imidazo [1,5-a] pyrazin-1-yl) -N (4-fluoropyridin-2-yl) benzamide, (5) -4- (8-amino-3- (1- (2-chloropyrimidine-4 -carbonyl) piperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-propylpyridin-2-yl) benzamide, (5, £ ') - 4- (8-amino-3 - (1- (4-methoxybut-2-enoyl) piperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4- (trifluoromethyl) pyridin-2-yl) benzamide, (5 ) -4- (3- (1-acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N- (4 (trifluoromethyl) pyridin-2-yl) benzamide, ( 5) -4- (8-amino-3- (1-but-2-inoylpiperidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -2methoxy-N- (4-propylpyridin-2 -yl) benzamide, (5, £ ') - 4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidin-2-yl) imidazo [1,5a] pyrazin-1-yl ) -2-methoxy-N- (4-propylpyridin-2-yl) be nzamide, 4- (8-amino-3- (but-2-inamidomethyl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2yl) benzamide, (5) -4- (8 -amino-3- (1- (N-methylbut-2-yamido) ethyl) imidazo [1,5-a] pyrazin-1-yl) N- (4-propylpyridin-2-yl) benzamide, (5, £ ') -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -2-fluoro-N- ( 4-propylpyridin-2-yl) benzamide, (5) -4- (8-amino-3- (1- (2-chloropyrimidine-4-carbonyl) piperidin-2-yl) imidazo [1,5a] pyrazin-1 -yl) -N- (4- (trifluoromethyl) pyridin-2-yl) benzamide, (5) -4- (8-amino-3- (1-but-2-inoylpiperidin-2-yl) imidazo [1, 5-a] pyrazin-1-yl) -N (5-ethylthiazol-2-yl) benzamide, (5) -4- (3- (1-acryloylpiperidin-2-yl) -8-aminoimidazo [1,5- a] pyrazin-1-yl) -N- (5ethylthiazol-2-yl) benzamide, / 123 (5) -4- (8-amino-3- (1- (2-chloropyrimidine-4-carbonyl) piperidin-2 -yl) imidazo [1,5a] pyrazin-1-yl) -N- (5-ethylthiazol-2-yl) benzamide, (5) -4- (8-amino-3- (1- (2-chloropyrimidine- 4-carbonyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4- (trifluoromethyl) pyridin-2-yl) benzamide, (R, £) -4- (8- amino-3- (4- (4-methoxybut-2-enoyl) mo rfolin-3-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide, (5, £) -4- (8-amino-3- (1- (4 -methoxybut-2-enoyl) piperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-propylpyridin-2-yl) benzamide, (5) -4- (3- (1 -acrylylpyrrolidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N- (4cyanopyridin-2-yl) benzamide, (5) -4- (8-amino-3- ( 1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (4-methoxypyridin-2-yl) benzamide, (5) -4- (3- (1 -acrylylpyrrolidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N- (4methylpyridin-2-yl) benzamide, (5) -4- (3- (1-acryloylpyrrolidin- 2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N- (4propylpyridin-2-yl) benzamide, (5) -4- (3- (1-acryloylpyrrolidin-2-yl ) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N- (4ethylpyridin-2-yl) benzamide, (5, £ ') - 4- (8-amino-3- (1- ( 4- (dimethylamino) but-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide, (5, £ ') - 4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4- (trifluoromethyl) pyridin-2- yl) benzamide, (5) -4- (8-amino-3- (1- (2-c loropyrimidine-4-carbonyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4-methylpyridin-2-yl) benzamide, (5) -4- (8-amino-3 - (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (4-cyanopyridin-2-yl) benzamide, (5) -4- (8- amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (4-ethylpyridin-2-yl) benzamide, (5) -4- (8-amino-3- (1-but-2-yoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N26 / 123 (4-phenylpyridin-2-yl) benzamide, and (5) -4- (3- (1-acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N- (4phenylpyridin-2-yl) benzamide.
[00097] The invention also relates to those compounds in which all the specific definitions of R1 through R14 and all the substituent groups in the various aspects of the inventions defined hereinbefore occur in any combination within the definition of the fused pyridine ring compounds. 6 to 5 members ie 8-amino-imidazo [1,5-a] pyrazine and 4 amino-imidazo [1,5-f] [1,2,4] triazine compounds of formula I.
[00098] The 6- to 5-membered fused pyridine ring compounds like the 8-amino-imidazo [1,5-a] pyrazine and 4-amino-imidazo [1,5f] [1,2,4] triazine compounds of the invention inhibit Btk kinase activity. All compounds of the invention have an EC50 of 10 μΜ or lower.
[00099] In another aspect the invention relates to compounds of formula I that have an EC50 of less than 100 nM. In yet another aspect, the invention relates to compounds of formula I that have an EC 50 of less than 10 nM.
[000100] The term EC50 means the concentration of the test compound that is required for 50% inhibition of its maximum effect in vitro.
[000101] Inhibition of kinase activity can be measured using the Immobilized Metal Assay for testing phosphochemicals (IMAP). IMAP is a homogeneous fluorescence polarization (FP) assay based on the affinity capture of phosphorylated peptide substrates. IMAP uses peptide substrates labeled with fluorescein which, in phosphorylation by a protein kinase, binds to the so-called IMAP nanoparticles, which are derived with trivalent metal complexes. The binding causes a change in the rate of molecular movement of the peptide, and results in an increase in the observed FP value for the fluorescein label attached to the substrate peptide (Gaudet et al. A homogeneous fluorescence polarization assay / 123 adaptable for a range of protein serine / threonine and tyrosine kinases. J. Biomol. Screen (2003) 8, 164-175).
[000102] The compounds of Formula I can form salts that are also within the scope of this invention. Reference to a compound of Formula (I) herein is understood to include reference to its salts, unless otherwise indicated. The term "salt (s)", as used herein, indicates acid salts formed with inorganic and / or organic acids, as well as basic salts formed with inorganic and / or organic bases. In addition, when a compound of Formula (I) contains both a basic portion, such as, but not limited to a pyridine or imidazole, and an acidic portion, such as, but not limited to a carboxylic acid, zwitterions (“internal salts ”) Can be formed and are included within the term“ salt (is) ”as used herein. Such acidic and basic salts used within the scope of the invention are pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable salts). The salts of the compounds of Formula (I) can be formed, for example, by reacting a compound of Formula (I) with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitate or in an aqueous medium followed by lyophilization. [000103] Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, bromidides, iodides, lactates, maleates, methanesulfonates, oxhthalenes , phosphates, propionates, salicylates, succinates, sulphates, tartrates, thiocyanates, toluenesulfonates (also known as tosylates) and the like. In addition, acids that are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al, / 123
Journal of Pharmaceutical Sciences (1977) 66 (1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and The Orange Book (Food & Drug Administration, Washington, D.C. on its website). These descriptions are hereby incorporated by reference.
[000104] Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines ) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups can be quarternized with agents such as lower alkyl halides (for example, methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (for example, dimethyl, diethyl, and dibutyl sulfates) ), long chain halides (for example, decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (for example, benzyl and phenethyl bromides), and others.
[000105] The compounds of Formula I can contain asymmetric or chiral centers, and therefore exist in stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of Formula I as well as their mixtures, including racemic mixtures, form part of the present invention. In addition, the present invention encompasses all geometric and positional isomers. For example, if a compound of Formula (I) incorporates a double bond or a fused ring, both the cis and trans forms, as well as mixtures, are included within the scope of the invention. [000106] Diastereomeric mixtures can be separated into their individual diastereomers based on their physical-chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and / or fractional crystallization. Enantiomers can be separated by converting the enantiomeric / 123 mixture to a diastereomeric mixture by reacting with an appropriate optically active compound (eg, chiral auxiliary such as a chiral alcohol or Mosher acid chloride), separating the diastereomers and converting (by hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, some of the compounds of Formula I can be atropisomers (for example, substituted biaryls) and are considered to be part of this invention. Enantiomers can also be separated by using the chiral HPLC column.
[000107] It is also possible that the compounds of Formula I may exist in different tautomeric forms, and all such forms are included within the scope of the invention. Also, for example, all forms of keto-enol and imine-enamine of the compounds are included in the invention.
[000108] All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs ), such as those that may exist due to asymmetric carbons in various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are considered to be within the scope of this invention, as o are positional isomers. The individual stereoisomers of the compounds of the invention, for example, can be substantially free of other isomers, or they can be mixed, for example, as racemates or with all the others, or other selected stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by IUPAC 1974 Recommendations. The use of the terms "salt", "solvate", "ester", "prodrug" and the like, is intended to apply equally to salt, solvate, ester and enantiomer prodrug, / 123 stereoisomers, rotamers , tautomers, positional isomers, racemates or prodrugs of the inventive compounds.
[000109] A pro-drug debate is provided in T. Higuchi and V. Stella, Pro-Drugs As Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press. The term "prodrug" means a compound (e.g., a drug precursor) that is transformed in vivo to produce a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound. Transformation can occur by several mechanisms (for example by the metabolic or chemical processes), such as, for example, through hydrolysis in the blood. A debate on the use of pro-drugs is provided by T. Higuchi and W. Stella, “Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
[000110] The compounds of the invention can form hydrates or solvates. It is known to those of skill in the art that the charged compounds form hydrated species when lyophilized with water, or form solvated species when concentrated in a solution with an appropriate organic solvent. The compounds of this invention include the hydrates or solvates of the compounds listed.
[000111] One or more compounds of the invention can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and the invention is intended to encompass both solvated and unsolvated forms. "Solvate" means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain cases the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated into the crystalline lattice of the crystalline solid. “Solvate” covers both the solution phase and isolable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. "Hydrate" is a solvate in which the solvent molecule is H2O.
[000112] The present invention also relates to a pharmaceutical composition comprising the 6 to 5-membered fused pyridine ring compounds as the imidazopyrazine and imidazotriazine compounds or pharmaceutically acceptable salts thereof having the general formula I in admixture with auxiliaries pharmaceutically acceptable and optionally other therapeutic agents. The auxiliaries must be "acceptable" in the sense that they are compatible with the other ingredients of the composition and not harmful to their recipients.
[000113] The invention further includes a compound of formula I in combination with one or more other drugs.
[000114] The compositions include, for example, those suitable for oral, sublingual, subcutaneous, intravenous, intramuscular, nasal, local, or rectal administration, and the like, all in oral dosage forms for administration.
[000115] For oral administration, the active ingredient can be presented as separate units, such as tablets, capsules, powders, granules, solutions, suspensions, and the like.
[000116] For parenteral administration, the pharmaceutical composition of the invention can be presented in unit dose or multiple dose containers, for example, injection liquids in predetermined quantities, for example in sealed vials and ampoules, and can also be stored in a condition freeze dried which requires only the addition of a sterile liquid carrier, for example water, before use.
/ 123 [000117] Mixed with such pharmaceutically acceptable auxiliaries, for example as described in the standard reference, Gennaro, AR et al., Remington: The Science and Practice of Pharmacy (20th Edition., Lippincott Williams & Wilkins, 2000, see especially the Part 5: Pharmaceutical Manufacturing), the active agent can be compressed into solid dosage units, such as pills, tablets, or processed into capsules or suppositories. By means of pharmaceutically acceptable liquids the active agent can be applied as a fluid composition, for example as an injection preparation, in the form of a solution, suspension, emulsion, or as a spray, for example a nasal spray.
[000118] To manufacture solid dosage units, the use of conventional additives such as fillers, dyes, polymeric binders and the like is considered. In general any pharmaceutically acceptable additive that does not interfere with the function of the active compounds can be used. Suitable carriers with which the active agent of the invention can be administered as solid compositions include lactose, starch, cellulose derivatives and the like, or mixtures thereof, used in suitable amounts. For parenteral administration, aqueous suspensions, isotonic saline solutions and sterile injectable solutions can be used, which contain pharmaceutically acceptable dispersing agents and / or wetting agents, such as propylene glycol or butylene glycol.
[000119] The invention further includes a pharmaceutical composition, as described above, in combination with packaging material suitable for said composition, said packaging material including instructions for using the composition for use as described above.
[000120] The exact dose and regime of administration of the active ingredient, or a pharmaceutical composition thereof, may vary with the particular compound, the route of administration, and the age and condition of the individual individual to whom the drug is to be administered.
/ 123 [000121] In general, parenteral administration requires lower dosages than other methods of administration that are more dependent on absorption. However, a dosage for humans preferably contains from 0.0001 to 25 mg per kg of body weight. The desired dose can be presented as one dose or as multiple sub-doses administered at appropriate intervals throughout the day, or, in the case of female recipients, as doses to be administered at appropriate daily intervals throughout the menstrual cycle. The dosage as well as the administration regimen may differ between a female and a male recipient.
[000122] In the compounds of the generic Formula I, atoms can exhibit their natural isotopic abundances, or one or more of the atoms can be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from atomic mass or mass number predominantly found in nature. The present invention is intended to include all suitable isotopic variations of the compounds of generic Formula I. For example, isotopic forms other than hydrogen (H) include protium (H) and deuterium (H). Procium is the predominant hydrogen isotope found in nature. Deuterium enrichment can provide certain therapeutic advantages, such as increased in vivo half-life or reduced dosage requirements, or it can provide a compound useful as a standard for the characterization of biological samples. The isotopically enriched compounds within the generic Formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples here using appropriate isotopically enriched reagents and / or intermediates.
[000123] The compounds according to the invention can be used in therapy.
[000124] Another aspect of the invention resides in the use of fused pyridine ring compounds of 6 to 5 members or a pharmaceutically acceptable salt thereof, having general formula I for the manufacture of a medicament to be used for the treatment of diseases mediated by Btk or conditions mediated by Btk.
[000125] Another aspect of the invention resides in the use of 6 to 5-membered fused pyridine ring compounds or a pharmaceutically acceptable salt thereof having general formula I for the manufacture of a medicament to be used for the treatment of disorders of chronic B cell in which T cells play a prominent role.
[000126] In yet another aspect the invention resides in the use of 6 to 5-membered fused pyridine ring compounds such as the 8-amino-imidazo [1,5-a] pyrazine and 4-amino-imidazo [1 , 5-f] [1,2,4] triazine having the general formula I for the manufacture of a medicine to be used for the treatment of diseases or conditions mediated by Btk. These include, but are not limited to, the treatment of B-cell lymphomas that result from signaling the chronic active B-cell receptor.
[000127] Thus, the compounds according to the invention can be used in therapies to treat or prevent diseases or disorders mediated by Bruton's Tyrosine Kinase (Btk). Btk-mediated disorders or Btk-mediated condition as used herein, means any disease state or other deleterious condition in which B cells, mastoids, myeloid cells or osteoclasts play a central role. These diseases include, but are not limited to, immune, autoimmune and inflammatory diseases, allergies, infectious diseases, bone resorption disorders and proliferative diseases.
[000128] The immune, autoimmune and inflammatory diseases that can be treated or prevented with the compounds of the present invention include / 123 rheumatic diseases (e.g., rheumatoid arthritis, psoriatic arthritis, infectious arthritis, progressive chronic arthritis, deforming arthritis, osteoarthritis, arthritis traumatic, gouty arthritis, Reiter's syndrome, polychondritis, acute synovitis and spondylitis), glomerulonephritis (with or without nephrotic syndrome), autoimmune haematological disorders (for example, hemolytic anemia, aplastic anemia, idiopathic thrombocytopenia, and neutropenia), autoimmune gastritis, and autoimmune inflammatory bowel diseases (eg, ulcerative colitis and Crohn's disease), host versus graft disease, allograft rejection, chronic thyroiditis, Graves' disease, scleroderma, diabetes (type I and type II), active hepatitis (acute and chronic), pancreatitis, primary biliary cirrhosis, myasthenia gravis, multiple sclerosis, systemic lupus erythematosus psoriasis, atopic dermatitis, contact dermatitis, eczema, sunburn of the skin, vasculitis (eg Behcet's disease), chronic kidney failure, Stevens-Johnson syndrome, inflammatory pain, idiopathic psilosis, cachexia, sarcoidosis, syndrome Guillain-Barré, uveitis, conjunctivitis, conjunctivitis keratitis, otitis media, periodontal disease, interstitial pulmonary fibrosis, asthma, bronchitis, rhinitis, sinusitis, pneumoconiosis, pulmonary insufficiency syndrome, pulmonary emphysema, pulmonary fibrosis, silicosis, chronic inflammatory lung disease (by chronic obstructive pulmonary disease) and other inflammatory or obstructive airways diseases.
[000129] Allergies that can be treated or prevented include, but are not limited to, food allergies, food additives, insect venom, dust mites, pollen, animal materials and contact allergens, type I allergic hypersensitivity asthma, allergic rhinitis , allergic conjunctivitis. [000130] Infectious diseases that can be treated or prevented include, but are not limited to, septicemia, septic shock, endotoxic shock, Gram negative bacteria septicemia, shigellosis, meningitis, cerebral malaria, pneumonia, tuberculosis, viral myocarditis, viral hepatitis (hepatitis A , hepatitis B and hepatitis C), HIV infection, retinitis caused by / 123 cytomegalovirus, influenza, herpes, treatment of infections associated with severe burns, myalgia caused by infections, cachexia secondary to infections, and veterinary viral infections such as lentivirus, viruses goat arthritic, visna-maedi virus, feline immunodeficiency virus, bovine immunodeficiency virus or canine immunodeficiency virus.
[000131] Bone resorption disorders that can be treated or prevented include, but are not limited to, osteoporosis, osteoarthritis, traumatic arthritis, gouty arthritis and bone disorders related to multiple myeloma. [000132] Proliferative diseases that can be treated or prevented include, but are not limited to, non-Hodgkin's lymphoma (in particular the subtypes of large diffuse B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL)), chronic lymphocytic leukemia cell B chronic lymphocytic leukemia and acute lymphoblastic leukemia (ALL) with mature B cell, ALL in particular.
[000133] In particular the compounds of the invention can be used for the treatment of B-cell lymphomas that result from signaling the chronic active B-cell receptor.
[000134] Inhibition of kinase activity can be measured using the immobilized metal assay for testing phosphochemicals (IMAP). IMAP is a homogeneous fluorescence polarization (FP) assay based on the affinity capture of phosphorylated peptide substrates. IMAP uses peptide substrates labeled with fluorescein which, in phosphorylation by a protein kinase, bind to nanoparticles called IMAP, which are derived with trivalent metal complexes. The binding causes a change in the rate of molecular movement of the peptide, and results in an increase in the observed FP value for the fluorescein label attached to the substrate peptide.
[000135] Btk activity can also be determined in B cell lines such as Ramos cells or in primary cell / 123 assays, for example, PBMC or whole human, monkey, rat or mouse blood or splenocytes isolated from monkey, rat or mouse. Inhibition of Btk activity can be investigated by measuring the production of MIP1P induced by anti-IgM (Ramos, PBMC, splenocytes), Btk induced by H ₂ O ₂ and PLCy2 phosphorylation (Ramos cells), or B cell proliferation induced by anti-IgM or CD86 expression in primary B cells (PBMC and splenocytes).
[000136] Regulation of Btk activity can also be determined in human, monkey, rat or mouse mastoids following activation of FcsR-induced degranulation, cytokine production and CD63-induced cell surface expression.
[000137] In addition, the regulation of Btk activity can be determined in CD14 + monocytes differentiated after treatment with M-CSF for osteoclasts and activated with RANKL.
[000138] The activity of Btk inhibitors can be investigated in mouse splenocytes following administration in vivo. In a typical experiment, mice can be euthanized 3 h after administration of the compound. Spleens can be extracted from mice treated for splenocyte isolation. Splenocytes can be plated on 96 well culture plates and stimulated with anti-IgM, without further compound addition. B-cell stimulation induced by anti-IgM and its inhibition by Btk inhibitors can be measured by B cell proliferation, MIP1P production or CD86 expression in CD19 + splenocyte B cells.
[000139] The efficacy of Btk inhibitors can also be investigated in the mouse collagen-induced arthritis model using a therapeutic protocol with initiation of treatment following disease onset, measurement of disease count, X-ray analysis of destruction bone, cartilage rupture and joint histology.
/ 123 [000140] The effectiveness of Btk inhibitors on the regulation of activated mastoids can be investigated in vivo using the passive cutaneous anaphylaxis model.
[000141] The effect of Btk inhibitors on bone resorption in vivo can be investigated using the rat OVX model. In this model, ovariectomized animals develop osteoporosis symptoms that can be regulated using a Btk inhibitor.
General Synthesis [000142] The 8-amino-imidazo [1,5-a] pyrazine and 4 amino-imidazo [1,5-f] [1,2,4] triazine derivatives of the present invention can be prepared by the well-known methods in the technique of organic chemistry. See, for example, J. March, "Advanced Organic Chemistry 4th edition, John Wiley and Sons. During synthetic sequences it may be necessary and / or desirable to protect sensitive or reactive groups in any of the molecules involved. This is achieved by means of conventional protection groups, such as those described in TW Greene and PGM Wutts 'Protective Groups in Organic Synthesis' 3rd Edition, John Wiley and Sons, 1999. Protection groups are optionally removed at a convenient subsequent stage using methods well known in the art.
[000143] The reaction products are optionally isolated and purified, if desired, using conventional techniques, but not limited to, filtration, distillation, crystallization, chromatography and the like. Such materials are optionally characterized using conventional means, which include physical constants and spectral data.
[000144] The 8-amino-imidazo [1,5-a] pyrazine compounds of formula I, in which R ₁ -R ₅ have the meanings precisely defined, can be prepared by the general synthetic route shown in scheme I.
12/39
Scheme I [000145] The reduction of 3-chloropyrazine-2-carbonitrile (II) can be accomplished by hydrogenation in the presence of a system of suitable catalysts and solvent, for example Raney Nickel to provide (3chloropyrazin-2-yl) methanamine (III). This can then be reacted with an appropriately protected amino acid in the amine. The CbzN (R ₂ ) CR ₃ R4) COOH reaction can be carried out in a solvent such as DMF, THF or DCM in the presence of a base such as DIPEA, Nmethylmorpholine, 4-DMAP or triethylamine and in the presence of a binding reagent such as PyBOP, TBTU, EDCI or HATU to form the N - ((3chloropyrazin-2-yl) methyl) amide IV. Cyclopyridine IV cyclization can be performed using condensation reagents such as phosphorous oxychloride under heating conditions to provide the 8-chloroimidazo [1,5-a] pyrazine derivatives. Subsequent bromination can be performed using bromine or N-bromosuccinamide in a solvent suitable as DCM or DMF at the appropriate temperature to obtain the compounds of formula VI. The derivatives of 8-aminoimidazo [1,5-a] pyrazine (VII) can be prepared from compounds VI using ammonia (gas) in isopropanol at elevated temperature in a pressure vessel (> 4 atm). The compounds of formula IX can be prepared from the compounds of formula VII using an appropriate boronic acid or pinacol ester (VIII), in the presence of a suitable palladium catalyst system and solvent, for example bis (diphenylphosphine chloride) complex ) -ferrocene palladium (II) or tetracis (triphenylphosphino) palladium (0) in the presence of potassium carbonate, in dioxane / water provides the compounds of formula IX. Finally, cleaving the protective group of compounds with formula IX gives the unprotected amine which after functionalization, using methods well known in the art, with appropriate warheads with the meanings previously defined, provided the compounds of formula I. An example of such a protective strategy is the use of the benzyloxycarbonyl protecting group to protect the amine from the amino acids used, and then deprotection with 33% HBr / HOAc or HCl conc. gave the resulting amines.
[000146] The amino acids HN (R ₂ ) CR ₃ R ₄ ) COOH are commercially available or they can be easily prepared using methods well known to the qualified organic chemist, to introduce protecting groups such as benzyloxycarbonyl or tert-butyloxycarbonyl.
[000147] Palladium catalysts and the conditions for forming pinacol esters or for binding boronic acids or pinacol esters with 1-bromoimidazo [1,5-a] pyrazin-8-amine are well known to the qualified organic chemist - see, for example, Ei-ichi Negishi (Editor), Armin de Meijere (Associate Editor), Handbook of Organopalladium Chemistry for Organic Synthesis, John Wiley and Sons, 2002.
[000148] The 4-amino-imidazo [1,5-f] [1,2,4] triazine compounds of formula I, in which R ₁ -R ₅ have the meanings previously defined, can be prepared by the general synthetic route shown in scheme II / 123
XIV XV XVI
Scheme II [000149] The starting material 3-amino-6- (aminomethyl) -1,2,4-triazin5 (4H) -one X can be prepared by means of a condensation reaction of ethyl bromopyruvate, dibenzylamine, and aminoguanidine carbonate, followed by debenzylation via hydrogenation in a Pd-C catalyst [Mitchel, WL et al, J. Heterocycl. Chem. 21 (1984) p. 697]. This can then be reacted with an appropriately protected amino acid in the amine. The CbzN (R ₂ ) CR ₃ R ₄ ) COOH reaction can be carried out in a solvent such as DMF, THF or DCM in the presence of a base such as DIPEA, Nmethylmorpholine, 4-DMAP or triethylamine and in the presence of a linkage such as PyBOP, TBTU, EDCI or HATU to form N - (((3 amino-5-oxo-4,5- dihydro-,2,2- triazin-6-yl) methyl) amide XI. The cyclization of amino-triazinone XI can be performed using condensation reagents such as phosphorous oxychloride under heating conditions to provide 2-aminoimidazo derivatives [1,5 - /] [1,2,4] triazin-4 (3H) - ona XII. Subsequent iodination can be carried out using iodine or Niodosuccinimide in a suitable solvent such as DCM or DMF at the appropriate temperature to obtain the compounds of Formula XIII. The removal of the 2-amino group in the 2-aminoimidazo derivatives [1,542 / 123
f] [1,2,4] triazin-4 (3H) -one XIII can be performed using tbutyl nitrite in solvents such as DMF / THF at room temperature to form the imidazo derivatives [1,5-f] [1, 2.4] triazin-4 (3H) -one XIV. The 4-amino-imidazo [1,5-f] [1,2,4] triazine derivatives XV can be prepared from compounds XIV using phosphorous oxychloride, 1,2,4-triazole in pyridine and subsequent ammonolysis with ammonia (gas) in isopropanol at room temperature. Formula XVI compounds can be prepared from Formula XV compounds using an appropriate boronic acid or pinacol ester (VIII), in the presence of a suitable palladium catalyst system and solvent, for example bis (diphenylphosphine chloride) complex ) ferrocene palladium (II) or yeirac / 5 (triphenylphosphine) palladium (0) in the presence of potassium carbonate in dioxane / water provide compounds of the formula XVI. Finally, the cleavage of the protection group of the compounds with Formula XVI gives the unprotected amine which, after functionalization, using methods well known in the art, with appropriate arrowheads with the meanings previously defined, provided the compounds of Formula I An example of such a protective strategy is the use of the benzyloxycarbonyl protecting group to protect the amine from the amino acids used, and after deprotection with 33% HBr / HOAc or HCl conc. gave the resulting amines.
[000150] The amino acids HN (R ₂ ) CR ₃ R ₄ ) COOH are commercially available or they can be easily prepared using methods well known to the qualified organic chemist, to introduce protecting groups such as benzyloxycarbonyl or ich-butyloxycarbonyl.
[000151] Palladium catalysts and the conditions for forming pinacol esters or for binding boronic acids or pinacol esters with 5-iodoimidazo [1,5-f] [1,2,4] triazin-4-amine are well known to the qualified organic chemist - see, for example, Ei-ichi Negishi (Editor), / 123
Armin de Meijere (Associate Editor), Handbook of Organopalladium Chemistry for Organic Synthesis, John Wiley and Sons, 2002.
[000152] The present invention also includes within its scope all stereoisomeric forms of 8-amino-imidazo [1,5a] pyrazine and 4-amino-imidazo [1,5-f] [1,2,4] derivatives triazine according to the resulting invention, for example, because of configurational or geometric isomerism. Such stereoisomeric forms are enantiomers, diastereoisomers, cis and trans isomers etc. For example, where azepane-2-carboxylic acid is used as an amino acid, there is a mixture of two enantiomers. In the case of the individual stereoisomers of the compounds of formula I or their salts or solvates, the present invention includes the previously mentioned stereoisomers substantially free, that is, associated with less than 5%, preferably less than 2% and in particular less than than 1% of the other stereoisomer. Mixing the stereoisomers in any proportion, for example a racemic mixture comprising substantially equal amounts of two enantiomers, is also included within the scope of the present invention.
[000153] Chiral compounds, methods for asymmetric synthesis by means of which pure stereoisomers are obtained are well known in the art, for example, synthesis with chiral induction, synthesis starting from chiral intermediates, enantioselective enzymatic conversions, separation of stereoisomers using chromatography in chiral medium. Such methods are described in Chirality in Industry (edited by A. N. Collins, G. N. Sheldrake and J. Crosby, 1992; John Wiley). Likewise, methods for the synthesis of geometric isomers are also well known in the art.
[000154] The 8-amino-imidazo [1,5-a] pyrazine and 4-aminoimidazo [1,5-f] [1,2,4] triazinated derivatives of the present invention, which may be in the form of a free base , can be isolated from the reaction mixture in the / 123 form of a pharmaceutically acceptable salt. Pharmaceutically acceptable salts can also be obtained by treating Formula I free base with an organic or inorganic acid such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, acetic acid, propionic acid, glycolic acid , maleic acid, malonic acid, methanesulfonic acid, fumaric acid, succinic acid, tartaric acid, citric acid, benzoic acid, and ascorbic acid.
[000155] The 8-amino-imidazo [1,5-a] pyrazine and 4-amino-imidazo [1,5-f] [1,2,4] triazine derivatives of the present invention also exist as amorphous forms. Multiple crystalline forms are also possible. All physical forms are included within the scope of the present invention. [000156] The preparation of solvates is generally known. Thus, for example, M. Caira et al, J. Pharmaceutical Sci., 93 (3), 601-611 (2004) describes the preparation of the solvates of the antifungicide fluconazole in ethyl acetate as well as water. Similar preparations of solvates, hemisolvate, hydrates and the like are described by E. C. van Tonder et al, AAPS PharmSciTech., 5 (1), article 12 (2004); and A. L. Bingham et al, Chem. Commun. 603-604 (2001). A typical, non-limiting process involves dissolving the inventive compound in desired amounts of the desired solvent (organic or water or mixtures thereof) at a higher temperature than room temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods. Analytical techniques such as, for example IR spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).
[000157] The present invention also encompasses isotopically labeled compounds of the present invention that are identical to those cited herein, but due to the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass / 123 or mass number usually found in nature. Examples of isotopes that can be incorporated within the compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as ² H, ³ H, ¹³ C, ¹⁴ C, ¹⁵ N, ¹⁷ O, ¹⁸ O, ³¹ P, ³² P, ³⁵ S, ¹⁸ F, and ³⁶ Cl, respectively.
[000158] Certain isotopically-labeled compounds of Formula I (e.g., those labeled with ³ H and ¹⁴ C) are useful in ₃ tissue distribution assay in compound and / or substrate. The tritiated (i.e., H) and carbon14 (i.e., ¹⁴ C) isotopes are particularly preferred in terms of their ease of preparation and detectability. In addition, substitution with heavier isotopes such as deuterium (i.e., H) can provide certain therapeutic advantages that result from increased metabolic stability (for example, increased in vivo half-life or reduced dosage requirements) and therefore may be preferred in some circumstances. The isotopically labeled compounds of formula I in general can be prepared by the procedures which follow analogues to those described in the Schemes and / or in the Examples here below, by substituting an appropriate isotopically labeled reagent for a non-isotopically labeled reagent.
[000159] The invention is illustrated by the examples that follow.
Examples [000160] The following examples are illustrative embodiments of the invention, which do not limit the scope of the invention in any way. The reagents are either commercially available or prepared according to procedures in the literature.
[000161] Mass Spectrometry: Electron Spray spectra were recorded on the Applied Biosystems API-165 single quad mass spectrometer in alternating positive and negative ion mode using Flow Injection. the mass range was 120 to 2000 Da and scanned with / 123 at a stepwise rate of 0.2 Da. and the capillary voltage was adjusted to 5000 V. N2 gas was used for nebulization.
[000162] LC-MS (Waters) spectrometer Detector: PDA (200 to 320 nm), Mass detector: ZQ and Eluent: A: acetonitrile with 5% trifluoroacetic acid, B: acetronitrile / water = 1/9 (v / v) with 5% trifluoroacetic acid.
LCMS Method (A)
Column 1: Chromolith Performance, RP-18e, 4.6 x 100 mm, Gradient method: Flow: 4 ml / min
Time (min) THE (%) B (%) 0.00 100 0 3.60 0 100 4.00 0 100 4.05 100 0 6.00 100 0
LCMS Method (B)
Column 2: XBridge C18, 3.5 pm, 4.6 x 20 mm Gradient method: Flow: 4 ml / min
Time (min.) A (%) B (%) 0.0 100 0 1.60 0 100 3.10 0 100 3.20 100 0 5.00 100 0
[000163] UPLC: UPLC Water acquity system; Column: BEH C18 1.7 pm, 2.1 x 100 mm, Detector: PDA (200-320 nm), Mass detector: SQD [000164] Eluent: A: acetonitrile with 0.035% trfluoroacetic acid, B: acetronitrile / water = 1/9 (v / v) with 0.035% trofluoroacetic acid / 123
UPLC method (A)
Method 60 100
UPLC (B) UPLC (C)
Method 40 80 Method 0 60
Flow: 0.75 ml / min Flow: 0.65 ml / min Flow: 0.60 ml / min Time (min) THE ( %) B (%) A (%) B ( %) THE ( %) B ( %) 0.0 40 60 60 40 100 0 3.00 0 100 20 80 40 60 3.20 0 100 0 100 0 100 3.69 0 100 0 100 0 100 3.70 40 60 60 40 100 0
[000165] The preparative HPLC was conducted in a column (50 x 10 mm ID, 5 µm, Xterra Prep MS C18) at a flow rate of 5 ml / min, injection volume 500 μΐ, at room temperature and the Detection of 210 nm UV.
[000166] The following abbreviations are used throughout the application related to chemical terminology:
HATU O- (7-Azabenzotriazol-1-yl) -1,1,3,3tetramethyluronium hexafluorophosphate
Cbz
DMF
DCM
EtOAc
DIPEA
THF
EtOH
EDCI.HCl
4-DMAP
PyBOP phosphonium
TBTU
Benzyloxycarbonyl
N, N-Dimethylformamide
Dichloromethane
Ethyl acetate
N, N-Diisopropylethylamine
Tetrahydrofuran
Ethanol 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride. 4-Dimethylamino pyridine O-Benzotriazol-1-yl-oxy-trispirrolidinotetrafluoroborate O-Benzotriazol-1-yl-N, N, N ', N'-tetra48 / 123 methyluronium
HBr
HCl
HOAc
Z
Pro
POCl3
HPLC
UPLC
LiHMDS
MeOH
Gly
N-BuLi Ward
CO2 [000167]
Hydrogen bromide
Hydrogen chloride z
Acetic Acid
Benzyloxycarbonyl
Proline
Phosphorous oxychloride
High Pressure Liquid Chromatography
Lithium hexamethyldisilazide Methanol Glycine Alanine n-Butyllithium carbon dioxide
The final product names in the examples are generated using Chemdraw Ultra (version 9.0.7).
Intermediate 1
Cl
N
cn
N
Cl
nh,
Cbz
Cl
Cl
Cbz
Br
Cl
Cbz
NH, ² Br
Cbz
2- (8-Amino-1-bromoimidazo [1,5-a] pyrazin-3-yl) pyrrolidine-1-carboxylate (S) -benzyl (a) (3-chloropyrazin-2-yl) methanamine hydrochloride.
[000168] To a solution of 3-chloropyrazine-2-carbonitrile (160 g, 1.147 / 123 mol) in acetic acid (1.5 liter) was added Raney Nickel (50% slurry in water, 70 g, 409 mmol). The resulting mixture was stirred under 4 bar hydrogen at room temperature overnight. Raney Nickel was removed by filtration over decalite and the filtrate was concentrated under reduced pressure and coevaporated with toluene. The remaining brown solid was dissolved in ethyl acetate at 50 ° C and cooled in an ice bath. A 2 M solution of hydrogen chloride in diethyl ester (1.14 liters) was added in 30 min. The mixture was allowed to stir at room temperature over the weekend. The crystals were collected by filtration, washed with diethyl ester and dried under reduced pressure at 40 ° C. The obtained brown solid product was dissolved in methanol at 60 ° C. The mixture was filtered and partially concentrated, cooled to room temperature and the diethyl ester (1000 ml) was added. The mixture was allowed to stir at room temperature overnight. The solids formed were collected by filtration, washed with diethyl ester and dried under reduced pressure at 40 ° C to give 153.5 g of (3-chloropyrazin-2-yl) methanamine hydrochloride as a brown solid (74.4 %, content of 77%).
(b) 2 - ((3-chloropyrazin-2-yl) methylcarbamoyl) (S) benzyl pyrrolidine-1-carboxylate [000169] To a solution of (3-chloropyrazin-2-yl) methanamine.HCl (9.57 g, 21.26 mmol, 40% by weight) and Z-Pro-OH (5.3 g, 21.26 mmol) in dichloromethane (250 ml) triethylamine (11.85 ml, 85 mmol) was added and the mixture reaction was cooled to 0 ° C. After 15 min stirring at 0 ° C, HATU (8.49 g, 22.33 mmol) was added. The mixture was stirred for 1 hour at 0 ° C and then overnight at room temperature. The mixture was washed with 0.1 M HCl solution, 5% NaHCO3, water and brine, dried over sodium sulfate and concentrated in vacuo. The product was purified using silica gel chromatography (heptane / ethyl acetate = 1/4% v / v) to give 5 g of 2 - ((3-chloropyrazin-2-yl) methylcarbamoyl) pyrrolidine-1-carboxylate (S) 50/123 benzyl (62.7%).
(c) 2- (8) Chlorimidazor 1,5-alpyrazin-3-yl) (S) benzyl pyrrolidine-1-carboxylate [000170] 2 - ((3-chloropyrazin-2-yl) methylcarbamoyl) pyrrolidine-1carboxylate (S) -benzyl (20.94 mmol, 7.85 g) was dissolved in acetonitrile (75 ml), 1,3-dimethyl-2-imidazolidinone (62.8 mmol, 6.9 ml, 7.17 g) was added and the reaction mixture was cooled to 0 ° C before POCl ₃ (84 mmol, 7.81 ml, 12.84 g) was added to the drops while the temperature remained at around 5 ° C. The reaction mixture was refluxed at 60 to 65 ° C overnight. The reaction mixture was carefully poured into 25% ammonium hydroxide in water (250 ml) / crushed ice (500 ml) to give a yellow suspension (pH ~ 8 to 9) which was stirred for 15 min until no ice was present in the suspension. Ethyl acetate was added, the layers were separated and the aqueous layer was extracted with ethyl acetate (3x). The organic layers were combined and washed with brine, dried over sodium sulfate, filtered and evaporated to give 7.5 g of crude product. The crude product was purified using silica gel chromatography (heptane / ethyl acetate = 1/4% v / v) to give 6.6 g of 2- (8-chloroimidazo [1,5alpirazin-3-yl) pyrrolidine (S) -benzyl -1-carboxylate (88%).
(d) 2- (1-bromo-8-chloroimidazo [1,5-alpyrazin-3-yl) pyrrolidine-1-carboxylate (S) -benzyl [000171] N-Bromosuccinimide (24.69 mmol, 4.4 g) was added to a stirred solution of (S) -benzyl 2- (8-chloroimidazo [1,5-alpyrazin-3-yl) pyrrolidine-1-carboxylate (24.94 mmol, 8.9 g) in DMF (145 ml). The reaction was stirred for 3 hours at room temperature. The mixture was poured (slowly) into a stirred mixture of water (145 ml), ethyl acetate (145 ml) and brine (145 ml). The mixture was then transferred to a separatory funnel and extracted. The aqueous layer was extracted with 2 x 145 ml of ethyl acetate. The combined organic layers were washed with 3 x 300 ml of / 123 water, 300 ml of brine, dried over sodium sulfate, filtered and evaporated. The product was purified using silica gel chromatography (ethyl acetate / heptane = 3/1% v / v) to give 8.95 g of 2- (1-bromo-8-chloroimidazo [1,5a] pyrazin-3 (S) -benzyl -yl) pyrrolidine-1-carboxylate (82.3%).
(e) 2- (8-amino-1-bromoimidazo [1,5-a] pyrazin-3-yl) (S) -benzyl pyrrolidine-1-carboxylate [000172] 2- (8-amino-1-bromoimidazo (S) -benzyl [1,5-a] pyrazin-3-yl) pyrrolidine-1 carboxylate (20.54 mmol, 8.95 g) was suspended in 2propanol (113 ml) in a pressure vessel. 2-propanol (50 ml) was cooled to 78 ° C in a pre-weighed flask (with stopper and stir bar) and ammonia gas (646 mmol, 11 g) was introduced for 15 minutes. The resulting solution was added to the suspension in the pressure vessel. The vessel was closed and stirred at room temperature and a slight increase in pressure was observed. Then the suspension was heated to 110 ° C which resulted in a pressure increased to 450 kPa (4.5 bar). The clear solution was stirred at 110 ° C, 450 kPa (4.5 bar) overnight. After 18 hours the pressure remained 400 kPa (4 bar). The reaction mixture was concentrated in vacuo, the residue was suspended in ethyl acetate and subsequently washed with water. The layers were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water, saturated sodium chloride solution, dried over sodium sulfate and concentrated to give 7.35 g of 2- (8-amino-1-bromoimidazo [1,5-a] pyrazin3-yl ) (S) -benzyl pyrrolidine-1-carboxylate (86%).
Intermediate 2 nh
Br //
N
Cbz
/ 123 (5) -4- (8-Amino-3- (pyrrolidin-2-yl) imidazo [1,5-alpirazin-1-yl) -N- (pyridin-2yl) benzamide (a) 2- (8 (S) -benzyl-amino-1- (4- (pyridin-2-ylcarbamoyl) phenyl) imidazo [1,5-alpyrazin-3yl) pyrrolidine-1-carboxylate [000173] 2- (8-amino-1 - (S) -benzyl bromoimidazo [1,5-a] pyrazin-3-yl) pyrrolidine-1 carboxylate (0.237 mmol, 98.5 mg) and 4- (pyridin-2-ylaminocarbonyl) benzenoboronic acid (0.260 mmol, 63 , 0 mg) were suspended in a mixture of 2N aqueous potassium carbonate solution (2.37 mmol, 1.18 ml) and dioxane (2.96 ml). Nitrogen was bubbled through the mixture, followed by the addition of 1,1'-bis (diphenylphosphino) ferrocene palladium (II) chloride (0.059 mmol, 47.8 mg). The reaction mixture was heated for 20 z
minutes at 140 ° C in the microwave. Water was added to the reaction mixture, followed by extraction with ethyl acetate (2x). The combined organic layer was washed with brine, dried over magnesium sulfate and evaporated. The product was purified using silica gel and dichloromethane / methanol = 9/1% v / v as eluent to produce 97.1 mg of 2 (8-amino-1- (4- (pyridin-2-ylcarbamoyl) phenyl) imidazo (5) -benzyl [1,5-alpyrazin-3yl) pyrrolidine-1-carboxylate (77%).
(b) (5) -4- (8-Amino-3- (pyrrolidin-2-yl) imidazo [1,5-alpyrazin-1-yl) -N- (pyridin-2yl) benzamide [000174l Ao 2- ( A (S) -benzyl 8-amino-1- (4- (pyridin-2-ylcarbamoyl) phenyl) imidazo [1,5alpyrazin-3-yl) pyrrolidine-1-carboxylate (0.146 mmol, 78 mg) to 33% hydrobromic acid / acetic acid (11.26 mmol, 2 ml) and the mixture was left at room temperature for 1 hour. The mixture was diluted with water and extracted with dichloromethane. The aqueous phase was neutralized using 2N sodium hydroxide solution, and then extracted with dichloromethane. The organic layer was dried over magnesium sulfate, filtered and evaporated to give 34 mg of (5) -4- (8-Amino-3- (pyrrolidin-2-yl) imidazo [1,5alpirazin-1-yl) -N - (pyridin-2-yl) benzamide (58%).
/ 123
Example 1
(5) -4- (3- (1-Acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-alpyrazin-1-yl) -N (pyridin-2-yl) benzamide [000175] To a solution of (5) -4- (8-amino-3- (pyrrolidin-2-yl) imidazo [1,5-alpirazin-1-yl) -N- (pyridin-2-yl) benzamide (0.626 mmol, 250 mg) in dichloromethane (25 ml) at 0 ° C triethylamine (0.626 mmol, 0.087 ml, 63.3 mg) was added and, in drops, acryloyl chloride (0.657 mmol, 0.053 ml, 59.5 mg). The resulting mixture was stirred at 0 ° C for 2 hours. The mixture was washed with water, dried over magnesium sulfate. After evaporation, the residue was purified by preparative HPLC. The fractions containing the product were collected and lyophilized to produce 126 mg of (5) -4- (3- (1-acryloylpyrrolidin2-yl) -8-aminoimidazo [1,5-alpirazin-1-yl) -N- ( pyridin-2-yl) benzamide (44.4% yield). Data: UPLC (C) R _t : 1.50 min; m / z 454.3 (M + H) +.
Example 2
N
/ 123 (5, E) -4- (8-amino-3- (1 - (4- (pyrrolidin-1-yl) but-2-enoyl) pyrrolidin-2-yl) imidazor 1,5-a] pyrazin -1-yl) -N- (pyridin-2-yl) benzamide [000176] To a solution of (5) -4- (8-Amino-3- (pyrrolidin-2-yl) imidazo [1,5-alpirazin -1-yl) -N- (pyridin-2-yl) benzamide (intermediate 2b, 19.7 mg, 0.049 mmol), triethylamine (20 mg, 0.197 mmol, 0.027 ml) and acid hydrochloride (£ ') - 4 - (pyrrolidin-1-yl) but-2-enoic (9.45 mg, 0.049 mmol) in dichloromethane (2 ml) was added HATU (18.75 mg, 0.049 mmol). The mixture was stirred for 30 min at room temperature. The mixture was washed with water, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by preparative HPLC. The product containing fractions were collected and reduced to dryness to produce 7.1 mg of (5, £) -4- (8-amino3- (1- (4- (pyrrolidin-1-yl) but-2- enoyl) pyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) N- (pyridin-2-yl) benzamide (26.8% yield). Data: UPLC (C) R _t : 1.25 min; m / z 537.4 (M + H) +.
Example 3
(5, £ ') - 4- (8-Amino-3- (1- (4- (dimethylamino) but-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) - N- (pyridin-2-yl) benzamide [000177] This compound was prepared, in an analogous manner as described in Example 2, from the compound described in intermediate 2b and (£) -4- (dimethylamino) but-2 acid -enonic, to produce the title compound (11.8 mg, 46.6%). Data: UPLC (C) Rt: 1.29 min; m / z 511.0 (M + H) +.
/ 123
Intermediate 3
(E) -4-Methoxybut-2-enoic acid [000178] Sodium methoxide (30% / Methanol, 30.3 mmol, 5.68 ml) was added via glass syringe to a stirred acid solution
4-bromocrotonic (6.06 mmol, 1 g) in methanol (60 ml) at room temperature. The light yellow solution was stirred for 30 min at room temperature and 2 h. at reflux. After cooling the reaction mixture, the solvent was removed under reduced pressure. The residue was partitioned between water (50 ml) and diethyl ester (50 ml). 2 M aq. Hydrochloride solution (3.5 ml) was added until the pH was ~ pH 1. The aqueous layer was separated and extracted with diethyl ester (3 x 20 ml). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo, to give 650 mg of (£) -4-Methoxybut-2-enoic acid (92%).
Example 4
o (5, E) -4- (8-amino-3- (1 - (4-methoxybut-2-enoyl) pyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- ( pyridin-2-yl) benzamide [000179] This compound was prepared, in a manner analogous to that described in Example 2, from the compound described in intermediate 2b and (£) -4-methoxybut-2-enoic acid (Intermediate 3 ), to produce the title compound (11 mg, 29.9%). Data: UPLC (C) R 1.58 min; m / z 498.3 (M + H) +.
/ 123
Example 5
ci (5) -4- (8-amino-3- (1- (2-chloropyrimidine-4-carbonyl) pyrrolidin-2-yl) imidazor 1,5-a] pyrazin-1-yl) -N- (pyridin -2-yl) benzamide [000180] This compound was prepared, in a manner analogous to that described in Example 2, from the compound described in intermediate 2b and 2-chloropyrimidine-4-carboxylic acid, to produce the title compound ( 8.3 mg, 40.4%). Data: UPLC (C) Rt: 1.64 min; m / z 540.1 (M + H) +.
Example 6 (5) -4- (8-amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (pyridin-2-yl ) benzamide [000181] This compound was prepared, in a manner analogous to that described in Example 2, from the compound described in intermediate 2b and 2-butinoic acid, to produce the title compound (10.5 mg, 18.0 %).
/ 123
Data: LCMS (B) Rt: 2.08 min; m / z 466.1 (M + H) +.
Intermediate 4 o
f
N- (4-fluoropyridin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl) benzamide (a) 4- (4,4,5, 5-Tetramethyl-1,3,2-dioxaborolan-2-yl) benzoyl [000182] To a cold solution (0 ° C) of 4- (4,4,5,5-tetramethyl-1,3,2dioxaborolan- 2-yl) benzoic (40.3 mmol, 10.01 g) in dichloromethane (206 ml) a catalytic amount of DMF was added. A solution of oxalyl chloride (101 mmol, 8.66 ml, 12.8 g) was added to the drops. After stirring for 30 min at 0 ° C, the reaction mixture was allowed to warm to room temperature and the mixture was stirred for an additional 3 hours. The reaction mixture was concentrated to give 10.9 g of crude 4- (4,4,5,5-tetramethyl1,3,2-dioxaborolan-2-yl) benzoyl chloride (101%).
(b) N- (4-fluoropyridin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl) benzamide [000183] To a solution of 4- (4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl) benzoyl (1,688 mmol, 450 mg) in acetonitrile (24.8 ml) 2-amino-4-fluoropyridine (4.22 mmol, 473 mg). The reaction mixture was stirred at room temperature for 1.5 h. The reaction mixture was concentrated to a small volume, 3% aq. citric acid (18 ml) was added and the mixture was extracted with dichloromethane (2 x 15 ml). The combined organic layer was washed with 3% aq. citric acid, / 123 dried over magnesium sulfate, filtered and evaporated to yield 542.2 mg of N- (4-fluoropyridin-2-yl) -4- (4,4,5,5-tetramethyl-1,3 , 2-dioxaborolan-2yl) benzamide (94%) as a yellowish white solid.
Intermediate 5
(5) -4- (8-Amino-3- (pyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4fluoropyridin-2-yl) benzamide [000184] This intermediate was prepared, in a manner analogous to that described for intermediate 2b, from 2- (8-amino-1bromoimidazo [1,5-a] pyrazin-3-yl) pyrrolidine-1-carboxylate of (S) -benzyl (Intermediate 1e) and N- (4-fluoropyridin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl) benzamide (intermediate 4b) to produce the compound titer (331 mg, 93%).
Example 7 f
N / 123 (5, E ') - 4- (8-Amino-3- (1- (4- (dimethylamino) but-2-enoyl) pyrrolidin-2-yl) imidazo [1,5-a] pyrazin- 1-yl) -N- (4-fluoropyridin-2-yl) benzamide [000185] This compound was prepared, in an analogous manner as described in Example 2, from the compound described in intermediate 5 and acid (£) - 4- (dimethylamino) but-2-enoic, to produce the title compound (33.4 mg, 54.1%). Data: UPLC (C) Rt: 1.72 min; m / z 529.3 (M + H) +. Intermediate 6
N- (4-Methylpyridin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl) benzamide [000186] To a stirred solution of 4-methylpyridin-2- amine (7.86 mmol, 850 mg) in THF (50 ml) a 1M solution of LiHMDS in THF (8.0 mmol, 8 ml) was added dropwise at room temperature. After the reaction mixture turned dark green, a 4- (4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl) benzoyl chloride solution (9.6 mmol, 2.56 g ) in dichloromethane (55 ml) was added to the drops. The mixture was stirred at room temperature for 2.5 h and was then concentrated. 3% aq solution. citric acid (18 ml) was added and the mixture was extracted with dichloromethane (2 x 15 ml). The combined organic layer was washed with 3% aq. citric acid, dried over magnesium sulfate, filtered and evaporated. The residue was dissolved in THF (15 ml) and 6M NaOH solution (15 ml) was added. The mixture was stirred for 4 hours. at room temperature. Ethyl acetate was added and the layers were separated. The organic layer was washed with water and brine, dried over sodium sulfate / 123, filtered and evaporated. The residue was purified by chromatography on silica (eluent: DCM / MeOH = 98/2 for DCM / MeOH = 95/5) to yield 1.1 g of N- (4-methylpyridin-2-yl) -4- (4 , 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzamide (40.7%).
Intermediate 7
(5) -4- (8-Amino-3- (pyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4methylpyridin-2-yl) benzamide [000187] This intermediate was prepared, in an analogous manner as described for intermediate 2, from 2- (8) amino-1bromoimidazo [1,5-a] pyrazin-3-yl) pyrrolidine-1-carboxylate of (S) -benzyl (Intermediate 1e) and N- (4-methylpyridin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl) benzamide (intermediate 6) to produce the compound titer (125.5 mg, 82%).
Example 8
Ν '/ 123
CS ^, ) -4- (8-Amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5-alpirazin-1-yl) -N- (4methylpyridin-2-yl) benzamide [ 000188] This compound was prepared, in a manner analogous to that described in Example 2, from (5) -4- (8-amino-3- (pyrrolidin-2-yl) imidazo [1,5alpirazin-1-yl ) -N- (4-methylpyridin-2-yl) benzamide (intermediate 7) and 2-butanoic acid, to produce the title compound (6.3 mg, 27.2%). Data: UPLC (C) Rt: 1.56 min; m / z 480.3 (M + H) +.
Intermediate 8
N- (4-Propylpyridin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl) benzamide [000189] This compound was prepared, in an analogous manner as described in intermediate 6, starting from 4-propylpyridin-2-amine, to produce the title compound (371.5 mg, 54.1%).
Intermediate 9
nh / 123 (5) -4- (8-Amino-3- (pyrrolidin-2-yl) imidazori, 5-alpirazin-1-yl) -N- (4propylpyridin-2-yl) benzamide [000190] prepared, in a manner analogous to that described for intermediate 2, from 2- (8) amino-1-bromoimidazo [1,5alpirazin-3-yl) pyrrolidine-1-carboxylate (Intermediate 1e ) and N- (4Propylpyridin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzamide (intermediate 8) to produce the title compound (147 , 8 mg, 93%).
Example 9
o (5, E) -4- (8-Amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2-yl) imidazo [1,5a ^^ azim 1 -yl) -N- ( 4-propylpyridin-2-yl) benzamide [000191] This compound was prepared, in a manner analogous to that described in Example 2, from (5) -4- (8-amino-3- (pyrrolidin-2-yl ) imidazo [1,5a] pyrazin-1-yl) -N- (4-propylpyridin-2-yl) benzamide (intermediate 9) and (E) -4methoxybut-2-enoic acid (Intermediate 3), to produce the compound of the title (30.9 mg, 65.7%). Data: UPLC (C) Rt: 2.73 min; m / z 566.3 (M + H) +.
Intermediate 10
/ 123
4- (4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl) -N- (4- (trifluoromethyl) pyridin-2yl) benzamide [000192] This compound was prepared, in a analogous to that described in intermediate 6, starting from 4- (trifluoromethyl) pyridin-2-amine, to produce the title compound (657.2 mg, 89%).
Intermediate 11
(5) -4- (8-Amino-3- (pyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4 (trifluoromethyl) pyridin-2-yl) benzamide [ 000193] This intermediate was prepared, in a manner analogous to that described for intermediate 2, from 2- (8-amino-1bromoimidazo [1,5-a] pyrazin-3-yl) pyrrolidine-1-carboxylate ( S) -benzyl (Intermediate 1e) and 4- (4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl) -N- (4 (trifluoromethyl) pyridin-2-yl) benzamide ( intermediate 10) to produce the title compound (163 mg, 87%).
Example 10
The
/ 123 (5) -4- (8-Amino-3- (1-but-2-yoylpyrrolidin-2-yl) imidazo [1,5-alpirazin-1-yl) -N (4- (trifluoromethyl) pyridin- 2-yl) benzamide [000194] This compound was prepared, in a manner analogous to that described in Example 2, from (S ') - 4- (8-amino-3- (pyrrolidin-2-yl) imidazo [ 1,5alpyrazin-1-yl) -N- (4- (trifluoromethyl) pyridin-2-yl) benzamide (intermediate 11) and 2-butinoic acid, to produce the title compound (7.1 mg, 31.1% ). Data: UPLC (C) R _t : 2.63 min; m / z 534.2 (M + H) +.
Intermediate 12
N- (4-Ethylpyridin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzamide [000195] This compound was prepared in an analogous manner such as that described in intermediate 4, starting from 4-ethylpyridin-2-amine, to produce the title compound (334.5 mg, 50.6%).
Intermediate 13
(5) -4- (8-Amino-3- (pyrrolidin-2-yl) imidazo [1,5-alpirazin-1-yl) -N- (4-ethyl pyridin-2-yl) benzamide / 123 [000196 ] This intermediate was prepared, in an analogous manner as described for intermediate 2, from 2- (8-amino-1-bromoimidazo [1,5a] pyrazin-3-yl) pyrrolidine-1-carboxylate ) -benzyl (Intermediate 1e) and N- (4ethylpyridin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzamide (intermediate 12) to produce the title compound (133.8 mg, 89%).
Example 11
o (5, E ') - 4- (8-Amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-ethylpyridin-2-yl) benzamide [000197] This compound was prepared, in a manner analogous to that described in Example 2, from (S) -4- (8-amino-3- (pyrrolidin-2- il) imidazo [1,5a] pyrazin-1-yl) -N- (4-ethylpyridin-2-yl) benzamide (intermediate 13) and (E) -4methoxybut-2-enoic acid (Intermediate 3), to produce the title compound (10.6 mg, 28.8%). Data: UPLC (C) R: 1.60 min; m / z 526.3 (M + H) +.
Intermediate 14
N- (4,5,6,7-Tetrahydrobenzo [d] thiazol-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl) benzamide / 123 (a ) 4-Bromo-N- (4,5,6,7-tetrahydrobenzo [d] thiazol-2-yl) benzamide [000198] 4-Bromobenzoyl chloride (1.5 g, 6.83 mmol) and 4.5 , 6,7 Tetrahydro-1,3-benzothiazole-2-amine (1.054 g, 6.83 mmol) were dissolved in Pyridine (15 ml) and stirred at 50 ° C for 1.5 h. The reaction mixture was cooled to room temperature and poured into water. The formed solid was filtered, washed with water. The solids were coevaporated with toluene twice to yield 1.8 g of 4-bromo-N- (4,5,6,7-tetrahydrobenzo [d] thiazol-2-yl) benzamide (78%) as a yellow solid.
(b) N- (4,5,6,7-Tetrahydrobenzo [d] thiazol-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2dioxaboro-lan-2-yl) benzamide [000199] To a solution of 4-bromo-N- (4,5,6,7-tetrahydrobenzo [d] thiazol-2yl) benzamide (1.8 g, 5.34 mmol) dioxane (40 ml) was added bis (pinacolato) diboro (1.762 g, 6.94 mmol) and potassium acetate (1.048 g, 10.68 mmol). The reaction mixture was degassed with nitrogen. Subsequently 1,1'-bis (diphenylphosphino) ferrocenopalladium (II) dichloride (0.218 g, 0.267 mmol) was added and the reaction mixture was stirred at 80 ° C for 5 days. The mixture was cooled to room temperature and after adding water extracted three times with EtOAC. The organic layers were combined, washed with brine, dried over sodium sulfate, filtered and evaporated. The crude product was purified using silica gel chromatography (3/7 to 7/3% v / v heptane / ethyl acetate) to give 600 mg of N- (4,5,6,7-tetrahydrobenzo [d] thiazole -2-yl) -4- (4,4,5,5-tetramethyl1,3,2-dioxaboro-lan-2-yl) benzamide (29.3%).
Intermediate 15
nh / 123 (5) -4- (8-Amino-3- (pyrrolidin-2-yl) imidazo [1,5-a1pyrazin-1-yl) -N- (4,5,6,7tetrahydrobenzo Γ d1thiazol-2 -il) benzamide [000200] This intermediate was prepared, in a manner analogous to that described for intermediate 2, from 2- (8-amino-1bromoimidazo [1,5-a1pyrazin-3-yl) pyrrolidine-1 - (S) -benzyl carboxylate (Intermediate 1e) and N- (4,5,6,7-tetrahydrobenzo [d1thiazol-2-yl) -4- (4,4,5,5tetramethyl-1,3,2-dioxaborolan -2-yl) benzamide (intermediate 14b) to produce the title compound (260 mg, 60%).
Example 12 (5) -4- (8-Amino-3- (1-but-2-yoylpyrrolidin-2-yl) imidazo [1,5-a1pyrazin-1-yl) -N (4,5,6,7 -tetrahydrobenzo [d1thiazol-2-yl) benzamide [0002011 This compound was prepared, in a manner analogous to that described in Example 2, from (S) -4- (8-amino-3- (pyrrolidin-2yl) imidazo [1,5-a1pyrazin-1-yl) -N- (4,5,6,7-tetrahydrobenzo [d1thiazol-2yl) benzamide (intermediate 15) and 2-butinoic acid, to produce the title compound (7 mg, 19.2%). Data: UPLC (C) R _t : 2.41 min; m / z 526.3 (M + H) +.
/ 123
Intermediate 16
2-Fluoro-N- (pyridin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl) benzamide [000202] This compound was prepared in an analogous manner such as that described in intermediate 14, starting from 4-bromo-2-fluorobenzoic acid, to produce the title compound (2.54 g, 76%).
Intermediate 17 (5) -4- (8-Amino-3- (pyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -2-fluoro-N (pyridin-2-yl) benzamide [000203] This intermediate was prepared, in a manner analogous to that described for intermediate 2, from 2- (8-amino-1bromoimidazo [1,5-a] pyrazin-3-yl) pyrrolidine-1-carboxylate (S) -benzyl (Intermediate 1e) and 2-Fluoro-N- (pyridin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl) benzamide (intermediate 16) to produce the title compound (160 mg, 76%).
/ 123
Example 13
(5) -4- (3- (1-acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-alpyrazin-1-yl) -2fluoro-N - (pyridin-2-yl) benzamide [000204] This The compound was prepared, in a similar manner as described in Example 1, from (5) -4- (8-amino-3- (pyrrolidin-2yl) imidazo [1,5-alpirazin-1-yl) -2 -fluoro-N- (pyridin-2-yl) benzamide (intermediate 17) and acryloyl chloride, to produce the title compound (13 mg, 38.4%). Data: UPLC (C) R _t : 1.67 min; m / z 472.3 (M + H) +. Intermediate 18
2-Methoxy-N- (pyridin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl) benzamide [000205] This compound was prepared in an analogous manner such as that described in intermediate 14, starting from 4-bromo-2-methoxybenzoic acid, to produce the title compound (2.6 g, 90%).
/ 123
Intermediate 19
(5) -4- (8-Amino-3- (pyrrolidin-2-yl) imidazori, 5-alpirazin-1-yl) -2-methoxy-N (pyridin-2-yl) benzamide [000206] This intermediate was prepared, in a manner analogous to that described for intermediate 2, from 2- (8) amino-1bromoimidazo [1,5-a] pyrazin-3-yl) pyrrolidine-1-carboxylate (S) -benzyl ( Intermediate 1e) and 2-methoxy-N- (pyridin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl) benzamide (intermediate 18) to produce the compound of the title (175 mg, 56.6%).
Example 14 (5) -4- (3- (1-Acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-alpyrazin-1-yl) -2methoxy-N- (pyridin-2-yl) benzamide [000207 ] This compound was prepared, in a manner analogous to that described in Example 1, from (S) -4- (8-amino-3- (pyrrolidin-271/123 yl) imidazo [1,5-a] pyrazin -1-yl) -2-methoxy-N- (pyridin-2-yl) benzamide (intermediate 19) and acryloyl chloride, to produce the title compound (14 mg, 35.5%). Data: UPLC (C) Rt: 1.74 min; m / z 484.3 (M + H) +.
Intermediate 20
(5) -4- (8-Amino-3- (pyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N- (thiazol-2yl) benzamide [000208] This intermediate was prepared , in a manner analogous to that described for intermediate 2, starting from 2- (8-amino-1bromoimidazo [1,5-a] pyrazin-3-yl) pyrrolidine-1-carboxylate (Intermediate) 1e) and N-2-thiazolyl 4-boronobenzamide commercially available to produce the title compound (229 mg, 73.1%).
Example 15
• n '/ 123 (5, £') - 4- (8-Amino-3- (1- (4- (dimethylamino) but-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin- 1-yl) -N- (thiazol-2-yl) benzamide [000209] This compound was prepared, in a manner analogous to that described in Example 2, from (S) -4- (8-amino-3- (pyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (thiazol-2-yl) benzamide (intermediate 20) and (Λ ') - 4 (dimethylamino) but-2-enoic , to produce the title compound (18.9 mg, 29.7%). Data: UPLC (C) Rt: 1.38 min; m / z 517.3 (M + H) +.
Intermediate 21
(5) -4- (8-Amino-3- (piperidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2yl) benzamide [000210] This intermediate was prepared , in a similar way as described for intermediate 1, starting from (S) -1 (benzyloxycarbonyl) piperidine-2-carboxylic acid to obtain 2- (8-amino-1bromoimidazo [1,5-a] pyrazin -3-yl) (S) -benzyl piperidine-1-carboxylate. The subsequent reaction with commercially available 4- (pyridin-2-yl-aminocarbonyl) benzenoboronic acid, analogous as described for intermediate 2, produced the title compound (491 mg, 91%).
/ 123
Example 16
o (S, E) -4- (8-Amino-3- (1- (4-methoxybut-2-enoyl) piperidin-2-yl) imidazo [1,5alpyrazin-1-yl) -N- (pyridin- 2-yl) benzamide [000211] This compound was prepared, in a manner analogous to that described in Example 2, from (S) -4- (8-amino-3- (piperidin-2yl) imidazo [1,5 -a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide (intermediate 21) and (E) -4-methoxybut-2-enoic acid (intermediate 3), to produce the title compound (21 , 1 mg, 54.3%). Data: LCMS (B) R _t : 2.22 min; m / z
512.3 (M + H) +.
Intermediate 22
(S) -4- (8-Amino-3- (piperidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4fluoropyridin-2-yl) benzamide [000212] This intermediate was prepared, in an analogous manner as described for intermediate 1, from (S) -174 / 123 (benzyloxycarbonyl) piperidine-2-carboxylic acid to obtain 2- (8-amino-1bromoimidazo [1,5 -a] (S) -benzyl pyrazin-3-yl) piperidine-1-carboxylate. The subsequent reaction with N- (4-fluoropyridin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl) benzamide (Intermediate 4), analogous as described for intermediate 2 produced the title compound (160 mg, 71.8%).
Example 17 (5) -4- (3- (1-Acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N- (4fluoropyridin-2-yl) benzamide [000213 ] This compound was prepared, in a manner analogous to that described in Example 1, from (S) -4- (8-amino-3- (piperidin-2yl) imidazo [1,5-a] pyrazin-1- il) -N- (4-fluoropyridin-2-yl) benzamide (intermediate 22) and acryloyl chloride, to produce the title compound (12 mg, 42.7%). Data: UPLC (C) Rt: 2.29 min; m / z 486.3 (M + H) +. Intermediate 23 nc
/ 123
N- (4-Cyanopyridin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzamide [000214] This compound was prepared in an analogous manner such as that described in intermediate 4, starting from 2-aminoisonicotinonitrile, to produce the title compound (1.3 g, 99%).
Intermediate 24 nc (5) -4- (8-Amino-3- (piperidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4cyanopyridin-2-yl) benzamide [000215 ] This intermediate was prepared, in a similar manner as described for intermediate 1, from (S) -1 (benzyloxycarbonyl) piperidine-2-carboxylic acid to obtain 2- (8-amino-1bromoimidazo [1, (S) -benzyl 5-a] pyrazin-3-yl) piperidine-1-carboxylate. The subsequent reaction with N- (4-cyanopyridin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl) benzamide (Intermediate 23), analogous as described for intermediate 2 produced the title compound (82 mg, 35.7%).
Example 18 n / 123 (5) -4- (3- (1-Acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-alpirazin-1-yl) -N- (4cyanopyridin-2-yl) benzamide [ 000216] This compound was prepared, in a manner analogous to that described in Example 1, from (S) -4- (8-amino-3- (piperidin-2-yl) imidazo [1,5alpirazin-1-yl ) -N- (4-cyanopyridin-2-yl) benzamide (intermediate 24) and acryloyl chloride, to produce the title compound (4.8 mg, 10.4%). Parameter: UPLC (C)
R _t : 2.31 min.
Intermediate 25 f „c
(5) -4- (8-Amino-3- (piperidin-2-yl) imidazo [1,5-alpirazin-1-yl) -N- (4 (trifluoromethyl) pyridin-2-yl) benzamide [000217] This intermediate was prepared, in an analogous manner as described for intermediate 1, from (S) -1 (benzyloxycarbonyl) piperidine-2-carboxylic acid to obtain 2- (8-amino-1bromoimidazo [1,5 (S) -benzyl-alpyrazin-3-yl) piperidine-1-carboxylate. The subsequent reaction with 4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -N- (4 (trifluoromethyl) pyridin-2-yl) benzamide (Intermediate 10), analogue as described for intermediate 2 produced the title compound (144 mg, 59.1%).
/ 123
Example 19
(5) -4- (8-Amino-3- (1- (vinylsulfonyl) piperidin-2-yl) imidazo [1,5-alpirazin-1-yl) N- (4- (trifluoromethyl) pyridin-2-yl ) benzamide [000218] This compound was prepared, in a manner analogous to that described in Example 1, from (S) -4- (8-amino-3- (piperidin-2yl) imidazo [1,5-alpirazin- 1-yl) -N- (4- (trifluoromethyl) pyridin-2-yl) benzamide (intermediate 25) and ethylene sulfonyl chloride prepared according to the procedures described in King et al. in Can. J. Chem. 66 (1988) pgs. 1109-1116, to produce the title compound (6.1 mg, 20.5%). Data: UPLC (B) R _t : 1.24 min; m / z 572.2 (M + H) +.
Intermediate 26
N- (Pyrimidin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzamide [000219] This compound was prepared, in an analogous manner as described in intermediate 14, starting from 2-aminopyrimidine, to produce the title compound (855 mg, 42.6%).
/ 123
Intermediate 27
(5) -4- (8-Amino-3- (piperidin-2-yl) imidazori, 5-alpirazin-1-yl) -N- (pyrimidin-2yl) benzamide [000220] This intermediate was prepared, in a analogous to that described for intermediate 1, starting from (S) -1 (benzyloxycarbonyl) piperidine-2-carboxylic acid to obtain 2- (8-amino-1bromoimidazo [1,5-alpirazin-3-yl) piperidine (S) -benzyl -1-carboxylate. The subsequent reaction with N- (pyrimidin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl) benzamide (Intermediate 26), analogous as described for intermediate 2 produced the title compound (100.8 mg, 95.4%).
Example 20 nO (5) -4- (3- (1-Acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-alpirazin-1-yl) -N (pyrimidin-2-yl) benzamide / 123 [000221 ] This compound was prepared, in a manner analogous to that described in Example 1, from (S) -4- (8-amino-3- (piperidin-2yl) imidazo [1,5-a] pyrazin-1- il) -N- (pyrimidin-2-yl) benzamide (intermediate 27) and acryloyl chloride, to produce the title compound (5.9 mg, 26.2%). Data: UPLC (C) R _t : 1.70 min; m / z 469.3 (M + H) +.
Intermediate 28
N- (4-Methylpyrimidin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl) benzamide [000222] This compound was prepared, in an analogous manner as described in intermediate 14, starting from 2-amino-4-methylpyrimidine, to produce the title compound (420 mg, 60.6%).
Intermediate 29 (5) -4- (8-Amino-3- (piperidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4methylpyrimidin-2-yl) benzamide / 123 [ 000223] This intermediate was prepared, in a manner analogous to that described for intermediate 1, from (S) -1 (benzyloxycarbonyl) piperidine-2-carboxylic acid to obtain 2- (8-amino-1bromoimidazo [1 , 5-a] pyrazin-3-yl) (S) -benzyl piperidine-1-carboxylate. The subsequent reaction with N- (4-methylpyrimidin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl) benzamide (Intermediate 28), analogous as described for intermediate 2 produced the title compound (83 mg, 50.4%).
Example 21 (5) -4- (3- (1-Acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N- (4methylpyrimidin-2-yl) benzamide [000224 ] This compound was prepared, in a manner analogous to that described in Example 1, from (S) -4- (8-amino-3- (piperidin-2yl) imidazo [1,5-a] pyrazin-1- il) -N- (4-methylpyrimidin-2-yl) benzamide (intermediate 29) and acryloyl chloride, to produce the title compound (4.5 mg, 27.4%). Data: UPLC (C) Rt: 1.79 min; m / z 483.3 (M + H) +. Intermediate 30
/ 123
N- (Pyrimidin-4-yl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzamide [000225] This compound was prepared, in an analogous manner as described in intermediate 14, starting from 4-aminopyrimidine, to produce the title compound (1 g, 59.4%).
Intermediate 31 (5) -4- (8-Amino-3- (piperidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyrimidin-4yl) benzamide [000226] This intermediate was prepared, in a similar manner as described for intermediate 1, from (S) -1 (benzyloxycarbonyl) piperidine-2-carboxylic acid to obtain 2- (8-amino-1bromoimidazo [1,5-a ] (S) -benzyl pyrazin-3-yl) piperidine-1-carboxylate. The subsequent reaction with N- (pyrimidin-4-yl) -4- (4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl) benzamide (Intermediate 30), analogous as described for intermediate 2 produced the title compound (66 mg, 42.8%).
Example 22/123 (5) -4- (8-Amino-3- (1-but-2-yoylpiperidin-2-yl) imidazo [1,5-alpirazin-1-yl) -N (pyrimidin-4-yl ) benzamide [000227] This compound was prepared, in a manner analogous to that described in Example 2, from (S) -4- (8-amino-3- (piperidin-2yl) imidazo [1,5-alpirazin- 1-yl) -N- (pyrimidin-4-yl) benzamide (intermediate 31) and 2-butinoic acid, to produce the title compound (10.3 mg, 26.9%). Data: UPLC (C) Rt: 1.91 min; m / z 481.3 (M + H) +.
Intermediate 32
N- (Pyridazin-3-yl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzamide [000228] This compound was prepared, in an analogous manner as described in intermediate 14, starting from 3-aminopyridazine, to produce the title compound (1.25 g, 71.3%).
Intermediate 33 (5) -4- (8-Amino-3- (piperidin-2-yl) imidazo [1,5-alpirazin-1-yl) -N- (pyridazin-3yl) benzamide / 123 [000229] This intermediate was prepared, in a similar manner as described for intermediate 1, from (S) -1 (benzyloxycarbonyl) piperidine-2-carboxylic acid to obtain 2- (8-amino-1bromoimidazo [1,5-a ] (S) -benzyl pyrazin-3-yl) piperidine-1-carboxylate. The subsequent reaction with N- (pyridazin-3-yl) -4- (4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl) benzamide (Intermediate 32) and deprotection, analogous as described for intermediate 2 produced the title compound (258 mg, 85%). Example 23 (5) -4- (8-Amino-3- (1-but-2-yoylpiperidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (pyridazin-3-yl ) benzamide [000230] This compound was prepared, in a manner analogous to that described in Example 2, from (S) -4- (8-amino-3- (piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridazin-3-yl) benzamide (intermediate 33) and 2-butinoic acid, to produce the title compound (11 mg, 31.8%). Data: UPLC (C) R _t : 1.92 min; m / z 481.3 (M + H) +.
Intermediate 34
/ 123
N- (Isoxazol-3-yl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzamide [000231] This compound was prepared, in an analogous manner as described in intermediate 14, starting from 3-aminoisoxazole, to produce the title compound (1.64 g, 95%).
Intermediate 35 (5) -4- (8-Amino-3- (piperidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N- (isoxazol-3yl) benzamide [000232] This intermediate was prepared, in a similar manner as described for intermediate 1, from (S) -1 (benzyloxycarbonyl) piperidine-2-carboxylic acid to obtain 2- (8-amino-1bromoimidazo [1,5-a ] (S) -benzyl pyrazin-3-yl) piperidine-1-carboxylate. The subsequent reaction with N- (isoxazol-3-yl) -4- (4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl) benzamide (Intermediate 34) and deprotection, analogous as described for intermediate 2 produced the title compound (72 mg, 129%). Example 24 n
/ 123 (5) -4- (8-Amino-3- (1-but-2-yoylpiperidin-2-yl) imidazo [1,5-alpyazin-1-yl) -N (isoxazol-3-yl) benzamide [000233] This compound was prepared, in a manner analogous to that described in Example 2, from (S) -4- (8-amino-3- (piperidin-2-yl) imidazo [1,5alpirazin-1- il) -N- (isoxazol-3-yl) benzamide (intermediate 35) and 2-butinoic acid, to produce the title compound (2 mg, 6.6%). Data: UPLC (C) R _t : 2.23 min; m / z 470.3 (M + H) +.
Intermediate 36
N- (5-Ethylthiazol-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzamide [000234] This compound was prepared in an analogous manner such as that described in intermediate 4, starting from 5-ethylthiazole-2-amine, to produce the title compound (191 mg, 34.2%).
Intermediate 37
(5) -4- (8-Amino-3- (piperidin-2-yl) imidazo [1,5-alpirazin-1-yl) -N- (5-ethylthiazol2-yl) benzamide [000235l This intermediate was prepared, in a similar manner as a / 123 described for intermediate 1, from (S) -1 (benzyloxycarbonyl) piperidine-2-carboxylic acid to obtain 2- (8-amino-1bromoimidazo [1,5-a] (S) -benzyl pyrazin-3-yl) piperidine-1-carboxylate. The subsequent reaction with N- (5-ethylthiazol-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl) benzamide (Intermediate 36) and deprotection, analogous as described for intermediate 2 it produced the title compound (146 mg, 52.4%).
Example 25
o (S, E) -4- (8-Amino-3- (1- (4-methoxybut-2-enoyl) piperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- ( 5-ethylthiazol-2-yl) benzamide [000236] This compound was prepared, in a manner analogous to that described in Example 2, from (S) -4- (8-amino-3- (piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (5-ethylthiazol-2-yl) benzamide (intermediate 37) and (E) -4-methoxybut-2-enoic acid (Intermediate 3), to produce the title compound (11.7 mg, 47.6%). Data: UPLC (C) R _t : 2.59 min; m / z
546.3 (M + H) +.
Intermediate 38
/ 123
2-Fluoro-N- (4-propylpyridin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl) benzamide [000237] This compound was prepared, in a analogous to that described in intermediate 4, starting from commercially available 2-fluoro-4- (4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl) benzoic acid and 4-propyl-pyridin-2 -ylamine, to produce the title compound (830 mg, 63.3%).
Intermediate 39
(5) -4- (8-Amino-3- (piperidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -2-fluoro-N- (4propylpyridin-2-yl) benzamide [ 000238] This intermediate was prepared, in a manner analogous to that described for intermediate 1, from (S) -1 (benzyloxycarbonyl) piperidine-2-carboxylic acid to obtain 2- (8-amino-1bromoimidazo [1 , 5-a] pyrazin-3-yl) (S) -benzyl piperidine-1-carboxylate. The subsequent reaction with 2-fluoro-N- (4-propylpyridin-2-yl) -4- (4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl) benzamide (Intermediate 38) and deprotection , analogous as described for intermediate 2 produced the title compound (75.4 mg, 62%).
/ 123
Example 26
(5) -4- (3- (1-Acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-a1pyrazin-1-yl) -2fluoro-N- (4-propylpyridin-2-yl) benzamide [000239 ] This compound was prepared, in a similar manner as described in Example 2, from (S) -4- (8-amino-3- (piperidin-2yl) imidazo [1,5-a1pyrazin-1-yl) -2-fluoro-N- (4-propylpyridin-2-yl) benzamide (intermediate 39) and acrylic acid, to produce the title compound (5.9 mg, 28.9%). Data: UPLC (C) Rt: 2.41 min; m / z 528.4 (M + H) +.
Intermediate 40
2-Methoxy-N- (4-propylpyridin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl) benzamide [000240] This compound was prepared, in a analogous to that described in intermediate 14, starting from commercially available 4-bromo-2-methoxybenzoic acid and 4-propyl-pyridin-2-ylamine, to produce the title compound (240 mg, 15.1%).
/ 123
Intermediate 41
(5) -4- (8-Amino-3- (piperidin-2-yl) imidazori, 5-alpirazin-1-yl) -2-methoxy-N- (4propylpyridin-2-yl) benzamide [000241] This intermediate was prepared, in a similar manner as described for intermediate 1, from (S) -1 (benzyloxycarbonyl) piperidine-2-carboxylic acid to obtain 2- (8-amino-1bromoimidazo [1,5-alpirazin -3-yl) (S) -benzyl piperidine-1-carboxylate. The subsequent reaction with 2-methoxy-N- (4-propylpyridin-2-yl) -4- (4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl) benzamide (Intermediate 40) and deprotection , analogous as described for intermediate 2 produced the title compound (74.5 mg, 75%).
Example 27
n / 123 (5, E ') - 4- (8-Amino-3- (1- (4- (dimethylamino) but-2-enoyl) piperidin-2-yl) imidazo [1,5-a] pyrazin- 1-yl) -2-methoxy-N- (4-propylpyridin-2-yl) benzamide [000242] This compound was prepared, in a manner analogous to that described in Example 2, from (S) -4- ( 8-amino-3- (piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -2-methoxy-N- (4-propylpyridin-2-yl) benzamide (intermediate 41) and acid (£ ) -4- (dimethylamino) but-2-enoic, to produce the title compound (13.1 mg, 38.4%). Data: UPLC (C) R _t : 1.86 min; m / z
597.4 (M + H) +.
Intermediate 42
3-Methyl-N- (pyridin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl) benzamide [000243] This compound was prepared in an analogous manner such as that described in intermediate 14, starting from commercially available 4-bromo-3-methylbenzoic acid and 2-aminopyridine, to produce the title compound (2.5 g, 71.3%).
Intermediate 43
/ 123
4- (8-Amino-3 - ((5) -piperidin-2-yl) imidazori, 5-alpirazin-1-yl) -3-methyl-N (pyridin-2-yl) benzamide [000244] This intermediate was prepared, in a manner analogous to that described for intermediate 1, from (S) -1 (benzyloxycarbonyl) piperidine-2-carboxylic acid to obtain 2- (8-amino-1bromoimidazo [1,5-alpirazin- (S) -benzyl 3-yl) piperidine-1-carboxylate. The subsequent reaction with 3-methyl-N- (pyridin-2-yl) -4- (4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl) benzamide (Intermediate 42) and deprotection, analogous as described for intermediate 2 produced the title compound (150 mg, 71.7%). Example 28
4- (8-Amino-3 - ((5) -1-but-2-yoylpiperidin-2-yl) imidazo [1,5-alpirazin-1-yl) -3methyl-N- (pyridin-2-yl) benzamide [000245] This compound was prepared, in a manner analogous to that described in Example 2, from 4- (8-amino-3 - ((5) -piperidin-2yl) imidazo [1,5-a] pyrazin -1-yl) -3-methyl-N- (pyridin-2-yl) benzamide (intermediate 43) and 2-butinoic acid, to produce the title compound (13.7 mg, 59.1%). Data: UPLC (C) Rt: 2.28 min; m / z 494.3 (M + H) +. Intermediate 44
nh.
/ 123
4- (8-Amino-3- (aminomethyl) imidazo [1,5-alpirazin-1-yl) -N- (pyridin-2yl) benzamide [000246] This intermediate was prepared, in a manner analogous to that described for intermediate 1, from Z-Gly-OH to obtain benzyl (8-amino-1bromoimidazo [1,5-alpyrazin-3-yl) methylcarbamate. The subsequent reaction with commercially available 4- (pyridin-2-yl-amino-carbonyl) benzenoboronic acid, analogous as described for intermediate 2, produced the title compound (261 mg, 81%).
Example 29
4- (3- (Acrylamidomethyl) -8-aminoimidazo [1,5-alpirazin-1-yl) -N- (pyridin-2yl) benzamide [000247] This compound was prepared, in a manner analogous to that described in Example 1 , from 4- (8-amino-3- (aminomethyl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide (intermediate 44) and acryloyl chloride, to produce the title compound (1.7 mg, 4%). Data: UPLC (C) R _t : 1.22 min; m / z 414.2 (M + H) +.
Intermediate 45
nh / 123 (5) -4- (8-Amino-3- (1-aminoethyl) imidazori, 5-a1pyrazin-1-yl) -N- (pyridin-2yl) benzamide [000248] This intermediate was prepared, in a analogous to that described for intermediate 1, starting from Z-Ala-OH to obtain benzyl 1- (8-amino-1-bromoimidazo [1,5-a] pyrazin-3-yl) ethylcarbamate (S) benzyl. The subsequent reaction with commercially available 4- (pyridin-2-ylaminocarbonyl) benzeneboronic acid and deprotection with 33% HBr / HOAc, analogous as described for intermediate 2, produced the title compound (133.6 mg, 80%).
Example 30
(S) -4-i8zAmino-3- £ 1-but-2-yamidoethyl) imidazo [1,5-alpyrazin-1-yl) -N2 (pyridin-2-yl) benzamide [000249] This compound was prepared in in a similar manner as described in Example 2, from (S) -4- (8-amino-3- (1-aminoethyl) imidazo [1,5a1pyrazin-1-yl) -N- (pyridin-2-yl ) benzamide (intermediate 45) and 2-butinoic acid, to produce the title compound (9.5 mg, 26.9%). Data: UPLC (C) R _t : 1.38 min; m / z 440.3 (M + H) +.
/ 123
Example 31
(5) -S-2- (2- (8-Amino-1- (4- (pyridin-2-ylcarbamoyl) phenyl) ethanothioate imidazo [1,5-a] pyrazin-3-yl) pyrrolidin-1 - il) -2-oxoethyl [000250] This compound was prepared, in a manner analogous to that described in Example 1, from the compound described in intermediate 2b and 2,5-dioxopyrrolidin-1-yl (acetylthio) acetate, to produce the title compound (12.3 mg, 31.8%). Data: UPLC (C) Rt: 1.51 min; m / z 516.3 (M + H) +.
Example 32
(5) -4- (8-Amino-3- (1- (4-hydroxy-4-methylpent-2-yl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide [000251] This compound was prepared, in a manner analogous to that described in Example 2, from the compound described in intermediate 2b and 4-hydroxy-4-methylpent-2-ionic acid, for yield the title compound (8.0 mg, 25.1%). Data: UPLC (C) R _t : 1.53 min; m / z 510.3 (M + H) +.
/ 123
Example 33
(5) -4- (8-Amino-3- (1- (6-chloropyrimidine-4-carbonyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2 -yl) benzamide [000252] This compound was prepared, in a manner analogous to that described in Example 2, from the compound described in intermediate 2b and 6-chloropyrimidine-4-carboxylic acid, to produce the title compound (2, 5 mg, 6.2%). Data: UPLC (C) Rt: 1.64 min; m / z 540.3 (M + H) +.
Example 34
(5) -4- (8-Amino-3- (1-pent-2-inoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (pyridin-2-yl) benzamide [0002531 This compound was prepared, in a manner analogous to that described in Example 2, from the compound described in intermediate 2b and pent-2-inoic acid, to produce the title compound (7.4 mg, 24.7% ).
/ 123
Data: UPLC (C) Rt: 1.73 min; m / z 480.3 (M + H) +. Example 35
(5) -4- (8-Amino-3- (1 - (3-cidopropylpropioloyl) pyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide [000254] This compound was prepared, in a manner analogous to that described in Example 2, from the compound described in intermediate 2b and 3-cyclopropylpropiolic acid, to produce the title compound (8 mg, 26%). Data: UPLC (C) Rt: 1.73 min; m / z 492.3 (M + H) +.
Example 36 (5) -4- (8-Amino-3- (1-hex-2-yoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N (pyridin-2-yl ) benzamide [000255] This compound was prepared, in a manner analogous to that described in Example 2, from the compound described in intermediate 2b and / 123 hex-2-inoic acid, to produce the title compound (8.1 mg , 26.2%). Data: UPLC (C) Rt: 1.94 min; m / z 494.3 (M + H) +.
Intermediate 46
4- (8-Amino-3- (azepan-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2yl) benzamide [000256] This intermediate was prepared, in a analogous to that described for intermediate 1, starting from 1 (benzyloxycarbonyl) azepane-2-carboxylic acid to obtain 2- (8-amino-1bromoimidazo [1,5-a] pyrazin-3-yl) azepane-1 benzyl carboxylate. The subsequent reaction with commercially available 4- (pyridin-2-yl-aminocarbonyl) benzene boronic acid, analogous as described for intermediate 2, produced the title compound (436 mg, quantitative, crude).
Example 37
n / 123
4- (3- (1-Acryloylazepan-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2yl) benzamide [000257] This compound was prepared, in a analogous to that described in Example 1, from 4- (8-amino-3- (azepan-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide (intermediate 46) and acryloyl chloride, to produce the title compound (11 mg, 32.6%). Data: UPLC (C) R _t : 1.88 min; m / z 482.3 (M + H) +.
Intermediate 47
(R) -4- (8-Amino-3- (morpholin-3-yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2yl) benzamide [000258] This intermediate was prepared , in a similar manner as described for intermediate 1, starting from (S) -4 (benzyloxycarbonyl) morpholino-3-carboxylic acid to obtain 3- (8-amino-1bromoimidazo [1,5-a] pyrazin -3-yl) (R) -benzyl morpholino-4-carboxylate. The subsequent reaction with commercially available 4- (pyridin-2-yl-aminocarbonyl) benzenoboronic acid, analogous as described for intermediate 2 and subsequent deprotection using TFA at 60 ° C, produced the title compound (62 mg, 69.5 %).
/ 123
Example 38
(R) -4- (8-Amino-3- (4-but-2-yoylmorpholin-3-yl) imidazo [1,5-a1pyrazin-1-yl) -N (pyridin-2-yl) benzamide [000259 ] This compound was prepared, in a similar way as described in Example 2, from (R) -4- (8-amino-3- (morpholin-3yl) imidazo [1,5-a1pyrazin-1-yl) -N- (pyridin-2-yl) benzamide (intermediate 47) and 2-butinoic acid, to produce the title compound (4.9 mg, 14.1%). Data: UPLC (C) Rt: 1.38 min; m / z 482.3 (M + H) +.
Intermediate 48
(5) -4- (8-Amino-3- (1- (methylamino) ethyl) imidazo [1,5-a1pyrazin-1-yl) -N- (4 (trifluoromethyl) pyridin-2-yl) benzamide [000260 ] This intermediate was prepared, in a similar way as described for intermediate 1, from (S) -2100 / 123 ((benzyloxycarbonyl) (methyl) amino) propanoic acid to obtain 1- (8-amino- 1bromoimidazo [1,5-a] pyrazin-3-yl) ethyl (methyl) carbamate of (5) -benzyl. The subsequent reaction with 4- (4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl) -N- (4 (trifluoromethyl) pyridin-2-yl) benzamide (Intermediate 10), analogue as described for intermediate 2 produced the title compound (71 mg, 64.7%). Example 39
(5) -4- (8-amino-3- (1- (N-methylbut-2-yamido) ethyl) imidazo [1,5-a] pyrazin-1-yl) N- (4- (trifluoromethyl) pyridin -2-yl) benzamide [000261] This compound was prepared, in a manner analogous to that described in Example 2, from (S) -4- (8-amino-3- (1 (methylamino) ethyl) imidazo [ 1,5-a] pyrazin-1-yl) -N- (4- (trifluoromethyl) pyridin-2yl) benzamide (intermediate 48) and 2-butinoic acid, to produce the title compound (11.5 mg, 33, 4%). Data: UPLC (C) R _t : 2.54 min; m / z 522.2 (M + H) +.
Intermediate 49 z
4- (Dimethylamino) but-2-inoic acid [000262] w-BuLi in hexane (2.5 M, 24.06 mmol, 9.62 ml) was slowly added to a solution of A, A-dimethylprop-2- in-1-amine (24.06 mmol, 2.59 ml, 2 g) in dry THF (10 ml) at -78 ° C. The mixture was stirred for 1 h at -78 ° C, then compressed CO ₂ (241 mmol, 10.59 g) was added in one portion and the reaction mixture was stirred for an additional
101/123 of 10 min. The resulting solution was poured into water and washed with ethyl acetate. The aqueous layer was evaporated in vacuo to give the crude amino acid. This was dissolved in methanol, and the insoluble salts were removed by filtration. The filtrate was evaporated to give 3.25 g of 4 (dimethylamino) but-2-inoic acid (106%).
Example 40
(5) -4- (8-Amino-3- (1- (4- (dimethylamino) but-2-yoyl) pyrrolidin-2-yl) imidazo [1,5-alpirazin-1-yl) -N- ( pyridin-2-yl) benzamide [000263] This compound was prepared, in a manner analogous to that described in Example 2, from the compound described in intermediate 2b and 4- (dimethylamino) but-2-inoic acid (Intermediate 49) , to produce the title compound (5.6 mg, 12%). Data: UPLC (C) R _t : 0.97 min; m / z 509.3 (M + H) +.
Intermediate 50
4-Methoxybut-2-inoic acid [000264] «-BuLi in hexane (2.5 M, 28.5 mmol, 11.41 ml) was slowly added to a solution of 3-methoxyprop-1-ino (28.5 mmol, 2.41 ml, 2 g) in dry THF (10 ml) at -78 ° C. The mixture was stirred for 1 h at 78 ° C, then compressed CO ₂ (285 mmol, 12.56 g) was added in one portion and the reaction mixture was stirred for an additional 10 min. The resulting solution was poured into water and washed with ethyl acetate. THE
102/123 aqueous layer was evaporated in vacuo to give the crude amino acid. This was dissolved in methanol, and the insoluble salts were removed by filtration. The filtrate was evaporated to give 3.35 g of 4-methoxybut-2-non-acid (103%).
Example 41
(5) -4- (8-Αηιΐηο-3- (1 - (4-methoxybut-2-inoyl) pyrrolidin-2-yl) imidazori, 5alpirazin-1-yl) -N- (pyridin-2-yl) benzamide [000265] This compound was prepared, in a manner analogous to that described in Example 2, from the compound described in intermediate 2b and 4-methoxybut-2-inoic acid (Intermediate 50), to produce the title compound (9, 1 mg, 24.7%). Data: UPLC (C) R _t : 1.44 min; m / z 496.2 (M + H) ⁺ . [000266] Examples that follow have been synthesized following the methods described for examples 1 to 41.
Example Structure Name (M + H) ⁺ m / z UPLC (C) Rt 42 F ^ N o, / VN / ^H nh ₂ (5) -4- (3- (1-acryloylpyrrolidin-2-yl) - 8 aminoimidazo [1,5a] pyrazin-1-yl) -N- (4- 472.3 2.25 min 1 ¹ / N 9 fluoropyridin-2-yl) benzamide
103/123
Example Structure Name (M + H) ⁺ m / z UPLC (C) Rt 43 o V ² N y = P (5) -4- (3- (1-acryloylpyrrolidin-2-yl) - 8 aminoimidazo [1,5a] pyrazin-1-yl) -N- (4 (pyrrolidin-1-yl) pyridin-2yl) benzamide 523.3 1.72 min 44 y-NnÓ5 __0 (5) -4- (8-amino-3- (l-but-2inoylpiperidin-2yl) imidazo [1,5-a] pyrazin-1 yl) -N- (4-fluoropyridin-2yl) benzamide 498.3 2.47 min 45 / ^H nh ₂ ^N ód ^N 3 / '- N O (5) -4- (8-amino-3- (l-but-2inoylpiperidin-2yl) imidazo [1,5-a] pyrazin-1 yl) -N- (pyridin-2yl) benzamide 480.3 2.26 min LCMS (B) 46 Λ-NCXy iCP (5) -4- (3- (1-acryloylpiperidin2 -yl) - 8 - aminoimidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2yl) benzamide 468.3 2.49 min 47 ^ N o, / -VN n C- ^N - ^ (5) -4- (8-amino-3- (l-but-2inoylpyrrolidin-2yl) imidazo [1,5-a] pyrazin-1 yl) -N- (4-propylpyridin-2yl) benzamide 508.3 2.00 min 48 /Thefy Kpp À- (5, £) -4- (8-amino-3- (1- (4-methoxy-N-methylbut-2enamido) ethyl) imidazo [1,5a] pyrazin-1-yl) -N- (4propylpyridin-2-yl ) benzamide 528.3 1.89 min
104/123
Example Structure Name (M + H) ⁺ m / z UPLC (C) Rt 49 NNόγ (5) -4- (8-amino-3- (1 (vinylsulfonyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1 yl) -N- (4-propylpyridin-2yl) benzamide 546.3 2.15 min 50 0.V-NF / Y-Nή ΌN Y = ^0 (5) -4- (8-amino-3- (l-but-2inoylpyrrolidin-2yl) imidazo [1,5-a] pyrazin-1 yl) -2-fluoro-N- (pyridin-2yl) benzamide 484.3 1.84 min 51 / 0 Y ^ N 0,! γ-Ν N ^X f ^ Υ ^Ν Υ Ç ₀ 2nd (S, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2-il) imidazo [1,5-a] pyrazin-1 -il) -N- (4-methoxypyridin-2-il) benzamide 528.4 1.60 min 52 .9 YN F ^H NH ₂ ⁿ 7 (S, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2-il) imidazo [1,5-a] pyrazin-1 -il) -2-fluoro-N- (4-methoxypyridin-2-il) benzamide 516.3 1.79 min 53 rj-iYYx, f ffThe/ (S, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2-il) imidazo [1,5-a] pyrazin-1 -il) -N- (4-fluoropyridin-2-il) benzamide 516.3 2.31 min 54 Q ^z Cl ' ^z Vú ° o 1 (S, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidin2-yl) imidazo [1,5 -a] pyrazinl-yl) -N- (isoxazol-3yl) benzamide 502.3 2.01 min 55 Cj ^z ιΖΧγ o / (S, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidin2-yl) imidazo [1,5 -a] pyrazin1 -yl) -N - (pyrimidin-2yl) benzamide 513.3 1.79 min
105/123
Example Structure Name (M + H) ⁺ m / z UPLC (C) Rt 56 4- (8-amino-3 - ((5) -l- (2- 568.3 2.23 min 0, /y ~ N chloropyrimidine-4- carbonyl) piperidin-2- ^N il) imidazo [1,5-a] pyrazin-1 - ΐ ΛΑ ₀ w ci il) -3-methyl-N- (pyridin-2-il) benzamide 57 sP (5, £) -4- (8-amino-3- (1- (4-methoxybut-2- 512.4 1.67 min Xr enoyl) pyrrolidin-2- N X ^ il) imidazo [1,5-a] pyrazin-1 - 9 ₀ il) -N- (4-methylpyridin-2- B il) benzamide 58 ^ N (5, £) -4- (8-amino-3- (1- (4-methoxybut-2- 540.3 1.74 min 0 / VN J ^H enoyl) pyrrolidin-2- il) imidazo [1,5-a] pyrazin-1 - In il) -N- (4-isopropylpyridin-2- il) benzamide 59 (5, £) -4- (8-amino-3- (1- (4- 525.4 1.11 min The, / (dimethylamino) but-2- J ^H enoyl) pyrrolidin-2- nh ₂ = ^ il) imidazo [1,5-a] pyrazin-1 -^{N <} XAj il) -N- (4-methylpyridin-2- il) benzamide 60 at the (5) -4- (8-amino-3- (l-but-2- 472.0 2.24 min TheΎ-Ν inoylpyrrolidin-2- Í7 il) imidazo [1,5-a] pyrazin-1 - N il) -N- (thiazol-2-yl) benzamide ΐ I ~ / N0tr ^ 61 = ^ N (5) -4- (3- (1- acryloylpiperidin2 -yl) - 8 - aminoimidazo [1,5- 510.3 2.11 min N _{> 0} a] pyrazin-1-yl) -N- (4- N propylpyridin-2-yl) benzamide I ¹ M ₀62 ^{F F} (5) -4- (3- (1- 522.0 2.37 min = ^ N acryloylpyrrolidin-2-yl) - 8 - Ύ ~ ν aminoimidazo [1,5- THE a] pyrazin-1-yl) -N- (4- (trifluoromethyl) pyridin-2- 1 . N il) benzamide
106/123
Example Structure Name (M + H) ⁺ m / z UPLC (C) Rt 63 CF ^ NThe, /V-NnThe (5) -4- (8-amino-3- (l-but-2inoylpiperidin-2yl) imidazo [1,5-a] pyrazin-1 yl) -N- (4-(trifluoromethyl) pyridin-2-il) benzamide 548.3 1.09 min UPLC (B) 64 o, / VN / ^H nh ₂ õy 3 Λ-ν ⁷ o (5) -4- (8-amino-3- (l-but-2inoylpiperidin-2yl) imidazo [1,5-a] pyrazin-1 yl) -N- (4-propylpyridin-2yl) benzamide 522.3 2.29 min 65 y><NV = / ^Ν ^ ^Ν Ϊ 1 / N O (S, £) -4- (8-amino-3- (1- (4-(dimethylamino) but-2-enoyl) pyrrolidin-2-il) imidazo [1,5-a] pyrazin-1 -il) -N- (4-isopropylpyridin-2-il) benzamide 553.3 1.31 min 66 ry = NΟχ / y-Nn r IQ vb '° 4- (8-amino-3 - ((5) -l (vinylsulfonyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1 yl) -3-methyl-N- (pyridin-2yl) benzamide 518.3 2.20 min 67 ^ N Οχ / yN fr ^F N = ^ y, (2 (5) -4- (8-amino-3- (l-but-2inoylpiperidin-2yl) imidazo [1,5-a] pyrazin-1 yl) -2-fluoro-N- (4propylpyridin-2-yl) benzamide 540.3 2.56 min 68 ry 0 / yN N Λ ^N Cy y ^ / - N o 4- (3 - ((5) - 1-acryloylpiperidin2-yl) - 8 - aminoimidazo [1,5a] pyrazin-1-yl) -3-methyl-N (pyridin-2-yl) benzamide 482.2 1.98 min 69 yy = N o, / VN / ^H NH ₂ O M N-— / (£) -4- (8-amino-3 - ((4-(dimethyl amino) but-2-enamido) methyl)imidazo [1,5 -a] pyrazin-1 -11) -N- (pyridin-2-yl) benzamide 471.2 1.16 min
107/123
Example Structure Name (M + H) ⁺ m / z UPLC (C) Rt 70 (5) -4- (8-amino-3- (l- (2- 582.2 1.89 min nh ₂ τ F> o VJ o chloropyrimidine-4carbonyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1 yl) -N- (4-isopropylpyridin-2- 1Cl il) benzamide 71 M/ Vn (5) -4- (8-amino-3- (l- (2- 600.2 2.49 min F ^s Fr chloropyrimidine-4- n-FF carbonyl) pyrrolidin-2- F-V 9O o il) imidazo [1,5-a] pyrazin-1 yl) -N- (4,5,6,7- 1Cl tetrahydrobenzo [d] thiazol-2yl) benzamide 72 F ^ n o, r ^N (S, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidine- 513.3 1.84 min F ^H 2-yl) imidazo [1,5 -a] pyrazin- NH ₂ FF 1 -yl) -N- (pyridazin-3 - /The il) benzamide 73 THEF = No, /O-N (S, £) -4- (8-amino-3- (1- (4-(dimethylamino) but-2- 526.4 1.26 min F ^H enoyl) piperidin-2- NH ₂ = F il) imidazo [1,5-a] pyrazin-1 - n ' ⁷ fF i I 1 N ^L O ^N F u Ν' il) -N- (pyridazin-3- THE il) benzamide 74 FF (5) -4- (8-amino-3- (l- (2- 555.3 1.96 min Ov!O-N chloropyrimidine-4- F ^H carbonyl) piperidin-2-^NH 2 F il) imidazo [1,5-a] pyrazin-1 - Fn _n il) -N- (pyridazin-3- ÒFCl il) benzamide 75 F /> F ^F ' (S, £) -4- (8-amino-3- (1- (4- 554.2 2.47 min F methoxy-N-methylbut-2- HNF ° enamido) ethyl) imidazo [1,5- nh ₂ fF a] pyrazin-1-yl) -N- (4 (trifluoromethyl) pyridin-2- OFFn il) benzamide 76 (S, £) -4- (8-amino-3- (1- (4-(dimethylamino) -N-methylbut- 541.3 1.41 min HNy ° 2-enamido) ethyl) imidazo [1,5- F a] pyrazin-1-yl) -N- (4- NH ₂ FF propylpyridin-2-yl) benzamide Cf Fn ⁷
108/123
Example Structure Name (M + H) ⁺ m / z UPLC (C) Rt 77 (S, £) -4- (8-amino-3- (1- (4- 579.3 1.64 min // AA = N (pyrrolidin-1-yl) but-2- HN ^ O enoyl) pyrrolidin-2- THE il) imidazo [1,5-a] pyrazin-1 -^NH 2 b = F <x il) -N- (4-propylpyridin-2- Õb ° _K b B il) benzamide 78 í THE (S, £) -4- (8-amino-3- (1- (4- 525.3 2.10 min 0,γ-Ν = ^ N (dimethylamino) but-2- LCMS (B) A ^Henoyl) piperidin-2- nh ₂ AA _ il) imidazo [1,5-a] pyrazin-1 -^N bb ° _K il) -N- (pyridin-2- A _N O il) benzamide 79 (5) -4- (8-amino-3- (l- (2- 582.3 1.95 min = N chloropyrimidine-4- jW carbonyl) pyrrolidin-2- il) imidazo [1,5-a] pyrazin-1 - AA. il) -N- (4-propylpyridin-2- s,GO il) benzamide Cl 80 FF° K / -THE (5) -4- (8-amino-3- (l- (2- 572.3 2.45 min = N chloropyrimidine-4carbonyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1 - / H nh ₂ bb Α> il) -N- (4-fluoropyridin-2- FM il) benzamide N <y ^N Cl 81 Fy THE (S, £) -4- (8-amino-3- (1- (4- 530.3 2.38 min V ~ N / ^H nh ₂ bb -N methoxybut-2-enoyl) piperidin2-yl) imidazo [1,5 -a] pyrazinl-yl) -N- (4-fluoropyridin-2- V i. THE 0 ^ il) benzamide 82 ° v Y yN _v V3 = N (S, £) -4- (8-amino-3- (1- (4- 558.3 2.33 min THE Aa methoxybut-2- enoyl) pyrrolidin-2- A-nM ° il) imidazo [1,5-a] pyrazin-1 - B il) -N- (4,5,6,7tetrahydrobenzo [d] thiazol-2yl) benzamide
109/123
Example Structure Name (M + H) ⁺ m / z UPLC (C) Rt 83 í THE (5) -4- (8-amino-3- (l- (2- 570.3 2.01 min 0 Z V-N = ^ N chloropyrimidine-4- carbonyl) pyrrolidin-2- nh ₂ ΑΑ ' il) imidazo [1,5-a] pyrazin-1 - AA · kl 0 il) -2-methoxy-N - (pyridin-2- il) benzamide ^Ν Ύ Cl 84 k ^ -N (5) -4- (8-amino-3- (l- (2-chloropyrimidine-4- 558.2 1.95 min carbonyl) pyrrolidin-2- nh ₂ vA il) imidazo [1,5-a] pyrazin-1 - N ^ A- kA ⁿ o il) -2-fluoro-N- (pyridin-2- il) benzamide ΎCl 85 f THE 4- (8-amino-3 - ((5) -l - ((£) -4- 526.3 2.12 min V-N methoxybut-2-enoyl) piperidine- 2-yl) imidazo [1,5-a] pyrazin- nh ₂1-yl) -3-methyl-N- (pyridin-2- AA i il) benzamide 86 ( Nk (S, £) -4- (8-amino-3- (1- (4- 513.3 1.83 min ° xy-n methoxybut-2-enoyl) piperidine- A ^H2-yl) imidazo [1,5 -a] pyrazin- nh ₂1 -yl) -N- (pyrimidin-4- AA i THE--_ il) benzamide THE 87 k THE 4- (8-amino-3 - ((5) -l - ((£) -4- 554.4 1.86 min = ^ N methoxybut-2- ° V - N / ^Henoyl) pyrrolidin-2- nh ₂ = il) imidazo [1,5-a] pyrazin-1 - Ν ^ Α'Α il) -3-methyl-N- (4- 0The propylpyridin-2-yl) benzamide 88_k Aa (S, £) -4- (8-amino-3- (1- (4- 527.3 1.88 min 0 An methoxybut-2-enoyl) piperidine- mu A> you 2-yl) imidazo [1,5 -a] pyrazin- nAA 1 -yl) -N- (4-methylpyrimidin- 2- A / ¹ ~ ^{Λ ό}il) benzamide 89_k Aa (5) -4- (8-amino-3- (l-but-2- 495.3 1.97 min 0 N} = ^N inoilpiperidin-2- mu A> H il) imidazo [1,5-a] pyrazin-1 - N il) -N- (4-methylpyrimidin-2- AN _Z N ck K. il) benzamide
110/123
Example Structure Name (M + H) ⁺ m / z UPLC (C) Rt 90 (5) -4- (8-amino-3- (l- (2- 555.3 1.91 min Xn_/ H chloropyrimidine-4- nh ₂ O carbonyl) piperidin-2- NX _ / il) imidazo [1,5-a] pyrazin-1 - Vn ^ n _o X; y il) -N- (pyrimidin-2- Ν'Ν Xí 1x yCl il) benzamide 91 X ⁵ (5) -4- (8-amino-3- (l-methacryloylpyrrolidin-2- 468.4 1.61 min il) imidazo [1,5-a] pyrazin-1 - nh ₂ ΧΧ ^ il) -N- (pyridin-2- 1 ¹ / N VX 0 il) benzamide Xi 92 yy-N (5) -4- (8-amino-3- (l- (2-(trifluoromethyl) acryloyl) pyrrole 522.3 1.99 min X ^H idin-2-yl) imidazo [1,5- nh ₂ XX a] pyrazin-1 -yl) -N- (pyridin-2- xx il) benzamide Xi 93 y (5, £) -4- (8-amino-3- (l-but- 468.4 1.59 min Οχ /y-N 2-enoylpyrrolidin-2- X ^H il) imidazo [1,5-a] pyrazin-1 - nh ₂ XX il) -N- (pyridin-2- 1 ¹ / N 9 y ..... il) benzamide 94 yy-N (5) -4- (8-amino-3- (l-(cyanomethyl) pyrrolidin-2- 439.3 1.55 min il) imidazo [1,5-a] pyrazin-1 - nh ₂ yx ^ ÍtÁi il) -N- (pyridin-2- ....... X- il) benzamide 95 X (£) -4- (8-amino-3 - ((4- 458.2 1.35 min 0, /Xy methoxybut-2- enamido) methyl) imidazo [1,5- nh ₂ xx ^ a] pyrazin-1 -yl) -N- (pyridin-2- xy y ^ ° -'' NH il) benzamide 96 THE (5) -4- (8-amino-3- (l-but-2- 535.3 2.27 min inoylpyrrolidin-2- LCMS (B) X = NΟχ /Xn il) imidazo [1,5-a] pyrazin-1 - il) -N- (4- (pyrrolidin-1 - nh ₂ xx ^ n ^ X 1 ¹ / N x ^N X o il) pyridin-2-yl) benzamide
111/123
Example Structure Name (M + H) ⁺ m / z UPLC (C) Rt 97 Q (£) -4- (8-amino-3- (l- (4- 526.3 1.97 min V-N methoxybut-2-enoyl) azepan-2- il) imidazo [1,5-a] pyrazin-1 - nh ₂ il) -N- (pyridin-2- G3 ⁿ À-N il) benzamide 98 (5, £) -4- (8-amino-3- (1- (4- 523.3 2.12 min methoxybut-2- o, / VN / ^H enoyl) pyrrolidin-2- yes il) imidazo [1,5-a] pyrazin-1 - NH ₂ Ácz-U il) -N- (4-cyanopyridin-2- il) benzamide 99 Q (5) -4- (8-amino-3- (l-but-2- 496.3 1.87 min o, r ^N VN inoylpyrrolidin-2- il) imidazo [1,5-a] pyrazin-1 - nh ₂ il) -2-methoxy-N - (pyridin-2- V ⁿ ~ 7 ⁿ already cr ^ - il) benzamide 100 Q (5) -4- (3- (1- acrylamidoethyl) - 428.3 1.15 min 0, /VN 8 -aminoimidazo [1,5- a] pyrazin-1 -yl) -N- (pyridin-2- nh ₂ il) benzamide V/ 'Ά 101 VV-s (5) -4- (3- (1- 460.2 2.03 min c> / VN / ^H acryloylpyrrolidin-2-yl) - 8 - #v aminoimidazo [1,5- a] pyrazin-l-yl) -N- (thiazole-2- il) benzamide 102 C> HV-N / (5) -4- (8-amino-3- (l-but-2- 507.8 1.82 min / fy ^N Cv ^ inoylpyrrolidin-2- il) imidazo [1,5-a] pyrazin-1 - The il) -N- (4-isopropylpyridin-2- Ò ^ · il) benzamide 103 #v (5, £) -4- (8-amino-3- (1- (4- 528.3 1.84 min 0, /V-N methoxybut-2- fr ° enoyl) pyrrolidin-2- nh ₂ = ^ il) imidazo [1,5-a] pyrazin-1 - 1 ¹ / N V ^ NV ⁷ 0 il) -2-methoxy-N- (pyridin-2- v- il) benzamide
112/123
Example Structure Name (M + H) ⁺ m / z UPLC (C) Rt 104 Vyw (5, £) -4- (8-amino-3- (1-cinamoilpyrrolidin-2- 530.4 2.09 min il) imidazo [1,5-a] pyrazin-1 - nh ₂ il) -N- (pyridin-2- 1 ¹ / N il) benzamide 105 vγ-Ν (5) -N- (l- (8-amino-l- (4-(pyridin-2- 514.3 1.56 min V ^H ilcarbamoyl) phenyl) imidazo [1, nh ₂ 5-a] pyrazin-3-yl) ethyl) -2- 1 1 _Z N _Λ chloropyrimidine-4- V carboxamide H N ^ -Cl 106 Fyy (5) -4- (8-amino-3- (l-but-2- 484.2 2.38 min ^ N 0 / VN J ^H NH ₂ inoylpyrrolidin-2yl) imidazo [1,5-a] pyrazin-1 yl) -N- (4-fluoropyridin-2- il) benzamide 107 (5) -4- (8-amino-3- (l- (2- 596.3 2.19 min chloropyrimidine-4- HN = ° carbonyl) piperidin-2- V il) imidazo [1,5-a] pyrazin-1 - nh ₂ y = ^ il) -N- (4-propylpyridin-2- ^ ^N 1 vv y ci il) benzamide 108 cf = N0. / (5, £) -4- (8-amino-3- (1- (4- 580.3 1.03 min methoxybut-2-enoyl) piperidine- UPLC (B) / ^H 2-yl) imidazo [1,5 -a] pyrazin- nh ₂ == ^ l-yl) -N- (4- ód ^N (trifluoromethyl) pyridin-2-il) benzamide 109 cf ₃ v (5) -4- (3- (1- acryloylpiperidin- 536.3 1.02 min = ^ N 0-,! VN / ^H nh ₂ yV ^ 2 -yl) - 8 - aminoimidazo [1,5a] pyrazin-1-yl) -N- (4 (trifluoromethyl) pyridin-2- UPLC (B) N '^{;; b} V <A il) benzamide 0 110 ^ N (5) -4- (8-amino-3- (l-but-2-inoilpiperidin-2- 552.4 2.57 min VN / ^H il) imidazo [1,5-a] pyrazin-1 - fy-0 nh ₂ V = ^ il) -2-methoxy-N - (4- propylpyridin-2-yl) benzamide V-τ y__0 "
113/123
Example Structure Name (M + H) ⁺ m / z UPLC (C) Rt 111 = ^ N VN / ^H ry nh ₂ VV 0 (S, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidin2-yl) imidazo [1,5 -a] pyrazinl-yl) -2-methoxy-N- (4propylpyridin -2-yl) benzamide 584.4 2.49 min 112 ^ N Οχ 'VN 7 ^H nh ₂ y ^ ^ -N 4- (8-amino-3- (but-2inamidomethyl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2yl) benzamide 426.2 1.35 min 113 HN y = o nh ₂ A õy 3 zy ^ - (5) -4- (8-amino-3- (1- (N-methylbut-2-inamido) ethyl) imidazo [1,5a] pyrazin-1-yl) -N- (4propylpyridin-2-yl) benzamide 496.3 1.94 min 114 = n Οχ / VN / ^H ír ^F nh ₂ = ^ Vy ^N y ^ 0 ~~ - o (S, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidin2-yl) imidazo [1,5 -a] pyrazinl-yl) -2-fluoro-N- (4propylpyridin -2-yl) benzamide 572.4 2.48 min 115 cf ₃ x o = N Οχ / VN / ^H nh ₂ y = z ^c $ 2-q —y ci (5) -4- (8-amino-3- (1- (2-chloropyrimidine-4carbonyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1 yl) -N- (4-(trifluoromethyl) pyridin-2-il) benzamide 622.2 1.15 min UPLC (B) 116 0 o _x r ^N VN / ^H nh ₂ A v> ____ o (5) -4- (8-amino-3- (l-but-2inoylpiperidin-2yl) imidazo [1,5-a] pyrazin-1 yl) -N- (5-ethylthiazol-2yl) benzamide 514.3 2.68 min
114/123
Example Structure Name (M + H) ⁺ m / z UPLC (C) Rt 117 or VN / ^H nh ₂ (5) -4- (3- (1-acryloylpiperidin2 -yl) - 8 - aminoimidazo [1,5a] pyrazin-1-yl) -N- (5 ethylthiazol-2-yl) benzamide 502.3 2.53 min 118 λ ox ^N VN / ^H nh ₂ Cl (5) -4- (8-amino-3- (l- (2-chloropyrimidine-4-carbonyl) piperidin-2-il) imidazo [1,5-a] pyrazin-1 -il) -N- (5-ethylthiazole-2-il) benzamide 588.3 2.71 min 119 FF ^F F5 = N <λ! VN / ^H nh ₂ 1 ¹ / N OJ ^ N Cl (5) -4- (8-amino-3- (1- (2-chloropyrimidine-4carbonyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1 yl) -N- (4-(trifluoromethyl) pyridin-2-il) benzamide 608.2 2.68 min 120 /The (Ã, £) -4- (8-amino-3- (4- (4metoxibut-2-enoyl) morfolin3 -yl) imidazo [1,5 -a] pyrazinl-yl) -N- (pyridin-2yl) benzamide 514.3 1.34 min 121 HN y ^ o nh ₂ yA ^ vy O (5, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidin2-yl) imidazo [1,5 -a] pyrazin1 -yl) -N- (4-propylpyridin-2il ) benzamide 554.4 2.07 min 122 CN A VN J ^H nh ₂ 'y (5) -4- (3- (1-acryloylpyrrolidin-2-yl) - 8 aminoimidazo [1,5a] pyrazin-1-yl) -N- (4cyanopyridin-2-yl) benzamide 479.0 1.86 min
115/123
Example Structure Name (M + H) ⁺ m / z UPLC (C) Rt 123 / 0 ^ N o, / nh ₂ 1 ¹ / N Vm u. (5) -4- (8-amino-3- (l-but-2inoylpyrrolidin-2yl) imidazo [1,5-a] pyrazin-1 yl) -N- (4-methoxypyridin-2yl) benzamide 496.3 1.50 min 124 Vy = ^ N Οχ / VN / ^H NH ₂ y> 0 ò ' (5) -4- (3- (1-acryloylpyrrolidin-2-yl) - 8 aminoimidazo [1,5a] pyrazin-1-yl) -N- (4methylpyridin-2-yl) benzamide 468.1 1.37 min 125 y = N o, / VN / ^H nh ₂ y ^ ^l -yy (5) -4- (3- (1-acryloylpyrrolidin-2-yl) - 8 aminoimidazo [1,5a] pyrazin-1-yl) -N- (4propylpyridin-2-yl) benzamide 496.1 1.76 min 126 V ^ N Οχ / VN / ^H NH ₂ = ^ yN-y 9 ò ' (5) -4- (3- (1-acryloylpyrrolidin-2-yl) - 8 aminoimidazo [1,5a] pyrazin-1-yl) -N- (4ethylpyridin-2-yl) benzamide 482.1 1.53 min 127 ry = N 0 / yN / ^H nh ₂ = y ^ yy ^ y ^ y (5, £) -4- (8-amino-3- (1- (4-(dimethylamino) but-2-enoyl) pyrrolidin-2-il) imidazo [1,5-a] pyrazin-1 -il) -N- (pyridin-2-il) benzamide 511.0 1.29 min 128 ^FF yy ^ N 0,! yN T ^H nh ₂ % ^ν Ύ ^Ν 9 y— (5, £) -4- (8-amino-3- (1- (4-methoxybut-2enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1 yl) -N- (4-(trifluoromethyl) pyridin-2-il) benzamide 566.3 2.73 min 129 Vy = N <y! yN / ^H NH ₂ = ^ r'r yy-. O y ^N Cl (5) -4- (8-amino-3- (l- (2-chloropyrimidine-4-carbonyl) pyrrolidin-2-il) imidazo [1,5-a] pyrazin-1 -il) -N- (4-methylpyridin-2-il) benzamide 554.2 1.38 min
116/123
Example Structure Name (M + H) ⁺ m / z UPLC (C) Rt 130 CN O / VN / ^H NH ₂ VV 9 (5) -4- (8-amino-3- (l-but-2inoylpyrrolidin-2yl) imidazo [1,5-a] pyrazin-1 yl) -N- (4-cyanopyridin-2yl) benzamide 491.2 2.20 min 131 V ^ N o, / VN / ^H nh ₂ (5) -4- (8-amino-3- (l-but-2inoylpyrrolidin-2yl) imidazo [1,5-a] pyrazin-1 yl) -N- (4-ethylpyridin-2yl) benzamide 494.3 1.65 min 132 O, / VN / ^H nh ₂ (5) -4- (8-amino-3- (l-but-2inoylpyrrolidin-2yl) imidazo [1,5-a] pyrazin-1 yl) -N- (4-phenylpyridin-2yl) benzamide 542.3 2.57 min N ^ V ^ 1 ¹ / N 133 V = N O, / VN / ^H nh ₂ (5) -4- (3- (1-acryloylpyrrolidin-2-yl) - 8 aminoimidazo [1,5a] pyrazin-1-yl) -N- (4phenylpyridin-2-yl) benzamide 530.3 2.38 min TV
Example 134
Test Methods
Btk enzyme activity [000267] Btk enzyme activity is measured using the IMAP assay (fluorescence polarization based on immobilized metal ion affinity) as outlined below. The Btk enzyme (His-Btk (Millipore catalog # 14-552), is diluted to 0.4 U / ml in KR buffer (10 mM TrisHC1, 10 mM MgCl ₂ , 0.01% Tween-20 , 0.05% NaN ₃ , 1 mM DTT, 2 mM MnCl ₂ , pH 7.2).
[000268] Serial log10 dilutions of 2 mM to 63.2 nM of the test compounds are made in 100% DMSO. Dilutions in DMSO are then
117/123 diluted 50 times in KR buffer. The compound concentration range varies in the assay from 10 μΜ to 0.316 nM. 5 μΐ / test compound reservoir in KR buffer (final DMSO concentration in the assay is 1%) are mixed with 5 μΐ / 0.4 U / ml reservoir of Btk enzyme (the final assay concentration is 0 , 1 U / ml). The test compounds and Btk enzyme are pre-incubated 60 minutes at room temperature, before adding 5 μΐ / 200 nM reservoir of fluorescine-labeled substrate peptide (Blk / Lyntide substrate, for example # R7188 / # R7233, Molecular Devices) in KR buffer. The final substrate peptide concentration in the assay is 50 nM. The kinase assay is started by adding 5 μΐ / 20 μΜ reservoir of ATP in KR buffer (the final ATP concentration is 5 μΜ ATP, Km ATP in the Btk IMAP assay). Following incubation for 2 h at room temperature, the enzyme reaction is stopped by adding 40 μΐ / reservoir of IMAP Progressive Binding Solution (according to the supplier protocol (Molecular Devices) using 75% of 1 x buffer A and 25% 1 x buffer B with 1: 600 Progressive Binding Solution). After 60 min incubation at room temperature in the dark, the FP signal is read. Fluorescence at 535 nm is measured using parallel and perpendicular filters to determine differences in rotation due to the binding of the phosphorylated substrate peptide to the beads. Values are calculated as a percentage of the difference in reading (AmPi) of controls with and without ATP. EC50 values are determined by adjusting the curve of the experimental results using the Base Activity.
[000269] All examples have an EC50 of 10 μΜ or lower.
Table 1 EC50 values of Btk activity EC50 Example > 1μΜ 91, > 100nM<1μΜ 52, 53, 54, 55, 68, 72, 74, 85, 86, 87, 88, 90, 92, 93, 94, 104 > 10nM<100nM 2, 4, 5, 7, 11, 24, 40, 41, 50, 51, 56, 57, 58, 59, 60, 69, 70, 71, 73, 80, 81, 82, 83, 84, 89, 95, 96, 97, 98, 99, 103, 105, 106, 112, 113, 114, 119 <10 nM 1, 3, 6, 8, 9, 10, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 42, 43, 44, 45, 46, 47, 48, 49, 61, 62, 63, 64, 65, 66, 67, 75, 76, 77, 78, 79, 100, 101, 102, 107, 108, 109, 110, 111, 115, 116, 117, 118, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133
118/123
Lck enzyme activity [000270] Lck enzyme activity is measured using the IMAP (fluorescence polarization based on immobilized metal ion affinity) assay as outlined below.
[000271] The enzyme Lck (Millipore catalog # 14-442), is diluted to 0.4 U / ml in KR buffer (10 mM Tris-HCl, 10 mM MgCl ₂ , 0.01% Tween-20, 0.05% NaN3, 1 mM DTT, 2 mM MnCh, pH 7.2).
[000272] The serial log10 dilution of 2 mM to 63.2 nM of the test compounds are manufactured in 100% DMSO. Dilutions in DMSO are then diluted 50 times in KR buffer of which 5 µl are used in the assay, leading to a final compound concentration range in the assay of 10 gM to 0.316 nM. [000273] 5 gL / reservoir of the test compound in KR buffer (final DMSO concentration in the assay is 1%) are mixed with 5 gl / 0.4 U / ml Lck enzyme reservoir (the final assay concentration is 0.1 U / ml). The test compounds and the Lck enzyme are pre-incubated 60 minutes at room temperature, before adding 5 gL / substrate peptide reservoir labeled with 400 nM Fluorescin (substrate peptide p34cdc2, for example, # R7157 / # R7172, Molecular Devices) in KR buffer. The concentration of the final peptide substrate in the assay is 100 nM. The kinase assay is started by adding 5 gL / ATP reservoir to 24 gM in KR buffer (the final ATP concentration is 6 gM ATP, Km ATP in the Lck IMAP assay). Following incubation for 2 hours at room temperature, the enzyme reaction is stopped by adding 40 gL / reservoir of IMAP Progressive Binding Solution (according to the supplier's protocol (Molecular Devices) using 75% 1x buffer A and 25% 1x buffer B with 1: 600 Progressive Bonding Solution). After 60 min incubation at room temperature in the dark, the FP signal is read. Fluorescence at 535 nm is measured using parallel and perpendicular filters to determine differences in rotation due to the binding of the phosphorylated substrate peptide to the beads. The
119/123 values are calculated as a percentage of the difference in reading (AmPi) of the controls with and without ATP. EC50 values are determined by adjusting the curve of the experimental results using Base Activity.
Table 2 EC50 values of Lck activity EC50 Example > 1μΜ 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43,44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 63, 65, 66,67, 68, 69, 70, 71, 72, 73, 74, 75, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 123, 127, 128, 129, 130, 131 > 100nM<1μΜ 60, 62, 64, 76, 104, 122, 124, 125, 126, 132, 133
Src enzyme activity [000274] Src enzyme activity is measured using the IMAP assay (fluorescence polarization based on immobilized metal ion affinity) as outlined below.
[000275] The Src enzyme (Millipore catalog # 14-326), is diluted to 0.8 U / ml in KR buffer (10 mM Tris-HCl, 10 mM MgCl ₂ , 0.01% Tween-20 , 0.05% NaN ₃ , 1 mM DTT, 2 mM MnCl ₂ , pH 7.2). [000276] Serial log10 dilution of 2 mM to 63.2 nM of the test compounds are made in 100% DMSO. The dilutions in DMSO are then diluted 50 times in KR buffer of which 5 μΐ are used in the assay, leading to a concentration range of the final compound in the assay from 10 μΜ to 0.316 nM.
[000277] 5 pL / reservoir of the test compound in KR buffer (the final concentration of DMSO in the assay is 1%) are mixed with 5 μΐ / Src enzyme reservoir at 0.8 U / ml (the final assay concentration is 0.2 U / ml). The test compounds and the Src enzyme are pre-incubated 60 minutes at room temperature, before adding 5 μl / 400 nM reservoir of substrate peptide labeled with fluorescine (substrate peptide p34cdc2, for example, # R7157 / # R7172, Molecular Devices) in KR buffer. The concentration of the final peptide substrate in the assay is 100 nM. THE
120/123 kinase assay is started by adding 5 pL / reservoir of 16 μΜ ATP in KR buffer (the final ATP concentration is 4 μΜ ATP, Km ATP in the IMAP Src assay). Following incubation for 2 h at room temperature, the enzyme reaction is stopped by adding 40 pL / reservoir of IMAP Progressive Binding Solution (according to the supplier protocol (Molecular Devices) using 75% lx buffer A and 25% lx buffer B with 1: 600 Progressive Binding Solution). After 60 min incubation at room temperature in the dark, the FP signal is read. Fluorescence at 535 nm is measured using parallel and perpendicular filters to determine differences in rotation due to the binding of the phosphorylated substrate peptide to the beads. Values are calculated as a percentage of the difference in reading (AmPi) of controls with and without ATP. EC50 values are determined by adjusting the curve of the experimental results using Base Activity.
Table 2 i Sr50 Activity EC50 Values EC50 Example > 1μΜ 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66,67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133
FynT enzyme activity [000278] FynT enzyme activity is measured using the IMAP assay (fluorescence polarization based on immobilized metal ion affinity) as outlined below.
[000279] The FynT enzyme (Biomol catalog # SE-287), is diluted to 0.5 pg / ml in KR buffer (10 mM Tris-HCl, 10 mM MgCl ₂ , 0.01% Tween-20, 0.05% NaN ₃ , 1 mM DTT, 2 mM MnCl ₂ , pH 7.2). [000280] Serial log10 dilution of 2 mM to 63.2 nM of the test compounds is done in 100% DMSO. Dilutions in DMSO are then diluted 50 times in KR buffer of which 5 µl are used in the assay, leading to a
121/123 concentration range of the final compound in the test from 10 μΜ to 0.316 nM. [000281] 5 μΕ / test compound reservoir in KR buffer (the final concentration of DMSO in the assay is 1%) are mixed with 5 μΙ / 0.5 μμ / πιΐ reservoir of FynT enzyme (the final concentration in the assay is 125 ng / ml). The test compounds and the FynT enzyme are pre-incubated 60 minutes at room temperature, before adding 5 μΕ / 400 nM substrate peptide reservoir labeled with fluorescine (substrate peptide p34cdc2, for example, # R7157 / # R7172 , Molecular Devices) in KR buffer. The concentration of the final peptide substrate in the assay is 100 nM. The kinase assay is started by adding 5 μΕ / 0.8 μΜ reservoir of ATP in KR buffer (the final ATP concentration is 0.2 μΜ ATP, Km ATP in the FynT IMAP assay). Following incubation for 2 h at room temperature, the enzyme reaction is stopped by adding 40 pL / reservoir of IMAP Progressive Picture Solution (according to the supplier protocol (Molecular Devices) using 75% lx buffer A and 25 % lx buffer B with 1: 600 Progressive Fig. Solution). After 60 min incubation at room temperature in the dark, the FP signal is read. Fluorescence at 535 nm is measured using parallel and perpendicular filters to determine differences in rotation due to the binding of the phosphorylated substrate peptide to the beads. Values are calculated as a percentage of the difference in reading (AmPi) of controls with and without ATP. EC50 values are determined by adjusting the curve of the experimental results using the Base Activity.
Table 4 1 EC50 values of FynT activity EC50 Example > 1μΜ 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66,67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87,88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133
122/123
Lyn enzyme activity [000282] Lyn enzyme activity is measured using the IMAP assay (fluorescence polarization based on immobilized metal ion affinity) as outlined below.
[000283] Lyn enzyme (Millipore catalog # 14-510), is diluted to 250 mU / ml in KR buffer (10 mM Tris-HCl, 10 mM MgCl ₂ , 0.01% Tween-20, 0, 05% NaN3, 1 mM DTT, 2 mM MnCh, pH 7.2). [000284] The log10 serial dilution of 2 mM to 63.2 nM of the test compounds are made in 100% DMSO. The DMSO dilutions are then diluted 50 times in KR buffer of which 5 µl are used in the assay, leading to a concentration range of the final compound in the assay from 10 pM to 0.316 nM.
[000285] 5 pL / reservoir of test compound in KR buffer (the final concentration of DMSO in the assay is 1%) is mixed with 5 pl / reservoir of 250 mU / ml of Lyn enzyme (the final concentration in the assay is 62.5 mU / ml). The test compounds and the Lyn enzyme are pre-incubated 60 minutes at room temperature, before the addition of 5 µl / 400 nM substrate peptide reservoir labeled with fluorescine (Blk / Lyntide substrate, for example, # R7188 / # R7233 , Molecular Devices) in KR buffer. The concentration of the final peptide substrate in the assay is 100 nM. The kinase assay is started by adding 5 pL / 8 pM ATP reservoir in KR buffer (the final ATP concentration is 2 pM ATP, Km ATP in Lyn's IMAP assay). Following incubation for 2 h at room temperature, the enzyme reaction is stopped by adding 40 pL / reservoir of IMAP Progressive Binding Solution (according to the supplier protocol (Molecular Devices) using 75% 1x buffer A and 25 % of 1x buffer B with Progressive Bonding Solution 1: 600). After 60 min incubation at room temperature in the dark, the FP signal is read. Fluorescence at 535 nm is measured using parallel and perpendicular filters
123/123 to determine the differences in rotation due to the binding of the phosphorylated substrate peptide to the beads. Values are calculated as a percentage of the difference in reading (AmPi) of controls with and without ATP. EC50 values are determined by adjusting the curve of the experimental results using Base Activity.
Table 5 Lyn activity EC50 values EC50 Example > 1μΜ 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43,44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 63, 64,65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84,85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 127, 128, 129, 130, 131, 132 > 100nM<1μΜ 60, 124, 125, 126,133
1/29

权利要求:
Claims (61)
[1]
1. Compound, characterized by the fact that it is in accordance with formula (I)
Formula (I) or a pharmaceutically acceptable salt thereof, where:
X is CH, N, O or S;
Y is C (R6), N, O or S;
Z is CH, N or a bond;
A is CH or N;
B1 is N or C (R7);
B2 is N or C (R8);
B3 is N or C (R9);
B4 is N or C (R10);
R1 is R11C (O), R12S (O), R13SO2 or alkyl (1-6C) optionally substituted with R14;
R2 is H, alkyl (1-3C) or cycloalkyl (3-7C);
R3 is H, alkyl (1-6C) or cycloalkyl (3-7C); or
R2 and R3 form, together with the N atom to which R2 is
Petition 870190035670, of 15/04/2019, p. 7/36
[2]
2/29 attached, and the C atom to which R3 is attached, a heterocycloalkyl (3-7C) optionally substituted with one or more fluorine, hydroxyl, alkyl (1-3C), alkoxy (1-3C) or oxo;
R4 is H or (1-3C) alkyl;
R5 is H, halogen, cyano, alkyl (1-4C), alkoxy (1-3C), cycloalkyl (3-6C), any alkyl group of which is optionally substituted with one or more halogens; or R5 is aryl (6-10C) or heterocycloalkyl (2-6C);
R6 is H or (1-3C) alkyl; or
R5 and R6 together can form a cycloalkenyl (3-7C), or heterocycloalkenyl (2-6C); each optionally substituted with (1-3C) alkyl, or one or more halogens;
R7 is H, halogen or alkoxy (1-3C);
R8 is H or (1-3C) alkyl; or
R7 and R8 form, together with the carbon atom to which they are attached, an aryl (6-10C) or heteroaryl (1-9C);
R9 is H, halogen or alkoxy (1-3C)
R10 is H, halogen or alkoxy (1-3C)
R11 is independently selected from the group consisting of alkyl (1-6C), alkenyl (2-6C) and alkynyl (2-6C) each alkyl, alkenyl or alkynyl optionally substituted with one or more groups selected from hydroxyl, alkyl (1- 4C), cycloalkyl (3-7C), [alkyl (1-4C)] amino, di [alkyl (1-4C)] amino, alkoxy (1-3C), cycloalkoxy (3-7C), aryl (6-10C ) or heterocycloalkyl (3-7C); or
R11 is (1-3C) alkyl -C (O) -S-alkyl (1-3C); or
R11 is heteroaryl (1-5C) optionally substituted with one or more groups selected from halogen or cyano;
R12 and R13 are independently selected from the group consisting of alkenyl (2-6C) or alkynyl (2-6C) both optionally
Petition 870190035670, of 15/04/2019, p. 8/36
[3]
3/29 replaced with one or more groups selected from hydroxyl, alkyl (1-4C), cycloalkyl (3-7C), [alkyl (1-4C)] amino, di [alkyl (1-4C)] amino, alkoxy ( 13C), cycloalkoxy (3-7C), aryl (6-10C) or heterocycloalkyl (3-7C); or heteroaryl (1-5C) optionally substituted with one or more selected groups of halogen or cyano;
R14 is independently selected from the group consisting of halogen, cyano or alkenyl (2-6C) or alkynyl (2-6C) both optionally substituted with one or more selected groups of hydroxyl, alkyl (1-4C), cycloalkyl (3-7C ), [alkyl (1-4C)] amino, di [alkyl (1-4C)] amino, alkoxy (1-3C), cycloalkoxy (3-7C), aryl (6-10C), heteroaryl (1-5C) or heterocycloalkyl (3-7C);
with the proviso that
- from 0 to 2 atoms of X, Y, Z can be simultaneously a hetero atom;
- when an atom selected from X, Y is O or S, then Z is a bond and the other atom selected from X, Y may not be O or S;
- when Z is CH or N then Y is C (R6) or N and X is CH or N;
0 to 2 atoms of B1, B2, B3 and B4 are N, where heterocycloalkyl (3-7C) means a heterocycloalkyl group having 3-7 carbon atoms and one or two hetero atoms selected from N and / or O;
wherein heterocycloalkyl (2-6C) means a heterocycloalkyl group having 2-6 carbon atoms and an N, which may be attached via N, or a carbon atom;
wherein heterocycloalkenyl (2-6C) means a heterocycloalkenyl group having 2-6 carbon atoms and 1 heteroatom selected from N, O and / or S;
where heteroaryl (1-5C) means an aromatic group having
Petition 870190035670, of 15/04/2019, p. 9/36
[4]
4/29
1-5 carbon atoms and 1-2 N atoms.
2. Compound according to claim 1, characterized by the fact that B1 is C (R7); B2 is C (R8); B3 is C (R9); B4 is C (R10);
R7, R9, and R10 are each H; and
R8 is selected from the group consisting of hydrogen and methyl.
3. A compound according to any one of claims 1 to 2, characterized by the fact that R4 is selected from the group consisting of hydrogen and methyl.
Compound according to any one of claims 1 to 3, characterized in that the ring containing X, Y and Z is selected from the group consisting of pyridyl, pyrimidyl, pyridazyl, triazinyl, thiazolyl, oxazolyl, and isoxazolyl .
[5]
Compound according to any one of claims 1 to 4, characterized in that the ring containing X, Y and Z is selected from the group consisting of pyridyl, pyrimidyl, and thiazolyl.
[6]
A compound according to any one of claims 1 to 5, characterized by the fact that R5 is selected from the group consisting of hydrogen, fluorine, chlorine, alkyl (1-3C) and alkoxy (1-2C); the alkyl group (1-3C) from which it is optionally substituted with one or more halogens.
[7]
7. Compound according to any one of claims 1 to 6, characterized by the fact that R5 is selected from the group consisting of hydrogen, fluorine, methyl, ethyl, propyl, methoxy and trifluoromethyl.
[8]
A compound according to any one of claims 1 to 7, characterized by the fact that R2 is hydrogen or alkyl (1-3C); and R3 is alkyl (1-6C).
[9]
Compound according to any one of claims 1 to 7, characterized in that R2 and R3 together form a heterocycloalkyl ring selected from azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl, optionally substituted with one or more
Petition 870190035670, of 15/04/2019, p. 10/36
5/29 fluorine, hydroxyl, alkyl (1-3C), alkoxy (1-3C), or oxo.
[10]
A compound according to any one of claims 1 to 9, characterized by the fact that R1 is R11C (O) and R11 is independently selected from the group consisting of alkyl (1-6C), alkenyl (2-6C) or alkynyl (2-6C) each optionally substituted with one or more groups selected from hydroxyl, alkyl (1-4C), cycloalkyl (3-7C), [alkyl (14C)] amino, di [alkyl (1-4C) ] amino, alkoxy (1-3C), cycloalkoxy (3-7C), aryl (610C) or heterocycloalkyl (3-7C); or R11 is heteroaryl (1-5C) optionally substituted with one or more selected groups of halogen or cyano.
[11]
A compound according to any one of claims 1 to 10, characterized in that R1 is R11C (O) and R11 is selected from the group consisting of alkenyl (2-6C) or alkynyl (2-6C) each optionally substituted with one or more groups selected from hydroxyl, alkyl (1-4C), cycloalkyl (3-7C), di [alkyl (1-4C)] amino, alkoxy (1-3C), cycloalkoxy (3-7C) or heterocycloalkyl (3-7C).
[12]
12. A compound according to claim 1, characterized by the fact that it is selected from the group consisting of (5) -4- (3- (1-Acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-a ] pyrazin1-yl) -N- (pyridin-2-yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4- (pyrrolidin-1-yl) but-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1 - yl) -N- (pyridin-2-yl) benzamide;
(5, £) -4- (8-Amino-3- (1- (4- (dimethylamino) but-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N - (pyridin-2-yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin -2-yl) benzamide;
(5) -4- (8-amino-3- (1- (2-chloropyrimidine-4-carbonyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2 -yl) benzamide;
(5) -4- (8-amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide;
Petition 870190035670, of 15/04/2019, p. 11/36
6/29 (5, £) -4- (8-Amino-3- (1- (4- (dimethylamino) but-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl ) -N- (4-fluoropyridin-2-yl) benzamide;
(5) -4- (8-Amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-methylpyridin-2-yl) benzamide;
(5, £) -4- (8-Amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4 -propylpyridin-2-yl) benzamide;
(5) -4- (8-Amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4- (trifluoromethyl) pyridin-2 -yl) benzamide;
(5, £) -4- (8-Amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4 -ethylpyridin-2-yl) benzamide;
(5) -4- (8-Amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4,5,6,7- tetrahydrobenzo [d] thiazol-2-yl) benzamide;
(5) -4- (3- (1-acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin1-yl) -2-fluoro-N- (pyridin-2-yl) benzamide;
(5) -4- (3- (1-Acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin1-yl) -2-methoxy-N- (pyridin-2-yl) benzamide;
(5, £) -4- (8-Amino-3- (1- (4- (dimethylamino) but-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N - (thiazol-2-yl) benzamide;
(5, £) -4- (8-Amino-3- (1- (4-methoxybut-2-enoyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin -2-yl) benzamide;
(5) -4- (3- (1-Acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin1-yl) -N- (4-fluoropyridin-2-yl) benzamide;
(5) -4- (3- (1-Acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin1-yl) -N- (4-cyanopyridin-2-yl) benzamide;
(5) -4- (8-Amino-3- (1- (vinylsulfonyl) piperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4- (trifluoromethyl) pyridin-2- il) benzamide;
(5) -4- (3- (1-Acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N- (pyrimidin-2-yl) benzamide;
(5) -4- (3- (1-Acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-a] pyrazinPetition 870190035670, from 4/15/2019, page 12/36
7/29
1-yl) -N- (4-methylpyrimidin-2-yl) benzamide;
(5) -4- (8-Amino-3- (1-but-2-yoylpiperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyrimidin-4-yl) benzamide;
(5) -4- (8-Amino-3- (1-but-2-yoylpiperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridazin-3-yl) benzamide;
(5) -4- (8-Amino-3- (1-but-2-inoylpiperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (isoxazol-3-yl) benzamide;
(5, £) -4- (8-Amino-3- (1- (4-methoxybut-2-enoyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (5 -ethylthiazol-2-yl) benzamide;
(S) -4- (3- (1-Acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin1-yl) -2-fluoro-N- (4-propylpyridin-2-yl) benzamide ;
(5, £) -4- (8-Amino-3- (1- (4- (dimethylamino) but-2-enoyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -2 -methoxy-N- (4-propylpyridin-2-yl) benzamide;
4- (8-Amino-3 - ((5) -1-but-2-yoylpiperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -3-methyl-N- (pyridin-2- il) benzamide;
4- (3- (Acrylamidomethyl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N (pyridin-2-yl) benzamide;
(5) -4- (8-Amino-3- (1-but-2-yamidoethyl) imidazo [1,5-a] pyrazin-1yl) -N- (pyridin-2-yl) benzamide;
(5) -S-2- (2- (8-Amino-1- (4- (pyridin-2ylcarbamoyl) phenyl) -imidazo [1,5-a] pyrazin-3-yl) pyrrolidin-1-yl ethanothioate ) -2-oxoethyl;
(5) -4- (8-Amino-3- (1- (4-hydroxy-4-methylpent-2-yl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide;
(5) -4- (8-Amino-3- (1- (6-chloropyrimidine-4-carbonyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2 -yl) benzamide;
(5) -4- (8-Amino-3- (1-pent-2-yoylpyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide;
(5) -4- (8-Amino-3- (1- (3-cyclopropylpropioloyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide ;
Petition 870190035670, of 15/04/2019, p. 13/36
8/29 (5) -4- (8-Amino-3- (1-hex-2-inoylpyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2 -yl) benzamide;
4- (3- (1-Acryloylazepan-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) N- (pyridin-2-yl) benzamide;
(R) -4- (8-Amino-3- (4-but-2-yoylmorpholin-3-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide;
(5) -4- (8-amino-3- (1- (N-methylbut-2-yamido) ethyl) imidazo [1,5a] pyrazin-1-yl) -N- (4- (trifluoromethyl) pyridin- 2-yl) benzamide;
(5) -4- (8-Amino-3- (1- (4- (dimethylamino) but-2-yoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- ( pyridin-2-yl) benzamide;
(5) -4- (8-Amino-3- (1- (4-methoxybut-2-yoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2 -yl) benzamide;
(5) -4- (3- (1-acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin1-yl) -N- (4-fluoropyridin-2-yl) benzamide;
(5) -4- (3- (1-acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin1-yl) -N- (4- (pyrrolidin-1-yl) pyridin-2- il) benzamide;
(5) -4- (8-amino-3- (1-but-2-inoylpiperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-fluoropyridin-2-yl) benzamide;
(5) -4- (8-amino-3- (1-but-2-inoylpiperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide;
(5) -4- (3- (1-acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1yl) -N- (pyridin-2-yl) benzamide;
(5) -4- (8-amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-propylpyridin-2-yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4-methoxy-N-methylbut-2enamido) ethyl) imidazo [1,5-a] pyrazin-1-yl) -N- (4 -propylpyridin-2-yl) benzamide;
(5) -4- (8-amino-3- (1- (vinylsulfonyl) piperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-propylpyridin-2-yl) benzamide ;
(5) -4- (8-amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5Petition 870190035670, from 4/15/2019, page 14/36
9/29
a] pyrazin-1-yl) -2-fluoro-N- (pyridin-2-yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4 -methoxypyridin-2-yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -2-fluoro- N- (4-methoxypyridin-2-yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4 fluoropyridin-2-yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (isoxazole -3-yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyrimidin -2-yl) benzamide;
4- (8-amino-3 - ((5) -1- (2-chloropyrimidine-4-carbonyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -3-methyl-N- (pyridin-2-yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4 -methylpyridin-2-yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4 -isopropylpyridin-2-yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4- (dimethylamino) but-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N - (4-methylpyridin-2-yl) benzamide;
(5) -4- (8-amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (thiazol-2-yl) benzamide;
(5) -4- (3- (1-acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1 yl) -N- (4-propylpyridin-2-yl) benzamide;
(5) -4- (3- (1-acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin1-yl) -N- (4- (trifluoromethyl) pyridin-2-yl) benzamide;
(5) -4- (8-amino-3- (1-but-2-inoylpiperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4- (trifluoromethyl) pyridin-2 -yl) benzamide;
(5) -4- (8-amino-3- (1-but-2-inoylpiperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-propylpyridin-2-yl) benzamide;
Petition 870190035670, of 15/04/2019, p. 15/36
10/29 (5, £) -4- (8-amino-3- (1- (4- (dimethylamino) but-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl ) -N- (4-isopropylpyridin-2-yl) benzamide;
4- (8-amino-3 - ((5) -1- (vinylsulfonyl) piperidin-2-yl) imidazo [1,5a] pyrazin-1 -yl) -3-methyl-N- (pyridin-2-yl ) benzamide;
(5) -4- (8-amino-3- (1-but-2-inoylpiperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -2-fluoro-N- (4-propylpyridin- 2-yl) benzamide;
4- (3 - ((5) -1-acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1 yl) -3-methyl-N- (pyridin-2-yl) benzamide;
(£) -4- (8-amino-3 - ((4- (dimethyl amino) but-2enamido) methyl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2-yl ) benzamide;
(5) -4- (8-amino-3- (1- (2-chloro-pyrimidine-4-carbonyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4- isopropylpyridin-2-yl) benzamide;
(5) -4- (8-amino-3- (1- (2-chloro-pyrimidine-4-carbonyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4, 5,6,7-tetrahydrobenzo [d] thiazol-2-yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridazin -3-yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4- (dimethylamino) but-2-enoyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N - (pyridazin-3-yl) benzamide;
(5) -4- (8-amino-3- (1- (2-chloropyrimidine-4-carbonyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridazin-3 -yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4-methoxy-N-methylbut-2enamido) ethyl) imidazo [1,5-a] pyrazin-1-yl) -N- (4 - (trifluoromethyl) pyridin-2yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4- (dimethylamino) -N-methylbut-2enamido) ethyl) imidazo [1,5-a] pyrazin-1-yl) -N- (4-propylpyridin-2-yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4- (pyrrolidin-1-yl) but-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1 - yl) -N- (4-propylpyridin-2-yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4- (dimethylamino) but-2-enoyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N - (pyridin-2-yl) benzamide;
Petition 870190035670, of 15/04/2019, p. 16/36
11/29 (5) -4- (8-amino-3- (1- (2-chloropyrimidine-4-carbonyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- ( 4-propylpyridin-2-yl) benzamide;
(S) -4- (8-amino-3- (1- (2-chloropyrimidine-4-carbonyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4-fluoropyridine -2-yl) benzamide;
(S, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4 fluoropyridin-2-yl) benzamide;
(S, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4 , 5,6,7-tetrahydrobenzo [d] thiazol-2-yl) benzamide;
(5) -4- (8-amino-3- (1- (2-chloropyrimidine-4-carbonyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -2-methoxy-N- (pyridin-2-yl) benzamide;
(5) -4- (8-amino-3- (1- (2-chloropyrimidine-4-carbonyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -2-fluoro-N- (pyridin-2-yl) benzamide;
4- (8-amino-3 - ((5) -1 - ((£) -4-methoxybut-2-enoyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -3- methyl-N- (pyridin-2-yl) benzamide;
(S, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyrimidin -4-yl) benzamide;
4- (8-amino-3 - ((5) -1 - ((£) -4-methoxybut-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -3- methyl-N- (4-propylpyridin-2-yl) benzamide;
(S, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4 -methylpyrimidin-2-yl) benzamide;
(5) -4- (8-amino-3- (1-but-2-inoylpiperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-methylpyrimidin-2-yl) benzamide;
(S) -4- (8-amino-3- (1- (2-chloropyrimidine-4-carbonyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyrimidin-2 -yl) benzamide;
(5) -4- (8-amino-3- (1-methacryloylpyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide;
(5) -4- (8-amino-3- (1- (2- (trifluoromethyl) acryloyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2- il) benzamide;
(5, £) -4- (8-amino-3- (1-but-2-enoylpyrrolidin-2-yl) imidazo [1,5Petition 870190035670, from 4/15/2019, page 17/36
12/29
a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide;
(5) -4- (8-amino-3- (1- (cyanomethyl) pyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide;
(£) -4- (8-amino-3 - ((4-methoxybut-2-enamido) methyl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide;
(5) -4- (8-amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4- (pyrrolidin-1-yl ) pyridin-2-yl) benzamide;
(£) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) azepan-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2 -yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4 -cyanopyridin-2-yl) benzamide;
(5) -4- (8-amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -2-methoxy-N- (pyridin-2- il) benzamide;
(5) -4- (3- (1-acrylamidoethyl) -8-aminoimidazo [1,5-a] pyrazin-1-yl) -N (pyridin-2-yl) benzamide;
(5) -4- (3- (1-acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin1-yl) -N- (thiazol-2-yl) benzamide;
(5) -4- (8-amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-isopropylpyridin-2-yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -2-methoxy N- (pyridin-2-yl) benzamide;
(5, £) -4- (8-amino-3- (1-cinamoylpyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide;
(5) -N- (1 - (8-amino-1 - (4- (pyridin-2-ylcarbamoyl) phenyl) imidazo [1,5a] pyrazin-3-yl) ethyl) -2-chloropyrimidine-4-carboxamide ;
(5) -4- (8-amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-fluoropyridin-2-yl) benzamide;
(5) -4- (8-amino-3- (1- (2-chloropyrimidine-4-carbonyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4-propylpyridine -2-yl) benzamide;
Petition 870190035670, of 15/04/2019, p. 18/36
[13]
13/29 (5, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N - (4- (trifluoromethyl) pyridin-2-yl) benzamide;
(5) -4- (3- (1-acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1yl) -N- (4- (trifluoromethyl) pyridin-2-yl) benzamide;
(5) -4- (8-amino-3- (1-but-2-inoylpiperidin-2-yl) imidazo [1,5a] pyrazin-1 -yl) -2-methoxy-N- (4-propylpyridin- 2-yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -2-methoxy N- (4-propylpyridin-2-yl) benzamide;
4- (8-amino-3- (but-2-yamidomethyl) imidazo [1,5-a] pyrazin-1-yl) -N (pyridin-2-yl) benzamide;
(5) -4- (8-amino-3- (1- (N-methylbut-2-yamido) ethyl) imidazo [1,5a] pyrazin-1-yl) -N- (4-propylpyridin-2-yl ) benzamide;
(5, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -2-fluoro- N- (4-propylpyridin-2-yl) benzamide;
(5) -4- (8-amino-3- (1- (2-chloropyrimidine-4-carbonyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4- ( trifluoromethyl) pyridin-2-yl) benzamide;
(5) -4- (8-amino-3- (1-but-2-yoylpiperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (5-ethylthiazol-2-yl) benzamide;
(5) -4- (3- (1-acryloylpiperidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin-1 yl) -N- (5-ethylthiazol-2-yl) benzamide;
(5) -4- (8-amino-3- (1- (2-chloropyrimidine-4-carbonyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (5-ethylthiazole -2-yl) benzamide;
(5) -4- (8-amino-3- (1- (2-chloropyrimidine-4-carbonyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4- ( trifluoromethyl) pyridin-2-yl) benzamide;
(R, £) -4- (8-amino-3- (4- (4-methoxybut-2-enoyl) morpholin-3yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin -2-yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4 -propylpyridin-2-yl) benzamide;
(5) -4- (3- (1-acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-a] pyrazinPetition 870190035670, of 4/15/2019, page 19/36
[14]
14/29
1-yl) -N- (4-cyanopyridin-2-yl) benzamide;
(5) -4- (8-amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-methoxypyridin-2-yl) benzamide;
(5) -4- (3- (1-acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin1-yl) -N- (4-methylpyridin-2-yl) benzamide;
(5) -4- (3- (1-acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin1-yl) -N- (4-propylpyridin-2-yl) benzamide;
(5) -4- (3- (1-acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin1-yl) -N- (4-ethylpyridin-2-yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4- (dimethylamino) but-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N - (pyridin-2-yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4 - (trifluoromethyl) pyridin-2-yl) benzamide;
(5) -4- (8-amino-3- (1- (2-chloropyrimidine-4-carbonyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (4-methylpyridine -2-yl) benzamide;
(5) -4- (8-amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-cyanopyridin-2-yl) benzamide;
(5) -4- (8-amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-ethylpyridin-2-yl) benzamide;
(5) -4- (8-amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4-phenylpyridin-2-yl) benzamide and (5) -4- (3- (1-acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5-a] pyrazin1-yl) -N- (4-phenylpyridin-2-yl) benzamide.
13. A compound according to any one of claims 1 to 12, characterized in that it is for use in therapy.
14. Compound according to any one of claims 1 to 12, characterized by the fact that it is for use in the treatment of disorders mediated by Bruton's Tyrosine Kinase (Btk).
[15]
15. Use of a compound as defined in claim 1,
Petition 870190035670, of 15/04/2019, p. 20/36
15/29 characterized by the fact that it is for the manufacture of a medicine for the treatment of disorders mediated by Bruton Tyrosine Kinase (Btk), in which the disorder mediated by Btk is selected from a group consisting of rheumatoid arthritis, psoriatic arthritis, arthritis infectious, progressive chronic arthritis, deforming arthritis, osteoarthritis, traumatic arthritis, gouty arthritis, Reiter's syndrome, polychondritis, acute synovitis, spondylitis, glomerulonephritis with nephrotic syndrome, glomerulonephritis without nephrotic syndrome, autoimmune hematological disorders, anemia , neutropenia, autoimmune gastritis, autoimmune inflammatory bowel diseases, ulcerative colitis and Crohn's disease, host versus graft disease, allograft rejection, chronic thyroiditis, Graves' disease, scleroderma, type I diabetes, type II diabetes, acute active hepatitis, chronic active hepatitis, pancreatitis, biliary cirrhosis pr disease, myasthenia gravis, multiple sclerosis, systemic lupus erythematosus, psoriasis, atopic dermatitis, contact dermatitis, eczema, sunburn, vasculitis, Behcet's disease, chronic kidney failure, Stevens-Johnson syndrome, inflammatory pain, idiopathic psilosis, cachexia, sarcoidosis, GuillainBarré syndrome, uveitis, conjunctivitis, conjunctivitis keratosis, otitis media, periodontal disease, pulmonary interstitial fibrosis, asthma, bronchitis, rhinitis, sinusitis, pneumoconiosis, pulmonary failure syndrome, pulmonary emphysema, pulmonary fibrosis, silicosis, lung disease chronic inflammatory disease, chronic obstructive pulmonary disease, a proliferative disease, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma (DLBCL), chronic B-cell lymphocytic leukemia, mantle cell lymphoma (MCL), acute lymphoblastic leukemia, acute lymphoblastic leukemia with mature B-cell, B-cell lymphoma, mast cell proliferative disease and bone biopsy related to multiple myeloma.
[16]
16. Combination, characterized by the fact that it is a compound as defined in any of claims 1 to 12 and an agent
Petition 870190035670, of 15/04/2019, p. 21/36
Additional therapeutic 16/29.
[17]
17. Pharmaceutical composition, characterized in that it comprises a compound as defined in any one of claims 1 to 12 and a pharmaceutically acceptable excipient.
[18]
18. Compound according to claim 1, characterized by the fact that:
X, Y and Z are CH;
B1 is C (R7);
B2 is C (R8);
B3 is C (R9);
B4 is C (R10)
R1 is R11 C (O)
R2 and R3 form, together with the N atom to which R2 is attached, and the C atom to which R3 is attached, a pyrrolidinyl;
R4 is H;
R7, R9 and R10 are H; and
R8 is H or methyl.
[19]
19. Compound according to claim 1, characterized by the fact that it is selected from the group consisting of:
(S) -4- (3- (1-Acryloylpyrrolidin-2-yl) -8-aminoimidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide;
(S, £) -4- (8-Amino-3- (1- (4- (dimethylamino) but-2enoyl) pyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -N - (pyridin-2-yl) benzamide;
(S, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) pyrrolidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin -2-yl) benzamide;
(S) -4- (8-amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide;
(S) -4- (8-Amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5a] pyrazin-1 -yl) -N- (4- (trifluoromethyl) pyridin-2 -yl) benzamide;
Petition 870190035670, of 15/04/2019, p. 22/36
17/29 (5) -4- (8-Amino-3- (1- (4-hydroxy-4-methylpent-2-yoyl) pyrrolidin2-yl) imidazo [1,5-a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide;
(R) -4- (8-Amino-3- (4-but-2-yoylmorpholin-3-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide;
(5) -4- (8-Amino-3- (1- (4- (dimethylamino) but-2-yoyl) pyrrolidin2-yl) imidazo [1,5-a] pyrazin-1-yl) -N- ( pyridin-2-yl) benzamide;
(5, £) -4- (8-amino-3- (1- (4-methoxybut-2-enoyl) piperidin-2yl) imidazo [1,5-a] pyrazin-1-yl) -N- (isoxazole -3-yl) benzamide;
(5) -4- (8-amino-3- (1- (N-methylbut-2-yamido) ethyl) imidazo [1,5a] pyrazin-1-yl) -N- (4- (trifluoromethyl) pyridin- 2-yl) benzamide;
(5) -4- (8-amino-3- (1-but-2-ynoylpiperidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (pyridin-2-yl) benzamide;
(5) -4- (8-Amino-3- (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5a] pyrazin-1-yl) -N- (4- (trifluoromethyl) pyridin-2 -yl) benzamide.
[20]
20. Use according to claim 15, characterized by the fact that the disorder mediated by Btk is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis or osteoarthritis.
[21]
21. Use according to claim 15, characterized by the fact that the disorder mediated by Btk is selected from the group consisting of a proliferative disease, non-Hodgkin's lymphoma, diffuse large B cell lymphoma (DLBCL), cell lymphoma of the mantle (MCL), chronic B-cell lymphocytic leukemia, acute lymphoblastic leukemia, mature B-cell acute lymphoblastic leukemia, B-cell lymphoma, mast cell proliferative disease and multiple myeloma-related bone disorder.
[22]
22. Compound according to claim 1, characterized by the fact that it is in accordance with formula (I)
Petition 870190035670, of 15/04/2019, p. 23/36
18/29
Z
Formula (I) or a pharmaceutically acceptable salt thereof, where:
X is CH or S;
Y is C (R6);
Z is CH or a bond;
A is CH;
B1 is N or C (R7);
B2 is N or C (R8);
B3 is N or CH;
B4 is N or CH;
R1 is R11C (= O);
R2 is alkyl (1-3C);
R3 is alkyl (1-3C);
R2 and R3 form a heterocycloalkyl (3-7C) ring selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, and morpholinyl, optionally substituted with one or more fluorine, hydroxyl, alkyl (1-3C), alkoxy (1-3C );
R4 is H;
R5 is H, halogen, cyano, alkyl (1-4C), alkoxy (1-3C), or cycloalkyl (3-6C), any alkyl group of which is optionally substituted with one or more halogens;
Petition 870190035670, of 15/04/2019, p. 24/36
19/29
R6 is H or (1-3C) alkyl;
R7 is H, halogen or alkoxy (1-3C);
R8 is H or (1-3C) alkyl; or
R7 and R8 form, together with the carbon atom to which R7 is attached, and the carbon atom to which R8 is attached, an aryl (6-10C) or heteroaryl (1-9C);
R5 and R6 together can form a cycloalkenyl (3-7C), or heterocycloalkenyl (2-6C); each optionally substituted with (1-3C) alkyl, or one or more halogens;
R11 is independently selected from the group consisting of alkenyl (2-6C) and alkynyl (2-6C), wherein each alkenyl or alkynyl is optionally substituted with one or more substituents selected from the group consisting of hydroxyl, alkyl (1-4C) ), cycloalkyl (3-7C), [alkyl (1-4C)] amino, di [alkyl (1-4C)] amino, alkoxy (1-3C), cycloalkoxy (3-7C), aryl (6-10C) and heterocycloalkyl (3-7C);
with the proviso that
0 to 2 atoms of B1, B2, B3 and B4 are N.
[23]
23. Compound according to claim 1, characterized by the fact that it is in accordance with formula (I)
Formula (I)
Petition 870190035670, of 15/04/2019, p. 25/36
20/29 or a pharmaceutically acceptable salt thereof, where:
the ring containing X, Y and Z is selected from the group consisting of pyridyl, pyrimidyl, pyridazyl, triazinyl, thiazolyl, oxazolyl, and isoxazolyl.
A is CH;
B1 is CH;
B2 is CH;
B3 is CH;
B4 is CH;
R1 is C (O) R11;
R2 and R3 form, together with the N atom to which R2 is attached, and the C atom to which R3 is attached, a heterocycloalkyl (37C) ring selected from azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl, each optionally replaced with a fluorine, hydroxyl, alkyl (1-3C), alkoxy (1-3C), or oxo.
R4 is hydrogen;
R5 is H, halogen, cyano, alkyl (1-4C), alkoxy (1-3C), or cycloalkyl (3-6C), any alkyl group of which is optionally substituted with one or more halogens;
R11 is alkenyl (2-6C) or alkynyl (2-6C), each optionally substituted with one or more groups selected from hydroxyl, alkyl (1-4C), cycloalkyl (3-7C), di [alkyl (1-4C )] amino, alkoxy (1-3C), cycloalkoxy (3-7C), or heterocycloalkyl (3-7C).
[24]
24. Composite, characterized by the fact that it has the structure:
Petition 870190035670, of 15/04/2019, p. 26/36
21/29
[25]
25. Pharmaceutical composition, characterized by the fact that it comprises a pharmaceutically acceptable carrier or diluent and the compound as defined in claim 24.
[26]
26. Pharmaceutically acceptable salt of a compound, characterized by the fact that the compound has the structure:
[27]
27. Pharmaceutically acceptable salt according to claim 26, characterized in that the salt is selected from the group consisting of acetate, ascorbate, benzoate, benzenesulfonate, bisulfate,
Petition 870190035670, of 15/04/2019, p. 27/36
22/29 borate, butyrate, citrate, camphorate, camphorsulfonate, fumarate, hydrochloride, hydrobromide, iodhydrate, lactate, maleate, methanesulfonate, naphthalenesulfonate, nitrate, oxalate, phosphate, propionate, salicylate, succinate, sulfate, tartarate, tolate, thiocyanate, thiocyanate.
[28]
28. Pharmaceutical composition, characterized in that it comprises a pharmaceutically acceptable carrier or diluent and pharmaceutically acceptable salt as defined in claim 26.
[29]
29. Pharmaceutical composition, characterized in that it comprises a pharmaceutically acceptable carrier or diluent and pharmaceutically acceptable salt as defined in claim 27.
[30]
30. Compound, characterized by the fact that it has the structure:
[31]
31. Pharmaceutical composition, characterized by the fact that it comprises a pharmaceutically acceptable carrier or diluent and the compound as defined in claim 30.
[32]
32. Pharmaceutically acceptable salt of a compound, characterized by the fact that the compound has the structure:
Petition 870190035670, of 15/04/2019, p. 28/36
23/29
[33]
33. Pharmaceutically acceptable salt according to claim 32, characterized in that the salt is selected from the group consisting of acetate, ascorbate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, fumarate, hydrochloride, hydrobromide, iodine, lactate, maleate, methanesulfonate, naphthalenesulfonate, nitrate, oxalate, phosphate, propionate, salicylate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate.
[34]
34. Pharmaceutical composition, characterized in that it comprises a pharmaceutically acceptable carrier or diluent and pharmaceutically acceptable salt as defined in claim 32.
[35]
35. Pharmaceutical composition, characterized in that it comprises a pharmaceutically acceptable carrier or diluent and pharmaceutically acceptable salt as defined in claim 33.
[36]
36. Composed, characterized by the fact that it has the structure:
Petition 870190035670, of 15/04/2019, p. 29/36
24/29
[37]
37. Pharmaceutical composition, characterized by the fact that it comprises a pharmaceutically acceptable carrier or diluent and the compound as defined in claim 36.
[38]
38. Pharmaceutically acceptable salt of a compound, characterized by the fact that the compound has the structure:
Petition 870190035670, of 15/04/2019, p. 30/36
25/29
[39]
39. Pharmaceutically acceptable salt according to claim 38, characterized in that the salt is selected from the group consisting of acetate, ascorbate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, fumarate, hydrochloride, hydrobromide, iodine, lactate, maleate, methanesulfonate, naphthalenesulfonate, nitrate, oxalate, phosphate, propionate, salicylate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate.
[40]
40. Pharmaceutical composition, characterized in that it comprises a pharmaceutically acceptable carrier or diluent and pharmaceutically acceptable salt as defined in claim 38.
[41]
41. Pharmaceutical composition, characterized in that it comprises a pharmaceutically acceptable carrier or diluent and pharmaceutically acceptable salt as defined in claim 39.
[42]
42. Compound, characterized by the fact that it has the structure:
[43]
43. Pharmaceutical composition, characterized in that it comprises a pharmaceutically acceptable carrier or diluent and pharmaceutically acceptable salt as defined in claim 42.
Petition 870190035670, of 15/04/2019, p. 31/36
26/29
[44]
44. Pharmaceutically acceptable salt of a compound, characterized by the fact that the compound has the structure:
[45]
45. Pharmaceutically acceptable salt according to claim 44, characterized in that the salt is selected from the group consisting of acetate, ascorbate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, fumarate, hydrochloride, hydrobromide, iodine, lactate, maleate, methanesulfonate, naphthalenesulfonate, nitrate, oxalate, phosphate, propionate, salicylate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate.
[46]
46. Pharmaceutical composition, characterized in that it comprises a pharmaceutically acceptable carrier or diluent and pharmaceutically acceptable salt as defined in claim 44.
[47]
47. Pharmaceutical composition, characterized in that it comprises a pharmaceutically acceptable carrier or diluent and pharmaceutically acceptable salt as defined in claim 45.
[48]
48. Composite, characterized by the fact that it has the structure:
Petition 870190035670, of 15/04/2019, p. 32/36
27/29
[49]
49. Pharmaceutical composition, characterized in that it comprises a pharmaceutically acceptable carrier or diluent and the compound as defined in claim 48.
[50]
50. Pharmaceutically acceptable salt of a compound, characterized by the fact that the compound has the structure:
Petition 870190035670, of 15/04/2019, p. 33/36
28/29
[51]
51. Pharmaceutically acceptable salt according to claim 50, characterized in that the salt is selected from the group consisting of acetate, ascorbate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, fumarate, hydrochloride, hydrobromide, iodine, lactate, maleate, methanesulfonate, naphthalenesulfonate, nitrate, oxalate, phosphate, propionate, salicylate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate.
[52]
52. Pharmaceutical composition, characterized in that it comprises a pharmaceutically acceptable carrier or diluent and pharmaceutically acceptable salt as defined in claim 50.
[53]
53. Pharmaceutical composition, characterized in that it comprises a pharmaceutically acceptable carrier or diluent and pharmaceutically acceptable salt as defined in claim 51.
[54]
54. Compound, characterized by the fact that it is (5) -4- (8-amino-3 (1-but-2-inoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin-1-yl) -2 -methoxy-N- (pyridin2-yl) benzamide, having the structure:
[55]
55. Pharmaceutical composition, characterized in that it comprises a pharmaceutically acceptable carrier or diluent and the compound as defined in claim 54.
[56]
56. Combination, characterized by the fact that it is a compound as defined in claim 54 and an additional therapeutic agent.
Petition 870190035670, of 15/04/2019, p. 34/36
29/29
[57]
57. Pharmaceutically acceptable salt of a compound, characterized in that the compound is (5) -4- (8-ammo-3- (1-but-2inoylpyrrolidin-2-yl) imidazo [1,5-a] pyrazin- 1-yl) -2-methoxy-N- (pyridin-2yl) benzamide and having the structure:
[58]
58. Pharmaceutically acceptable salt according to claim 18, characterized in that the salt is selected from the group consisting of acetate, ascorbate, benzoate, benzenesulfonate, bisulfats, borate, butyrate, citrate, camphorate, camphorsulfonate, fumarate, hydrochloride, hydrobromide, iodide, lactate, maleate, methanesulfonate, naphthalenesulfonate, nitrate, oxalate, phosphate, propionate, salicylate, succinate, sulfate, tartrate, thiocyanate and toluenesulfonate.
[59]
59. Pharmaceutical composition, characterized in that it comprises a pharmaceutically acceptable carrier or diluent and the pharmaceutically acceptable salt as defined in claim 57.
[60]
60. Pharmaceutical composition, characterized in that it comprises a pharmaceutically acceptable carrier or diluent and the pharmaceutically acceptable salt as defined in claim 58.
[61]
61. Combination, characterized by the fact that it is the pharmaceutically acceptable salt as defined in claim 57 and an additional therapeutic agent.

类似技术:

---

公开号 | 公开日 | 专利标题

---

AU2017279778B2|2019-09-19|4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as Btk- inhibitors

---

AU2012285988B2|2017-05-25|4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides Btk-inhibitors

---

JP2020189865A|2020-11-26|4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors

---

NZ716110B2|2017-10-31|4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors

---

NZ620085B2|2016-08-30|4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors

同族专利:

---

公开号 | 公开日

---

US20160159810A1|2016-06-09|

---

DK2734522T3|2019-02-18|

---

SI2734522T1|2019-03-29|

---

AU2017279778B2|2019-09-19|

---

US20140155385A1|2014-06-05|

---

BR112014001255A2|2017-02-21|

---

US20210230166A1|2021-07-29|

---

HUE041987T2|2019-06-28|

---

KR20140036324A|2014-03-25|

---

AU2019275591B2|2020-10-01|

---

US10934296B2|2021-03-02|

---

EA037644B1|2021-04-26|

---

PH12017500166A1|2017-09-04|

---

IL230511A|2019-05-30|

---

JP6749444B2|2020-09-02|

---

JP2018035184A|2018-03-08|

---

HRP20190135T1|2019-03-22|

---

AU2019275591A1|2020-01-02|

---

PL2734522T3|2019-04-30|

---

JP2016034968A|2016-03-17|

---

EA201992270A2|2020-01-16|

---

SG10201605913VA|2016-09-29|

---

EP3689878A1|2020-08-05|

---

EP3689878B1|2021-10-06|

---

CO6940411A2|2014-05-09|

---

US20160151364A1|2016-06-02|

---

AU2012285987C1|2016-09-08|

---

AU2012285987A1|2014-02-06|

---

CA2841886A1|2013-01-24|

---

JP6251220B2|2017-12-20|

---

MX2014000746A|2014-05-07|

---

HUS2100012I1|2021-05-28|

---

KR101802689B1|2017-11-28|

---

CR20140030A|2014-06-03|

---

TN2014000027A1|2015-07-01|

---

PT3689878T|2022-01-05|

---

CL2014000130A1|2014-08-22|

---

IL230511D0|2014-03-31|

---

EA201992270A3|2020-03-31|

---

US20180179212A1|2018-06-28|

---

GT201400009A|2017-09-28|

---

SI3689878T1|2021-12-31|

---

UA115312C2|2017-10-25|

---

US9290504B2|2016-03-22|

---

CN106243113A|2016-12-21|

---

CN106243113B|2018-12-18|

---

US9790226B2|2017-10-17|

---

AU2012285987B2|2016-03-10|

---

CA2841886C|2016-08-16|

---

DOP2014000008A|2014-04-30|

---

EA034558B1|2020-02-20|

---

EA201490300A1|2014-05-30|

---

AU2016203837A1|2016-06-30|

---

JP2014520870A|2014-08-25|

---

JP6617130B2|2019-12-11|

---

LT2734522T|2019-02-11|

---

PE20141681A1|2014-11-14|

---

KR101702727B1|2017-02-06|

---

JP2019108395A|2019-07-04|

---

EP2734522A1|2014-05-28|

---

NZ620085A|2016-05-27|

---

JP5826931B2|2015-12-02|

---

CN103889987A|2014-06-25|

---

ES2708224T3|2019-04-09|

---

IN2014CN00408A|2015-04-03|

---

CN103889987B|2016-09-14|

---

PH12017500166B1|2017-09-04|

---

RS58177B1|2019-03-29|

---

AU2016203837B2|2018-01-25|

---

EP3495368A1|2019-06-12|

---

ECSP14013217A|2015-03-31|

---

US20190276456A1|2019-09-12|

---

NZ716110A|2017-07-28|

---

KR20160117642A|2016-10-10|

---

IL266894D0|2019-07-31|

---

DK3689878T3|2021-11-08|

---

US9758524B2|2017-09-12|

---

MX342983B|2016-10-19|

---

US10239883B2|2019-03-26|

---

WO2013010868A1|2013-01-24|

---

EP2734522B1|2018-10-31|

---

AU2017279778A1|2018-01-25|

---

MA35348B1|2014-08-01|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

CZ2001960A3|1998-09-18|2001-10-17|Basf Aktiengesellschaft|Pyrrolopyrimidines functioning as protein kinase inhibitors|

---

CA2385769A1|1999-09-17|2001-03-22|Gavin C. Hirst|Kinase inhibitors as therapeutic agents|

---

US6921763B2|1999-09-17|2005-07-26|Abbott Laboratories|Pyrazolopyrimidines as therapeutic agents|

---

US6998391B2|2002-02-07|2006-02-14|Supergen.Inc.|Method for treating diseases associated with abnormal kinase activity|

---

WO2005014599A1|2003-06-04|2005-02-17|Cellular Genomics, Inc.|Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds|

---

AP2006003620A0|2003-10-15|2006-06-30|Osi Pharm Inc|Imidazopyrazine tyroshine kinase inhibitors|

---

ES2652440T3|2004-04-02|2018-02-02|OSI Pharmaceuticals, LLC|6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors|

---

PT2385053E|2005-11-17|2013-12-17|Osi Pharm Inc|Intermediates for the preparation of fused bicyclic mtor inhibitors|

---

AR057960A1|2005-12-02|2007-12-26|Osi Pharm Inc|BICYCLE PROTEIN QUINASE INHIBITORS|

---

PE20070855A1|2005-12-02|2007-10-14|Bayer Pharmaceuticals Corp|DERIVATIVES OF 4-AMINO-PYRROLOTRIAZINE SUBSTITUTE AS KINASE INHIBITORS|

---

JP5372737B2|2006-03-13|2013-12-18|オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー|Combination therapy using EGFR kinase inhibitors and agents that sensitize tumor cells to the effects of EGFR kinase inhibitors|

---

US20120101114A1|2007-03-28|2012-04-26|Pharmacyclics, Inc.|Inhibitors of bruton's tyrosine kinase|

---

EP2139487B1|2007-03-28|2015-11-11|Pharmacyclics LLC|Inhibitors of bruton's tyrosine kinase|

---

PT2526933E|2006-09-22|2015-06-23|Pharmacyclics Inc|Inhibitors of bruton's tyrosine kinase|

---

CA2708149A1|2007-12-13|2009-06-18|Novartis Ag|Combinations of therapeutic agents for treating cancer|

---

US9095592B2|2008-11-07|2015-08-04|The Research Foundation For The State University Of New York|Bruton's tyrosine kinase as anti-cancer drug target|

---

EP2424368B1|2009-04-29|2014-12-31|Locus Pharmaceuticals, Inc.|Pyrrolotriazine compounds|

---

JP5764145B2|2010-02-08|2015-08-12|メルク・シャープ・エンド・ドーム・ベー・フェー|8-Methyl-1-phenyl-imidazol [1,5-a] pyrazine compounds|

---

UY33288A|2010-03-25|2011-10-31|Glaxosmithkline Llc|INDOLINE DERIVATIVES INHIBITORS OF THE PROTEIN QUINASA R OF THE ENDOPLASMATIC RETICLE|

---

LT2578585T|2010-05-31|2016-10-10|Ono Pharmaceutical Co., Ltd.|Purinone derivative as btk kinase inhibitor|

---

EA031737B1|2010-06-03|2019-02-28|Фармасайкликс, Инк.|USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE FOR TREATING LEUKEMIA AND LYMPHOMA|

---

US20120053189A1|2010-06-28|2012-03-01|Pharmacyclics, Inc.|Btk inhibitors for the treatment of immune mediated conditions|

---

US9580427B2|2011-05-17|2017-02-28|The Regents Of The University Of California|Kinase inhibitors|

---

US20130178483A1|2011-06-28|2013-07-11|Pharmacyclics, Inc.|Methods and Compositions for Inhibition of Bone Resorption|

---

WO2013010136A2|2011-07-13|2013-01-17|Pharmacyclics, Inc.|Inhibitors of bruton's tyrosine kinase|

---

EP3495368A1|2011-07-19|2019-06-12|Merck Sharp & Dohme B.V.|-4-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-benzamide as btk-inhibitor|

---

AU2012285988B2|2011-07-19|2017-05-25|Merck Sharp & Dohme B.V.|4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides Btk-inhibitors|

---

EP2548877A1|2011-07-19|2013-01-23|MSD Oss B.V.|4-benzamides as BTK-inhibitors|

---

CN110801454A|2011-10-19|2020-02-18|药品循环有限责任公司|Use of Bruton's Tyrosine Kinase inhibitors|

---

US20140212425A1|2011-12-05|2014-07-31|Immunomedics, Inc.|Therapeutic use of anti-cd22 antibodies for inducing trogocytosis|

---

US8377946B1|2011-12-30|2013-02-19|Pharmacyclics, Inc.|Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors|

---

WO2014114185A1|2013-01-23|2014-07-31|Merck Sharp & Dohme Corp.|Btk inhibitors|

---

MX2015011733A|2013-03-14|2016-04-25|Pharmacyclics Llc|Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors.|

---

WO2014143807A2|2013-03-15|2014-09-18|Stromatt Scott|Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders|

---

CN111317821A|2013-04-08|2020-06-23|药品循环有限责任公司|Ibrutinib combination therapy|

---

WO2015018522A1|2013-08-06|2015-02-12|Oncoethix Sa|Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma |US20120101114A1|2007-03-28|2012-04-26|Pharmacyclics, Inc.|Inhibitors of bruton's tyrosine kinase|

---

EA031737B1|2010-06-03|2019-02-28|Фармасайкликс, Инк.|USE OF INHIBITORS OF BRUTON'S TYROSINE KINASEFOR TREATING LEUKEMIA AND LYMPHOMA|

---

HUE033019T2|2011-05-17|2017-11-28|Principia Biopharma Inc|Tyrosine kinase inhibitors|

---

US9376438B2|2011-05-17|2016-06-28|Principia Biopharma, Inc.|Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors|

---

WO2013010136A2|2011-07-13|2013-01-17|Pharmacyclics, Inc.|Inhibitors of bruton's tyrosine kinase|

---

EP2548877A1|2011-07-19|2013-01-23|MSD Oss B.V.|4-benzamides as BTK-inhibitors|

---

EP3495368A1|2011-07-19|2019-06-12|Merck Sharp & Dohme B.V.|-4-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-benzamide as btk-inhibitor|

---

US10954567B2|2012-07-24|2021-03-23|Pharmacyclics Llc|Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase |

---

EA027213B9|2012-09-10|2017-09-29|Принсипиа Биофарма Инк.|Pyrazolopyrimidine compounds as kinase inhibitors|

---

AU2013323426A1|2012-09-26|2015-04-23|The Regents Of The University Of California|Modulation of ire1|

---

US9296703B2|2012-10-04|2016-03-29|University Of Utah Research Foundation|Substituted N-phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors|

---

KR20160013204A|2013-05-30|2016-02-03|인피니티 파마슈티칼스, 인코포레이티드|Treatment of cancers using pi3 kinase isoform modulators|

---

WO2014113942A1|2013-01-23|2014-07-31|Merck Sharp & Dohme Corp.|Btk inhibitors|

---

WO2014114185A1|2013-01-23|2014-07-31|Merck Sharp & Dohme Corp.|Btk inhibitors|

---

US8957080B2|2013-04-09|2015-02-17|Principia Biopharma Inc.|Tyrosine kinase inhibitors|

---

SG10201900025UA|2013-07-31|2019-02-27|Merck Patent Gmbh|Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof|

---

WO2015057992A1|2013-10-16|2015-04-23|Izumi Raquel|Btk inhibitors for hematopoietic mobilization|

---

TW201609099A|2014-08-11|2016-03-16|艾森塔製藥公司|Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor|

---

CN105979948A|2013-12-05|2016-09-28|安塞塔制药公司|Therapeutic combination of a pi3k inhibitor and a btk inhibitor|

---

EP3082811B1|2013-12-20|2020-01-15|Merck Sharp & Dohme Corp.|Btk inhibitors|

---

EP3082809B1|2013-12-20|2021-01-20|Merck Sharp & Dohme Corp.|Btk inhibitors|

---

US10272083B2|2014-01-21|2019-04-30|Acerta Pharma B.V.|Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor|

---

WO2015110923A2|2014-01-21|2015-07-30|Acerta Pharma B.V.|Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor|

---

US10092569B2|2014-02-21|2018-10-09|Principia Biopharma Inc.|Salts and solid form of a BTK inhibitor|

---

WO2015181633A2|2014-04-11|2015-12-03|Acerta Pharma B.V.|Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase|

---

WO2015185998A2|2014-04-11|2015-12-10|Acerta Pharma B.V.|Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase|

---

US9949971B2|2014-06-17|2018-04-24|Acerta Pharma B.V.|Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor|

---

WO2016019233A1|2014-08-01|2016-02-04|Pharmacyclics Llc|Inhibitors of bruton's tyrosine kinase|

---

WO2016020901A1|2014-08-07|2016-02-11|Acerta Pharma B.V.|Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate|

---

US20170239351A1|2014-08-11|2017-08-24|Acerta Pharma B.V.|Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor|

---

WO2016024230A1|2014-08-11|2016-02-18|Acerta Pharma B.V.|Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, and/or a bcl-2 inhibitor|

---

WO2016128912A1|2015-02-12|2016-08-18|Acerta Pharma B.V.|Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor|

---

US20170224819A1|2014-08-11|2017-08-10|Acerta Pharma B.V.|Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor|

---

TW201618774A|2014-08-11|2016-06-01|艾森塔製藥公司|Methods of using BTK inhibitors to treat solid tumors and other diseases through modulation of the tumor microenvironment|

---

WO2016087994A1|2014-12-05|2016-06-09|Acerta Pharma B.V.|Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment|

---

CA2956270A1|2014-08-18|2016-02-25|Eisai R&D Management Co., Ltd.|Salt of monocyclic pyridine derivative and crystal thereof|

---

WO2016055982A1|2014-10-10|2016-04-14|Acerta Pharma B.V.|Quinoline and quinazoline compounds|

---

EA036269B1|2014-12-18|2020-10-21|Принсипиа Биофарма Инк.|Treatment of pemphigus|

---

WO2016106629A1|2014-12-31|2016-07-07|Merck Sharp & Dohme Corp.|Btk inhibitors|

---

WO2016106626A1|2014-12-31|2016-07-07|Merck Sharp & Dohme Corp.|Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors|

---

WO2016106623A1|2014-12-31|2016-07-07|Merck Sharp & Dohme Corp.|Benzamide imidazopyrazine btk inhibitors|

---

WO2016106624A1|2014-12-31|2016-07-07|Merck Sharp & Dohme Corp.|Tertiary alcohol imidazopyrazine btk inhibitors|

---

WO2016106625A1|2014-12-31|2016-07-07|Merck Sharp & Dohme Corp.|Btk inhibitors|

---

WO2016106627A1|2014-12-31|2016-07-07|Merck Sharp & Dohme Corp.|Btk inhibitors|

---

WO2016161571A1|2015-04-08|2016-10-13|Merck Sharp & Dohme Corp.|Indazole and azaindazole btk inhibitors|

---

WO2016192074A1|2015-06-04|2016-12-08|Merck Sharp & Dohme Corp.|Btk inhibitors|

---

MA42242A|2015-06-24|2018-05-02|Principia Biopharma Inc|TYROSINE KINASE INHIBITORS|

---

PL3613745T3|2015-07-02|2022-01-31|Acerta Pharma B.V.|Solid forms and formulations of -4-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-benzamide|

---

WO2017033113A1|2015-08-21|2017-03-02|Acerta Pharma B.V.|Therapeutic combinations of a mek inhibitor and a btk inhibitor|

---

US20190022092A1|2015-09-15|2019-01-24|Acerta Pharma B.V.|Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist|

---

MA44909A|2015-09-15|2018-07-25|Acerta Pharma Bv|THERAPEUTIC ASSOCIATION OF A CD19 INHIBITOR AND A BTK INHIBITOR|

---

EP3371189A1|2015-11-06|2018-09-12|Acerta Pharma B.V.|Imidazopyrazine inhibitors of bruton's tyrosine kinase|

---

EP3402503B1|2016-01-13|2020-10-21|Acerta Pharma B.V.|Therapeutic combinations of an antifolate and a btk inhibitor|

---

EP3480199B1|2016-06-30|2021-03-17|Hangzhou Bangshun Pharmaceutical Co., Ltd.|Imidazopyridinamine phenyl derivative and use thereof|

---

WO2018002958A1|2016-06-30|2018-01-04|Sun Pharma Advanced Research Company Limited|Novel hydrazide containing compounds as btk inhibitors|

---

CN109851620B|2016-08-17|2020-08-07|深圳市塔吉瑞生物医药有限公司|Fused bicyclic compounds for inhibiting tyrosine kinase activity|

---

WO2018064797A1|2016-10-05|2018-04-12|杭州领业医药科技有限公司|Crystal form of acp-196, preparation method therefor and pharmaceutical composition thereof|

---

CN107056786B|2016-10-14|2019-05-07|苏州明锐医药科技有限公司|Ah Ka replaces the preparation method of Buddhist nun|

---

CN108101905A|2016-11-24|2018-06-01|中国科学院上海药物研究所|Pyrimido [5,4-b] indolizine or pyrimido [5,4-b] pyrrole biopterin compound, preparation method and the usage|

---

WO2018116259A1|2016-12-21|2018-06-28|Acerta Pharma B.V.|Imidazopyrazine inhibitors of bruton's tyrosine kinase|

---

WO2018115965A1|2016-12-23|2018-06-28|Acerta Pharma Bv|Solid forms of imidazopyrazine compounds|

---

CN106588937B|2017-01-16|2018-09-21|东莞市真兴贝特医药技术有限公司|Imidazopyrazines and its preparation method and application|

---

WO2018134786A1|2017-01-19|2018-07-26|Acerta Pharma B.V.|Compositions and methods for the assessment of drug target occupancy for bruton's tyrosine kinase|

---

CN106831787B|2017-01-20|2018-10-23|成都倍特药业有限公司|Compound and its preparation method and application as bruton's tyrosine kinase inhibitor|

---

US10899770B2|2017-02-20|2021-01-26|Hangzhou Solipharma Co., Ltd.|Crystal form of ACP-196 salt and preparation method, pharmaceutical composition, and use thereof|

---

EP3585789A1|2017-02-24|2020-01-01|Gilead Sciences, Inc.|Inhibitors of bruton's tyrosine kinase|

---

AR110998A1|2017-02-24|2019-05-22|Gilead Sciences Inc|INHIBITORS OF THE TUTOSINA CINASA DE BRUTON|

---

US20210107903A1|2017-03-22|2021-04-15|Xibin Liao|Bruton's tyrosine kinase inhibitors|

---

US10800787B2|2017-04-20|2020-10-13|Apotex Inc.|Process for the preparation of acalabrutinib|

---

WO2018229613A1|2017-06-13|2018-12-20|Dr. Reddy's Laboratories Limited|Solid forms of acalabrutinib and process for preparation thereof|

---

CN107522701B|2017-09-01|2019-11-08|苏州富士莱医药股份有限公司|A kind of synthetic method for the BTK inhibitor Acalabrutinib treating chronic lymphocytic leukemia|

---

CN107602564B|2017-09-20|2019-08-30|南京亘泰医药技术有限公司|Bruton's tyrosine kinase inhibitor|

---

AU2018335617B2|2017-09-25|2021-12-09|Astrazeneca Ab|Combination of a BTK inhibitor and an inhibitor of CDK9 to treat cancer|

---

EP3706740A4|2017-11-06|2021-07-28|Suzhou Pengxu Pharmatech Co., Ltd.|Processes to produce acalabrutinib|

---

CN109836416A|2017-11-27|2019-06-04|苏州鹏旭医药科技有限公司|A kind of preparation method of compound|

---

KR20200106511A|2018-01-05|2020-09-14|크리스탈 파마슈티컬씨오., 엘티디.|New crystal form of acalabrutinib and its preparation method and use|

---

CN108250186B|2018-02-07|2020-01-14|杭州科巢生物科技有限公司|Synthesis method of Acaraburtinib and intermediate thereof|

---

CN110256438B|2018-03-12|2020-07-17|新发药业有限公司|Preparation method of Acotinib|

---

JPWO2019189241A1|2018-03-28|2021-03-18|エーザイ・アール・アンド・ディー・マネジメント株式会社|Hepatocellular carcinoma therapeutic agent|

---

US20210113568A1|2018-04-27|2021-04-22|Ono Pharmaceutical Co., Ltd.|PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT|

---

TW202014184A|2018-04-30|2020-04-16|瑞典商阿斯特捷利康公司|Combinations for treating cancer|

---

WO2019239374A1|2018-06-13|2019-12-19|Acerta Pharma B.V.|Imidazopyrazine inhibitors of interleukin-2-inducible t-cell kinase|

---

KR20210022650A|2018-06-19|2021-03-03|리제너론 파아마슈티컬스, 인크.|Anti-factor XII/XIIa antibodies and uses thereof|

---

EP3587421A1|2018-06-29|2020-01-01|Sandoz AG|Crystalline forms of -4-pyrrolidin-2-yl)imidazo[1,5-alpha]pyrazin-1-yl-n-benzamide|

---

EA202190557A1|2018-08-29|2021-07-13|Асерта Фарма Б.В.|METHODS FOR PREPARING 4- {8-AMINO-3 - [ -1-PYRROLIDIN-2-YL] IMIDAZO [1,5-a] PYRAZIN-1-YL} -N-BENZAMIDE|

---

WO2020053795A2|2018-09-13|2020-03-19|Fresenius Kabi Oncology Ltd.|Process for the preparation of acalabrutinib and its intermediates|

---

EP3830091A1|2018-09-25|2021-06-09|Cipla Limited|Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor|

---

CN109020977B|2018-10-26|2020-11-13|安庆奇创药业有限公司|Preparation method of Acaraburtinib|

---

TW202038957A|2018-12-21|2020-11-01|日商第一三共股份有限公司|Combination of antibody-drug conjugate and kinase inhibitor|

---

WO2020176761A1|2019-02-27|2020-09-03|Optikira, LLC|Imidazolopyrazine compounds for ire1 inhibition|

---

EP3942045A1|2019-03-21|2022-01-26|Onxeo|A dbait molecule in combination with kinase inhibitor for the treatment of cancer|

---

WO2020198429A1|2019-03-27|2020-10-01|Assia Chemical Industries Ltd|Solid state forms of acalabrutinib|

---

WO2020225831A1|2019-05-09|2020-11-12|Msn Laboratories Private Limited, R&D Center|Improved process for the preparation of 4-{8-amino-3-[-1-pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-benzamide|

---

WO2021038540A1|2019-08-31|2021-03-04|Sun Pharma Advanced Research Company Limited|Cycloalkylidene carboxylic acids and derivatives as btk inhibitors|

---

CN110563733A|2019-09-12|2019-12-13|安帝康（无锡）生物科技有限公司|Imidazopyrazines as selective BTK inhibitors|

---

WO2021089419A1|2019-11-04|2021-05-14|Astrazeneca Ab|Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies|

---

WO2021089791A1|2019-11-08|2021-05-14|INSERM |Methods for the treatment of cancers that have acquired resistance to kinase inhibitors|

---

WO2021148581A1|2020-01-22|2021-07-29|Onxeo|Novel dbait molecule and its use|

---

WO2021255246A1|2020-06-19|2021-12-23|Acerta Pharma B.V.|Acalabrutinib maleate dosage forms|

---

CN113264938B|2021-07-21|2021-11-02|北京鑫开元医药科技有限公司|Imidazo [1,5-a ] pyrazine-8-amine compound, preparation method, pharmaceutical composition and application|

法律状态:
2018-01-23| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

---

2018-04-03| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2018-07-31| B65X| Notification of requirement for priority examination of patent application|

---

2018-08-21| B65Y| Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)|

---

2018-12-18| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

---

2019-01-15| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|

---

2019-03-26| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

---

2019-04-02| B07B| Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]|Free format text: ANULADA A PUBLICACAO CODIGO 7.5 NA RPI NO 2516 DE 26/03/2019 POR TER SIDO INDEVIDA. |

---

2019-04-30| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2019-07-02| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/07/2012, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/07/2012, OBSERVADAS AS CONDICOES LEGAIS |

优先权:

---

申请号 | 申请日 | 专利标题

---

US201161509397P| true| 2011-07-19|2011-07-19|

---

EP11174578.2|2011-07-19|

---

US61/509397|2011-07-19|

---

EP11174578|2011-07-19|

---

PCT/EP2012/063552|WO2013010868A1|2011-07-19|2012-07-11|4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors|

---